<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004913.pub2" GROUP_ID="INFECTN" ID="691603101716560216" MERGED_FROM="" MODIFIED="2008-11-10 17:07:22 +0100" MODIFIED_BY="Reive Robb" REVIEW_NO="WMET" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2008-11-08 17:36:04 +0000" MODIFIED_BY="[Empty name]">
<TITLE>Vaccines for preventing smallpox</TITLE>
<CONTACT>
<PERSON ID="18281" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Wolfram</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Metzger</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>wgmetzger@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Molecular Biology</DEPARTMENT>
<ORGANISATION>Max-Planck-Institute for Infection Biology</ORGANISATION>
<ADDRESS_1>Schumannstrasse 21/22</ADDRESS_1>
<ADDRESS_2/>
<CITY>Berlin</CITY>
<ZIP>10117</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 30 28460 460</PHONE_1>
<PHONE_2/>
<FAX_1>+49 30 28460 401</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-11-08 17:12:06 +0000" MODIFIED_BY="Harriet MacLehose">
<PERSON ID="18281" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Wolfram</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Metzger</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>wgmetzger@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Molecular Biology</DEPARTMENT>
<ORGANISATION>Max-Planck-Institute for Infection Biology</ORGANISATION>
<ADDRESS_1>Schumannstrasse 21/22</ADDRESS_1>
<ADDRESS_2/>
<CITY>Berlin</CITY>
<ZIP>10117</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 30 28460 460</PHONE_1>
<PHONE_2/>
<FAX_1>+49 30 28460 401</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="20002" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Benjamin</FIRST_NAME>
<MIDDLE_INITIALS>G</MIDDLE_INITIALS>
<LAST_NAME>Mordmueller</LAST_NAME>
<SUFFIX/>
<POSITION>Post-doc Fellow</POSITION>
<EMAIL_1>benjamin.mordmueller@uni-tuebingen.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Human Parasitology</DEPARTMENT>
<ORGANISATION>Institute for Tropical Medicine</ORGANISATION>
<ADDRESS_1>Wilhelmstrasse 27</ADDRESS_1>
<ADDRESS_2/>
<CITY>Tuebingen</CITY>
<ZIP>72074</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-08 17:36:04 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="30" MONTH="1" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="18" MONTH="12" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="1" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-08 17:13:47 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-08 17:13:47 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format with minor editing.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-08 17:13:58 +0000" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-08 17:36:31 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Vaccines for preventing smallpox</TITLE>
<SUMMARY_BODY>
<P>Smallpox is an acute viral infection unique to humans. A worldwide smallpox campaign (including mass vaccination, patient isolation, and surveillance) contributed to the eradication of the disease by 1980. However, there is growing concern that the virus could now be used as a biological weapon. Smallpox spreads from one person to another by infected saliva droplets. The incubation period is 7 to 17 days. The symptoms begin with severe headache, backache, and fever up to 40 °C, all beginning abruptly. Then a rash appears on the face and spreads, the spots become watery blisters containing pus that form scabs and leave pitted scars when they fall off. The infected person is contagious until the last smallpox scab has fallen off, although most of the transmission occurs in the first week. Most people with smallpox recover, but some do die and the risk depends on the strain of virus. The early vaccines were effective, but they had a number of adverse effects, including headache, fever, and reaction at the infection site, and also the possibility of death. New vaccines continue to be developed. The review identified 10 trials that involved 2412 participants. Overall, the quality of the trials was not high but the review showed that stockpiles of the vaccines maintained their effectiveness even when diluted. New second-generation vaccines seemed to be effective but still have adverse events. There were too few participants overall to be able to assess rare outcomes. Further research is needed, particularly on the third-generation vaccines.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-08-22 14:29:38 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Smallpox was eradicated by 1980, but its possible use as a bioweapon has rekindled interest in the development of protective vaccines. Therefore, stockpiled calf lymph-derived vaccines and recently developed cell-cultured vaccines have been investigated to contribute information to smallpox emergency response plans, while newer (non-replication competent) vaccines are developed.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of smallpox vaccines in preventing the disease, in inducing immunity, and in regard to adverse events.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>In December 2006, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (<I>The Cochrane Library</I> 2006, Issue 4), MEDLINE, EMBASE, LILACS, and Current Controlled Trials, and handsearched Index Medicus. We also searched three databases of vaccine safety in December 2005.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized controlled trials of smallpox vaccines versus placebo, other smallpox or non-smallpox vaccine, no intervention, or different dose of the same vaccine in people receiving smallpox vaccination irrespective of age.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-08-22 14:29:38 +0100" MODIFIED_BY="[Empty name]">
<P>Both authors independently assessed trial quality and extracted data. We combined dichotomous data using risk ratio with a random-effects model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Ten trials involving 2412 participants were included. The vaccines investigated were calf-lymph derived first-generation vaccines (Dryvax, APVS, Lancy-vaxina, Lister), and cell-cultured second-generation vaccines (ACAM, CCSV). Vaccines were investigated in different dilutions. All undiluted vaccines induced a reaction in 95% of people vaccinated in terms of pustule and immunogenicity. Also 1:10 dilutions were fully efficient when the starting concentration was defined. Serious adverse events were reported in 1% to 2% of the volunteers. Fever was observed in 11% to 22% of participants, and headache in roughly half of the participants. Fever was less frequent when new vaccines were administered, but rates of headache were similar in new and old vaccines.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The evidence shows that stockpiled vaccines have maintained their immunogenicity and new cell-cultured vaccines are similar to stockpiled vaccines in terms of vaccination success rate and immunogenicity. First- and second-generation vaccines diluted to at least 1:10 are as effective as undiluted vaccine in terms of clinical success rate and immunogenicity. Dilution did not reduce the frequency of adverse events. Success rate and immunogenicity were similar in naive and previously vaccinated persons, but there were fewer adverse events in previously vaccinated persons. The rate of adverse events found in this review reveals the need for further development and improvement of smallpox vaccines.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-08 17:36:31 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-11-08 17:36:31 +0000" MODIFIED_BY="[Empty name]">
<P>Smallpox is an acute viral disease that is unique to humans and is caused by the variola virus (an orthopoxvirus). The virus has two major variants named <I>Variola major</I> and <I>Variola minor</I>. After a worldwide smallpox eradication campaign comprising a broad array of measures such as mass vaccination, containment (patient isolation), and surveillance, the last case of endemic smallpox occurred in Somalia in 1977, and eradication of the disease was declared in 1980 (<LINK REF="REF-WHO-1980" TYPE="REFERENCE">WHO 1980</LINK>). However, there is growing concern that stores of variola virus may have resided in laboratories other than the two World Health Organization (WHO) designated repositories (<LINK REF="REF-Henderson-2001" TYPE="REFERENCE">Henderson 2001</LINK>). The virus is one of several widely known microorganisms that could be used as a biological weapon with great potential for devastation (<LINK REF="REF-Henderson-1999b" TYPE="REFERENCE">Henderson 1999b</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="2">Smallpox and how it spreads</HEADING>
<P>Smallpox is spread from one person to another by infected saliva droplets. There are no subclinical carriers (infected persons without symptoms) and no non-human hosts. Generally, direct and rather prolonged face-to-face contact is required, but also aerosols, infected body fluids, or contaminated objects such as bedding or clothing may transmit the disease. The incubation period is 7 to 17 days (mean, 10 to 12 days) and is followed by a prodromal phase of two or three days, which is characterized by severe headache, backache, and fever up to 40 °C, all beginning abruptly. Subsequently, a papular rash develops over the face and spreads to the extremities. The rash soon becomes vesicular (watery blisters) and later, pustular (blisters containing pus). The patient remains febrile throughout the evolution of the rash and experiences considerable pain as the pustules grow and expand. Gradually scabs form, which eventually separate, leaving pitted scars. The infected person is contagious until the last smallpox scab has fallen off although the vast majority of transmission occurs in the first week of illness. The majority of people with smallpox recover, but death may occur in 30% to 40% of cases during the second week in those who contracted <I>Variola major</I>. The case-fatality rate for <I>Variola minor</I> is 1% (<LINK REF="REF-Fenner-1988" TYPE="REFERENCE">Fenner 1988</LINK>; <LINK REF="REF-Henderson-1999a" TYPE="REFERENCE">Henderson 1999a</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Treatment and vaccination</HEADING>
<P>There is no specific treatment for smallpox disease, and vaccination is the only prevention measure besides containment. In 1796, Edward Jenner discovered that humans inoculated with cowpox became immune to smallpox. Since then the inoculum against smallpox has been distributed in a liquid form of often variable quality. The virus used in most smallpox vaccines is a live-attenuated virus (less virulent, causing less disease) of the Poxviridae family known as vaccinia virus, which is closely related to the variola virus. The vaccinia virus is derived from cowpox or possibly horsepox. Many different strains and application methods of vaccinia virus have been employed. From the 1920s onwards, some laboratories have produced air-dried or freeze-dried vaccines. After 1971, the freeze-dried vaccine was the only one used by any country engaged in a national smallpox eradication programme, with two strains in particular ('Lister' and 'New York City Board of Health' (NYCBOH)) being recommended by the WHO for administration (<LINK REF="REF-Fenner-1988" TYPE="REFERENCE">Fenner 1988</LINK>). Also the application methods were standardized and two new vaccination techniques were mainly used: intradermal inoculation by the jet injector and multiple-puncture inoculation with the bifurcated needle. Vaccination success rates (pustule at vaccination site, 'take' rate) were reported to be more than 90% when the bifurcated needle was used (<LINK REF="STD-Karchmer-1971" TYPE="STUDY">Karchmer 1971</LINK>; <LINK REF="STD-Vaughan-1972" TYPE="STUDY">Vaughan 1972</LINK>; <LINK REF="STD-Vaughan-1973" TYPE="STUDY">Vaughan 1973</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Smallpox eradication</HEADING>
<P>The progressive decrease of the disease that followed introduction of Jenner's vaccine in various European countries during the 19th century appeared to be the most persuasive evidence that vaccination was effective in preventing smallpox. However, in 1967, when the WHO started the intensified smallpox eradication programme, some 10 to 15 million cases were still occurring annually in more than 30 endemic countries worldwide (<LINK REF="REF-Fenner-1988" TYPE="REFERENCE">Fenner 1988</LINK>). A decade later, smallpox had totally disappeared. This was mainly attributed to the vaccine, but, in hindsight, one might ask to what extent the three main constituents of the programme (vaccination, containment, and surveillance) as well as other factors such as better life quality and hygiene contributed to the elimination of the disease (<LINK REF="REF-Hopkins-1988" TYPE="REFERENCE">Hopkins 1988</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Smallpox vaccines in the biowarfare scenario</HEADING>
<P>Concern that remaining variola virus, which can be grown in large quantities and aerosolized, might be used as a biological weapon has led to proposals that smallpox vaccination be offered to some, if not all, of the population in various countries (<LINK REF="REF-Bicknell-2002" TYPE="REFERENCE">Bicknell 2002</LINK>). There are two major concerns if smallpox vaccine is needed for protection against biowarfare or bioterrorism: first the availability of enough vaccine, and secondly the rate of adverse events that might occur. To address the first issue, several studies were initiated to find out if the vaccine doses available could be increased by diluting the vaccine that had been stored since the end of the eradication campaign (<LINK REF="STD-Frey-2002a" TYPE="STUDY">Frey 2002a</LINK>; <LINK REF="STD-Frey-2002b" TYPE="STUDY">Frey 2002b</LINK>; <LINK REF="STD-Frey-2003" TYPE="STUDY">Frey 2003</LINK>; <LINK REF="STD-Rock-2004" TYPE="STUDY">Rock 2004</LINK>; <LINK REF="STD-Talbot-2004" TYPE="STUDY">Talbot 2004</LINK>; <LINK REF="STD-Kim-2005" TYPE="STUDY">Kim 2005</LINK>; <LINK REF="STD-Hsieh-2006" TYPE="STUDY">Hsieh 2006</LINK>), and these studies are reviewed here. Adverse events are discussed in the next two sections and results from included trials are presented in this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Adverse effects of the vaccine in the eradication era</HEADING>
<P>Adverse effects caused by smallpox vaccination range from mild and self-limited to severe and life-threatening. The US Centers for Disease Control and Prevention (CDC) surveillance guidelines recommend that the following be reported after smallpox vaccination: superinfection of the vaccination site or regional lymph nodes; inadvertent autoinoculation; contact transmission; ocular vaccinia; generalized vaccinia; eczema vaccinatum; progressive vaccinia; erythema multiforme major or Stevens-Johnson Syndrome; fetal vaccinia; postvaccinial central nervous system disease; myo/pericarditis; and dilated cardiomyopathy (<LINK REF="REF-MMWR-2006" TYPE="REFERENCE">MMWR 2006</LINK>).</P>
<P>An early trial reported fever (&gt; 38.3 °C) in 6% (38/632) of vaccinees (<LINK REF="STD-Karchmer-1971" TYPE="STUDY">Karchmer 1971</LINK>). Serious adverse events (including death) that followed smallpox vaccination caused considerable public anxiety during the eradication period. The rate of all serious adverse events was estimated to be 40 to 400 cases per million vaccinations, with wide variations according to strains used, age groups, and pre-immunization status. Generalized vaccinia ranged from 1 to 70/10<SUP>6</SUP> vaccinations and eczema vaccinatum ranged from 8 to 80/10<SUP>6</SUP> vaccinations. Progressive vaccinia occurred in 1/10<SUP>6</SUP> vaccinations, and post-vaccination encephalitis or encephalopathy occurred in 2 to 1200/10<SUP>6</SUP> vaccinations. One in one million vaccinated persons died (<LINK REF="REF-Lane-1970a" TYPE="REFERENCE">Lane 1970a</LINK>; <LINK REF="REF-Lane-1970b" TYPE="REFERENCE">Lane 1970b</LINK>). A systematic review of risks from smallpox vaccination between 1963 and 1968 in the USA reported that 29% (11/38) of patients with post-vaccinial encephalitis and 15% (2/13) of patients with vaccinia necrosum died (<LINK REF="REF-Aragon-2003" TYPE="REFERENCE">Aragon 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Adverse events of the vaccine in the post-eradication era</HEADING>
<P>In December 2002, a programme to vaccinate up to 500,000 US military personnel was launched (<LINK REF="REF-Grabenstein-2003" TYPE="REFERENCE">Grabenstein 2003</LINK>), and smallpox vaccination of civilian volunteer healthcare workers began on 24 January 2003 (<LINK REF="REF-MMWR-2003" TYPE="REFERENCE">MMWR 2003</LINK>). In February 2003, the US Food and Drug Administration temporarily suspended all vaccinia trials due to adverse events noted in these civilian and military vaccination campaigns (<LINK REF="REF-MMWR-2003" TYPE="REFERENCE">MMWR 2003</LINK>). After completion of the military and healthcare worker trials in May 2003 and June 2003, respectively, myopericarditis was found to occur at a statistically elevated rate of up to 7.5 times higher than in the non-vaccinated population (<LINK REF="REF-Arness-2004" TYPE="REFERENCE">Arness 2004</LINK>). On the basis of historical experience, cardiac complications such as myocarditis and pericarditis were not expected with use of the US-licensed strain of smallpox vaccine. A mathematical model (hierarchical Bayesian approach) that included various strains used during the eradication campaign estimated the death toll during a present-day mass vaccination in Germany to range from 46.2 to 1381 deaths per million inhabitants (<LINK REF="REF-Kretschmar-2006" TYPE="REFERENCE">Kretschmar 2006</LINK>). One hundred and twenty-five people would be expected to die of complications after vaccination of the entire USA population of 282 million people with the NYCBOH strain only (<LINK REF="REF-Lane-2003" TYPE="REFERENCE">Lane 2003</LINK>). Indeed, more serious adverse events could reasonably be expected with resumption of widespread, indiscriminate vaccination given the increased prevalence of disease patterns with impaired immune responses, such as atopic dermatitis and immune deficiency syndromes. Also, as the vaccinia virus may be transmitted accidentally from vaccinees, it could also cause adverse reactions in non-vaccinated individuals (<LINK REF="REF-Neff-2002" TYPE="REFERENCE">Neff 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Problems of research in smallpox vaccines</HEADING>
<P>Public discussion of the reintroduction of smallpox mass vaccination has become highly controversial and is charged with bias both for and against this intervention. Vaccines still in use will be replaced soon by a new generation of smallpox vaccines that are expected to reduce adverse effects and increase protection (<LINK REF="REF-Drexler-2003" TYPE="REFERENCE">Drexler 2003</LINK>). Attenuation (lessening of virulence) of viral vaccines may be achieved by multiple passages of the virus through unusual host cells, by unusual environmental growth conditions, or by recombinant DNA technology (gene engineering). However, immunological surrogate markers that could provide information about the potential protective efficacy of smallpox vaccines do not exist in the absence of a good animal model and, even if the disease was still present, challenge studies or field trials would be considered unethical. In this situation randomized controlled trials investigating immunogenic efficacy and adverse events of smallpox vaccines are the only way to investigate new vaccines.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Types of smallpox vaccines</HEADING>
<P>Smallpox vaccines are generally called first generation if they are old vaccines prepared on the skin of live animals, usually containing viable bacteria, and usually not able to guarantee that adventitious animal viruses are not present in the vaccine. Second-generation vaccines are those that use the old seed viruses (Lister, NYCBOH, etc), but grow the vaccine in modern sterile media, ensuring they are free of bacteria and adventitious animal viruses. Third-generation are strains that have been in some way attenuated so that at least in theory or in animal models they are less pathogenic or reactogenic than first- and second-generation vaccines. The trials reviewed here are of dilutions of first- and second-generation vaccines, or are comparison of second-generation vaccines with first-generation vaccines generally accepted as being able to prevent smallpox. These latter trials are usually called trials of non-inferiority because they show that the newer vaccines behave in the same way as the older vaccines despite our lack of a proven surrogate index of efficacy. There are several third-generation vaccines in early stages of development, but in the absence of randomized clinical human trials within the time period of this literature research they are not reviewed here and will be included in a future update of the review.</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of smallpox vaccines in preventing the disease, in inducing immunity, and in regard to adverse events.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-08 17:32:09 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-11-08 17:32:08 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-08-22 14:18:09 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People of any age.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-11-08 17:14:13 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<P>Smallpox vaccine of any type and given by any route.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control</HEADING>
<P>Placebo, other smallpox vaccine, other (non-smallpox) vaccine, no intervention, or different dose of the same vaccine.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-08 17:32:08 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary</HEADING>
<UL>
<LI>Death from smallpox.</LI>
<LI>Cases of smallpox.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<UL>
<LI>Vaccination success rates (pustule at vaccination site,'take' rate).</LI>
<LI>Immunological outcomes (parameters of humoral and cell-mediated immunity, duration of the immune response).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<UL>
<LI>Serious adverse events (fatal, life threatening, or requiring hospitalization).</LI>
<LI>Other adverse events associated with the vaccine (referring to the case definitions of the Brighton Collaboration; <LINK REF="REF-Brighton-2004" TYPE="REFERENCE">Brighton 2004</LINK>).</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-08 17:32:08 +0000" MODIFIED_BY="[Empty name]">
<P>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).</P>
<P>We searched the following bibliographic databases using the search terms and strategy described in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>: Cochrane Infectious Diseases Group Specialized Register (December 2006); Cochrane Central Register of Controlled Trials (CENTRAL), published in <I>The Cochrane Library</I> (2006, Issue 4); MEDLINE (1966 to December 2006); EMBASE (1974 to December 2006); and LILACS (1982 to December 2006). We also searched the Current Controlled Trials website (accessed December 2006), using the search terms 'smallpox AND (vaccin* OR immuni*)'. We also handsearched Index Medicus (1920 to 1966).</P>
<P>We searched three databases of vaccine safety using the search terms 'smallpox AND (vaccin* OR immuni*)': The Brighton Collaboration (www.brightoncollaboration.org; December 2005); Institute of Vaccine Safety, Bloomberg School of Public Health (www.vaccinesafety.edu; December 2005); and Vaccine Adverse Event Reporting System (vaers.hhs.gov/; December 2005).</P>
<P>We checked the reference lists of all studies identified by the above methods.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-08 17:32:09 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2008-08-22 14:38:03 +0100" MODIFIED_BY="[Empty name]">
<P>We, Wolfram Metzger (WM) and Benjamin Mordmueller (BM), independently screened the titles and abstracts of the studies identified by the search strategy for potentially relevant studies. We obtained the full reports for those considered potentially relevant (and for those where there was uncertainty) and applied independently an eligibility form based on the inclusion criteria. We resolved any differences in opinion through discussion. We gave the reason for excluding any of the potentially relevant studies in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'. Trial reports were scrutinized to ensure that multiple publications from the same trial were included only once. Trial investigators were contacted for clarification if trial eligibility was unclear.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-11-08 17:32:09 +0000" MODIFIED_BY="[Empty name]">
<P>We independently extracted data using a standardized data extraction form. WM entered the data into <LINK REF="REF-Review-Manager-5" TYPE="REFERENCE">Review Manager 5</LINK>, and BM cross checked the data. We aimed to extract data according to the intention-to-treat principle (all randomized participants should be analysed in the groups to which they were originally assigned). If there was discrepancy in the number randomized and the numbers analysed in each treatment group, we reported this information. For dichotomous outcomes, we recorded the number of participants experiencing the event and the number analysed in each treatment group. We resolved disagreement through discussion, and, if necessary, involved a statistician or an Editor of the Cochrane Infectious Diseases Group.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-11-08 17:32:08 +0000" MODIFIED_BY="[Empty name]">
<P>We independently assessed the risk of bias in the included trials using the full-text article and a validity form. We classed generation of allocation and allocation concealment to be adequate, inadequate, or unclear according to <LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>. We considered the inclusion of participants in the analysis to be adequate if greater than 80% and inadequate if 80% or less. We classified blinding as open (all parties are aware of treatment), single (participant or care provider or assessor is aware of the treatment given), or double (trial uses placebo or a double-dummy technique such that neither the participant nor care provider or assessor know which treatment is given), and reported who specifically was blinded. We attempted to contact the authors if this information was not specified or if it was unclear. We resolved disagreement through discussion and displayed the results of the quality assessment in a table.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-11-08 17:32:08 +0000" MODIFIED_BY="[Empty name]">
<P>Where appropriate, we analysed data using <LINK REF="REF-Review-Manager-5" TYPE="REFERENCE">Review Manager 5</LINK>. All included participants were included in the analysis ('intention to treat'). We stratified the analysis by vaccine dilution, new generation versus original vaccine (Dryvax), and non-naive versus naive participants. We assessed the homogeneity of effect sizes between studies by visually examining the forest plots and by using the chi-squared test for heterogeneity (10% level of statistical significance) and the <I>I</I>
<SUP>2</SUP> test (50% level). We assessed homogeneity of participants, interventions, and outcomes before deciding to combine data. We combined dichotomous data (such as adverse events) using risk ratio and the random-effects model, and presented the results with 95% confidence intervals.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-08 17:32:09 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-11-08 17:32:08 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Identification of studies</HEADING>
<P>Of the 60 potentially relevant studies identified with the search strategy, 10 trials met the inclusion criteria (see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>') and 50 were excluded (see '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'). We also identified 33 registered ongoing (or newly completed) studies (see '<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>').</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Time-frame and participants</HEADING>
<P>The included trials were carried out from the year 2000 onward and included 2412 participants. Six investigated young healthy volunteers who had never been vaccinated before (naive), and four included older persons who had been vaccinated before (<LINK REF="STD-Frey-2003" TYPE="STUDY">Frey 2003</LINK>; <LINK REF="STD-Greenberg-2005" TYPE="STUDY">Greenberg 2005</LINK>; <LINK REF="STD-Kim-2005" TYPE="STUDY">Kim 2005</LINK>; <LINK REF="STD-Hsieh-2006" TYPE="STUDY">Hsieh 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Vaccines</HEADING>
<P>Seven trials analysed different dilutions of vaccines that were produced before smallpox was eradicated and had been stored since then (<LINK REF="STD-Frey-2002a" TYPE="STUDY">Frey 2002a</LINK>; <LINK REF="STD-Frey-2002b" TYPE="STUDY">Frey 2002b</LINK>; <LINK REF="STD-Frey-2003" TYPE="STUDY">Frey 2003</LINK>; <LINK REF="STD-Rock-2004" TYPE="STUDY">Rock 2004</LINK>; <LINK REF="STD-Talbot-2004" TYPE="STUDY">Talbot 2004</LINK>; <LINK REF="STD-Kim-2005" TYPE="STUDY">Kim 2005</LINK>; <LINK REF="STD-Hsieh-2006" TYPE="STUDY">Hsieh 2006</LINK>). Three trials compared safety and immunogenicity of new cell-cultured vaccines with the stored, calf lymph-derived vaccine from Dryvax/Wyeth (<LINK REF="STD-Weltzin-2003" TYPE="STUDY">Weltzin 2003</LINK>; <LINK REF="STD-Artenstein-2005" TYPE="STUDY">Artenstein 2005</LINK>; <LINK REF="STD-Greenberg-2005" TYPE="STUDY">Greenberg 2005</LINK>). Four trials included investigations to find out if naive participants differ from non-naive persons in regard to reaction profile and adverse events (<LINK REF="STD-Frey-2003" TYPE="STUDY">Frey 2003</LINK>; <LINK REF="STD-Greenberg-2005" TYPE="STUDY">Greenberg 2005</LINK>; <LINK REF="STD-Kim-2005" TYPE="STUDY">Kim 2005</LINK>; <LINK REF="STD-Hsieh-2006" TYPE="STUDY">Hsieh 2006</LINK>). Six different types of vaccine were investigated (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>The trials did not investigate the review's primary outcome measures &#8722; protective efficacy with regard to death or smallpox cases. All explored efficacy in terms of a major reaction to the vaccine (pustule at vaccination site, take rate) and immunogenicity in terms of humoral and/or cellular immune responses to the vaccines (neutralizing antibodies and/or cytokines).</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-08 17:32:09 +0000" MODIFIED_BY="[Empty name]">
<P>The trials differed in methodological quality (details provided in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'). Only two trials mentioned how the allocation sequence was generated (<LINK REF="STD-Talbot-2004" TYPE="STUDY">Talbot 2004</LINK>; <LINK REF="STD-Greenberg-2005" TYPE="STUDY">Greenberg 2005</LINK>), and none described allocation concealment. None of the trials was named quasi-randomized. Six trials blinded participants and investigators (<LINK REF="STD-Frey-2002b" TYPE="STUDY">Frey 2002b</LINK>; <LINK REF="STD-Weltzin-2003" TYPE="STUDY">Weltzin 2003</LINK>; <LINK REF="STD-Rock-2004" TYPE="STUDY">Rock 2004</LINK>; <LINK REF="STD-Talbot-2004" TYPE="STUDY">Talbot 2004</LINK>; <LINK REF="STD-Artenstein-2005" TYPE="STUDY">Artenstein 2005</LINK>; <LINK REF="STD-Greenberg-2005" TYPE="STUDY">Greenberg 2005</LINK>), while four trials blinded only the participants (<LINK REF="STD-Frey-2002a" TYPE="STUDY">Frey 2002a</LINK>; <LINK REF="STD-Frey-2003" TYPE="STUDY">Frey 2003</LINK>; <LINK REF="STD-Kim-2005" TYPE="STUDY">Kim 2005</LINK>; <LINK REF="STD-Hsieh-2006" TYPE="STUDY">Hsieh 2006</LINK>). All trials included an adequate (&gt; 80%) of participants in the analysis.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-08 17:32:09 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Death from smallpox and cases of smallpox</HEADING>
<P>None of the trials reported on these outcome measures.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Vaccination success rates</HEADING>
<P>Success (major reaction) of vaccination was measured as the presence of a vesicle seven to nine days after scarification.</P>
<SUBSECTION>
<HEADING LEVEL="4">Diluted versus undiluted vaccines</HEADING>
<P>Nine trials that compared dilutions of vaccines measured this outcome (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The undiluted vaccines generated success in 95% or more of the volunteers. Dilution of up to 1:10 of the stocked calf lymph-derived vaccines (Dryvax, APVS, Lancy-vaxina, and Lister) did not diminish success rates overall. However, dilutions of Dryvax vaccine (1:10 and 1:100) reduced the success rates in two trials (<LINK REF="STD-Frey-2002b" TYPE="STUDY">Frey 2002b</LINK>; <LINK REF="STD-Frey-2003" TYPE="STUDY">Frey 2003</LINK>). This was probably the result of different start concentrations in the original undiluted vaccines. Consequently, it was suggested that Dryvax can be diluted to a titre of 107 plaque-forming units per millilitre (<LINK REF="STD-Frey-2002a" TYPE="STUDY">Frey 2002a</LINK>). Dilutions of new cell-cultured vaccines maintained full success rates in all but the 1:20 dilution of one trial, <LINK REF="STD-Artenstein-2005" TYPE="STUDY">Artenstein 2005</LINK> (RR 0.86, 95% CI 0.79 to 0.93; 151 participants).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">New versus old vaccines</HEADING>
<P>No failures were seen in trials testing the new cell-cultured vaccines (ACAM1000, ACAM2000, and CCSV) compared with the old calf lymph-derived control vaccine (Dryvax) in three trials (with 430 participants) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) (<LINK REF="STD-Weltzin-2003" TYPE="STUDY">Weltzin 2003</LINK>; <LINK REF="STD-Artenstein-2005" TYPE="STUDY">Artenstein 2005</LINK>; <LINK REF="STD-Greenberg-2005" TYPE="STUDY">Greenberg 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Naive versus non-naive participants</HEADING>
<P>Three trials (with 410 participants) made this comparison and found no failures between the groups (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>) (<LINK REF="STD-Frey-2003" TYPE="STUDY">Frey 2003</LINK>; <LINK REF="STD-Greenberg-2005" TYPE="STUDY">Greenberg 2005</LINK>; <LINK REF="STD-Hsieh-2006" TYPE="STUDY">Hsieh 2006</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Immunological outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Humoral responses</HEADING>
<P>Humoral responses paralleled successful vaccination. Nearly all volunteers who showed a vesicle seroconverted in regard to antibodies neutralizing the smallpox vaccine virus (the definition of seroconversion in each trial is given in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'). Consequently, similar results to the success rates were shown in the comparisons of diluted versus undiluted vaccines (6 trials, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), new versus old vaccines (3 trials, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>), and naive versus non-naive participants (2 trials, <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cellular responses</HEADING>
<P>Cellular responses were investigated in five trials. Similar to humoral responses, almost all participants with vesicle formation had vaccinia virus-specific T-cell responses, increased numbers of interferon-gamma-producing T-cells, and lymphocyte proliferation (<LINK REF="STD-Frey-2002b" TYPE="STUDY">Frey 2002b</LINK>; <LINK REF="STD-Weltzin-2003" TYPE="STUDY">Weltzin 2003</LINK>; <LINK REF="STD-Greenberg-2005" TYPE="STUDY">Greenberg 2005</LINK>; <LINK REF="STD-Hsieh-2006" TYPE="STUDY">Hsieh 2006</LINK>). One trial reported that participants who did not report an adverse event presented different cytokine profiles from those who did report an adverse event (<LINK REF="STD-Rock-2004" TYPE="STUDY">Rock 2004</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Serious adverse events</HEADING>
<P>All 10 trials collected data on serious adverse events, but only three trials reported their occurrence: <LINK REF="STD-Frey-2002a" TYPE="STUDY">Frey 2002a</LINK> (12/680 participants (2%), dilution comparison); <LINK REF="STD-Talbot-2004" TYPE="STUDY">Talbot 2004</LINK> (4/340 participants (1%), dilution comparison); and <LINK REF="STD-Artenstein-2005" TYPE="STUDY">Artenstein 2005</LINK> (1/304 participants for ACAM2000 vaccine (0.03%), versus none for Dryvax vaccine). Of the 12 participants in <LINK REF="STD-Frey-2002a" TYPE="STUDY">Frey 2002a</LINK>, the trialists classified three with serious adverse events possibly (1) or definitely (2) related to the vaccine, and probably unrelated (2) or unrelated (7) to the vaccine. Comparisons of vaccine types and dilutions did not show significant differences because the number of these events was low. The reported serious adverse events were high fever (1), severe headache and nausea (1), large erythema (1), nausea/dehydration (1), orthostatic dizziness (1), facial nerve dispalsy (1), colitis flare (1), and myopericarditis (1). Retrospectively, and after the addition of cardiac screening questions, cardiac symptoms or chest pain were reported in 1% (5/340) of participants (<LINK REF="STD-Talbot-2004" TYPE="STUDY">Talbot 2004</LINK>), and 3% (11/353) of participants (ACAM2000: 8/304 (3%), Dryvax 3/49 (6%)) (<LINK REF="STD-Artenstein-2005" TYPE="STUDY">Artenstein 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fever</HEADING>
<P>In all trials, changes from baseline body temperature were seen with varying frequency, and as the trials differed in their definition of fever, we cannot make a conclusive statement. The reported fever frequencies were 21.5% (73/340) (<LINK REF="STD-Talbot-2004" TYPE="STUDY">Talbot 2004</LINK>), 8.9% (59/665) (<LINK REF="STD-Frey-2002a" TYPE="STUDY">Frey 2002a</LINK>), and 10.5% (32/304) (<LINK REF="STD-Artenstein-2005" TYPE="STUDY">Artenstein 2005</LINK>). Fever was not significantly reduced by vaccine dilution (4 trials, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) or use of new vaccines (2 trials, <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). Fever was less common in non-naive participants than in naive participants (2 trials, <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Headache</HEADING>
<P>Roughly half of the volunteers in five trials complained of headaches (<LINK REF="STD-Frey-2002a" TYPE="STUDY">Frey 2002a</LINK>; <LINK REF="STD-Talbot-2004" TYPE="STUDY">Talbot 2004</LINK>; <LINK REF="STD-Artenstein-2005" TYPE="STUDY">Artenstein 2005</LINK>; <LINK REF="STD-Greenberg-2005" TYPE="STUDY">Greenberg 2005</LINK>; <LINK REF="STD-Kim-2005" TYPE="STUDY">Kim 2005</LINK>), whereas, surprisingly, no complaint of headache was reported in three other trials (<LINK REF="STD-Frey-2002b" TYPE="STUDY">Frey 2002b</LINK>; <LINK REF="STD-Frey-2003" TYPE="STUDY">Frey 2003</LINK>; <LINK REF="STD-Rock-2004" TYPE="STUDY">Rock 2004</LINK>). One trial stated that "all 60 subjects experienced at least one adverse event" (<LINK REF="STD-Weltzin-2003" TYPE="STUDY">Weltzin 2003</LINK>), but it was not specified if headache was amongst them. Headache was not reduced significantly by vaccine dilution (4 trials, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). New vaccines performed similar to Dryvax in regard to headache (2 trials, <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). Interestingly, non-naive participants had significantly less headache when revaccinated than first-time vaccinated participants (2 trials, <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Local reactions</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Pain at vaccination site</HEADING>
<P>The different smallpox vaccines caused pain at the vaccination site in 68% (1208/1775) of the volunteers with studies ranging from 7% to 92%. The 1:20 dilution reduced pain, but only in one of the three dilution trials reporting on this outcome (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). Overall, there was no difference between new and old vaccines (2 trials, <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>), while naive participants reported more pain at the vaccination site than non-naive participants (1 trial, <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lymphadenopathy</HEADING>
<P>Lymphadenopathy was not mentioned in one trial (<LINK REF="STD-Frey-2002b" TYPE="STUDY">Frey 2002b</LINK>), but volunteers in all other trials showed signs of lymphadenopathy, with percentages ranging from 7% to 88%. The 1:5 and 1:10 dilutions in <LINK REF="STD-Frey-2002a" TYPE="STUDY">Frey 2002a</LINK>, one of the six dilution trials reporting on this outcome, reduced lymphadenopathy (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>), but no difference was shown between new and old vaccines (3 trials, <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). More naive participants presented with lymphadenopathy than non-naive participants (2 trials, <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other</HEADING>
<P>Three trials (with 1355 participants) reported the missing of scheduled duties or recreational activities and sleeping disorders in 36% (<LINK REF="STD-Frey-2002a" TYPE="STUDY">Frey 2002a</LINK>), 25% (<LINK REF="STD-Talbot-2004" TYPE="STUDY">Talbot 2004</LINK>), and 12% (<LINK REF="STD-Greenberg-2005" TYPE="STUDY">Greenberg 2005</LINK>) of participants. Dilution subgroups were not compared in regard to this parameter, and new and old vaccines did not differ significantly in regard to this parameter. Non-naive participants missed scheduled activities significantly less than naive participants (<LINK REF="STD-Greenberg-2005" TYPE="STUDY">Greenberg 2005</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-08 17:32:08 +0000" MODIFIED_BY="[Empty name]">
<P>This review's objective was to assess the effects of smallpox vaccines in preventing the disease, in inducing immunity, and in regards to adverse events. It was not surprising that we were not able to find randomized controlled trials reporting the efficacy of smallpox vaccines in terms of disease prevention. Such trials were not a must in the pre-eradication era, and, moreover, a placebo control group would have been considered unethical because the vaccine was presumed to be effective. We identified 10 randomized controlled trials with the primary goal to assess the immunogenicity of stocked calf lymph-derived first-generation vaccines or second-generation cell-cultured vaccines in terms of major reaction rate as well as humoral and cellular responses as surrogate markers of protection. The prevailing question in the bioterrorism debate, whether a possible attack with smallpox could be countered with sufficient vaccinations, was addressed in these trials investigating different dilutions of the vaccines.</P>
<P>Although the methodological quality of most of the trials was not optimal (eg none mentioned allocation concealment), and homogeneity of parameters was not perfect (eg the threshold for fever differed slightly), the basic question about immunogenicity of the vaccines in non-immune participants could be answered satisfactorily. All vaccines under investigation provided full immunogenicity (more than 95%) when undiluted, and even the 1:10 dilutions of the vaccines were still fully immunogenic when the starting concentration was defined. Thus, in case of a bioterrorist attack, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> shows that at least 1000 million doses of first generation vaccine would be available, at least to those with access to the stockpile of 100 million undiluted doses. It was not surprising that many of the humoral and cellular immunity tests being used do not fully correlate with each other. This is because no generally agreed-upon test for the level of humoral or cellular immunity proven to protect against smallpox was ever established during the eradication era, and modern trials cannot simply test for such a level when the disease is not existent. Therefore, studies meeting Prentice's conditions for the validation of these markers as surrogates for protection (<LINK REF="REF-Prentice-1989" TYPE="REFERENCE">Prentice 1989</LINK>) do not exist and nothing can be said about the predictive value of major reaction rate and immune responses.</P>
<P>None of the trials investigated the duration of protection. However, three trials working with non-naive participants reported rates of pre-existing antibody levels displaying long-lasting immune responses in most of the participants (<LINK REF="STD-Frey-2003" TYPE="STUDY">Frey 2003</LINK>; <LINK REF="STD-Greenberg-2005" TYPE="STUDY">Greenberg 2005</LINK>; <LINK REF="STD-Hsieh-2006" TYPE="STUDY">Hsieh 2006</LINK>). Both protective efficacy and duration of protection have been carefully formulated by the CDC as follows: "Smallpox vaccination provides high level immunity for 3 to 5 years and decreasing immunity thereafter. If a person is vaccinated again later, immunity lasts even longer. Historically, the vaccine has been effective in preventing smallpox infection in 95% of those vaccinated. In addition, the vaccine was proven to prevent or substantially lessen infection when given within a few days of exposure. It is important to note, however, that at the time when the smallpox vaccine was used to eradicate the disease, testing was not as advanced or precise as it is today, so there may still be things to learn about the vaccine and its effectiveness and length of protection" (<LINK REF="REF-CDC-2006" TYPE="REFERENCE">CDC 2006</LINK>).</P>
<P>Vaccines are frequently thought of as preventive measures which do much greater good than harm. So far, this does not apply to smallpox vaccines. The possible dangers of smallpox vaccines resurfaced in 2003 when mass vaccinations of healthcare workers and military were carried out and unforeseen cardiac complications were detected (<LINK REF="REF-Poland-2005a" TYPE="REFERENCE">Poland 2005a</LINK>). As a consequence, the USA released the Smallpox Emergency Personnel Protection Act of 2003, and a Smallpox Vaccine Injury Compensation Program was established in order to provide "medical, lost employment income, and death benefits for eligible individuals who sustained covered injuries as a result of receiving smallpox vaccine or other covered countermeasures, or as a result of accidental exposure to vaccinia" (<LINK REF="REF-HRSA-2006" TYPE="REFERENCE">HRSA 2006</LINK>).</P>
<P>The included trials reported no fatal adverse events, but 17 serious adverse events were registered. This number could possibly be higher because cardiac complications were taken into account only after some trials had already started. Moreover, a remarkable prevalence of local adverse events was observed. The rate of headache and fever in every second and tenth vaccinee, respectively, is in line with other studies (<LINK REF="REF-Frey-2002c" TYPE="REFERENCE">Frey 2002c</LINK>). Severe headache following smallpox vaccination seemed to be generally transient, but debilitating headache may occur (<LINK REF="REF-Sejvar-2005" TYPE="REFERENCE">Sejvar 2005</LINK>). As expected for a live virus, local reactions (inflammation at vaccination site, lymphadenopathy) were common, but the reporting of these events was too variable to give an overall rate. In the three trials with the biggest numbers of participants, roughly every fifth person was missing scheduled activities or reported sleeping disorders. All participants knew that they received smallpox vaccine, so this might be a reason to check this effect with a placebo vaccine.</P>
<P>Because of contraindications and safety concerns, the public probably will not accept the use of first- and second-generation vaccines unless there is a documented case of smallpox. Therefore, research leading to third-generation vaccines, such as vaccinia viruses that are further attenuated, inactivated viruses, or, more promising, subunit or peptide-based vaccines with or without adjuvants, should remain a significant goal of public health (<LINK REF="REF-Poland-2005b" TYPE="REFERENCE">Poland 2005b</LINK>). A crucial consideration in the development of future vaccines is the ability of the virus to replicate. LC16m8, a replication-competent attenuated smallpox vaccine, was developed in Japan during the 1960s by 53 serial passages of Lister strain through rabbit kidney cells in order to identify a less neutrovirulent strain (<LINK REF="REF-Wiser-2007" TYPE="REFERENCE">Wiser 2007</LINK>). Mass trials in the 1970s were promising with "major reaction" rates similar to the parent Lister strain. Research on LC16m8 was resumed in 2002 in order to acquire an emergency stockpile of attenuated smallpox vaccine (<LINK REF="REF-Kenner-2006" TYPE="REFERENCE">Kenner 2006</LINK>). Other research focuses on replication deficient, highly attenuated vaccines. The Modified Vaccinia Ankara strain (MVA) was developed in Germany during the 1970s by 572 serial passages of the Ankara strain in chicken embryo fibroblasts. In this process, the virus lost about 15% of its parental genome and its replication capability in most mammalian cells, including human cells (<LINK REF="REF-Drexler-2003" TYPE="REFERENCE">Drexler 2003</LINK>; <LINK REF="REF-Wiser-2007" TYPE="REFERENCE">Wiser 2007</LINK>). MVA was discussed as a vaccine candidate for immunosuppressed vaccinees and research on this strain was resumed in recent years. Research on subunit and DNA vaccines against smallpox is ongoing and first results are reviewed elsewhere (<LINK REF="REF-Wiser-2007" TYPE="REFERENCE">Wiser 2007</LINK>). We have identified a number of registered ongoing trials and will include these results in future updates of this review. The use of smallpox vaccines in the absence of the disease is a political decision. Like many political issues, there is a spectrum of opinion about the risk of bioterrorism and the need for pre-event vaccination. There is a rich literature about this subject, and a number of mathematical models have attempted to predict the nature of a smallpox outbreak with and without various levels of pre-event vaccination. This debate is outside the scope of this review.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>First- and second-generation vaccines diluted up to at least 1:10 are as effective as undiluted vaccine in terms of clinical success rate and immunogenicity. Dilutions did not reduce the frequency of adverse events. Success rate and immunogenicity were similar in naive and previously vaccinated persons, but adverse events were lower in previously vaccinated persons. </P>
<P>Smallpox vaccines display a high degree of immunogenicity plus a high rate of adverse events. Consequently a certain degree of protection can be expected, and there should be a high threshold for recommending smallpox vaccines. </P>
<P>The debate about biowarfare and its consequences, as well as the argument about the appropriate response to an attack with bioweapons, is outside the scope of this review.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>If the biowarfare threat is real, then it is relevant and important to have good data. To facilitate practical decisions, research on smallpox vaccines should be extended to reduce adverse events and maintain immunogenicity. Researchers should intensify efforts to educate the public about infection with smallpox and possible preventive measures.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The editorial base for the Cochrane Infectious Diseases Group is funded by the UK Department for International Development (DFID) for the benefit of developing countries.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Wolfram Metzger is the guarantor of the review and takes responsibility for the integrity of the work as a whole, from inception to publication. Benjamin Mordmueller assessed trial quality, extracted data and participated sufficiently in the work to take public responsibility for the content.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-11-08 17:19:21 +0000" MODIFIED_BY="[Empty name]">
<P>2007, Issue 3 (first review version): The protocol methods stated that we would analyse adverse events in non-randomized studies, but because this referred mainly to studies investigating vaccines of the pre-eradication era, and reviews that cover this period are available, we have dispensed with this analysis. We summarize adverse effects of vaccines of the pre-eradication era in the 'Background' section. We excluded quasi-randomized controlled trials from the inclusion criteria in order to increase the stringency of the findings and to align with CIDG policy. We added 'different doses of the same vaccine' as a control in the inclusion criteria because most of the included trials were comparisons of different vaccine dilutions.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-08 17:29:49 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-11-08 17:29:49 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-11-08 17:28:21 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Artenstein-2005" MODIFIED="2008-11-08 17:27:41 +0000" MODIFIED_BY="[Empty name]" NAME="Artenstein 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-08 17:27:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Artenstein AW, Johnson C, Marbury TC, Morrison D, Blum PS, Kemp T, et al</AU>
<TI>A novel cell culture-derived smallpox vaccine in vaccinia-naive adults</TI>
<SO>Vaccine</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>25</NO>
<PG>3301-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frey-2002a" NAME="Frey 2002a" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belshe RB, Newman FK, Frey SE, Couch RB, Treanor JJ, Tacket CO, et al</AU>
<TI>Dose-dependent neutralizing-antibody responses to vaccinia</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2004</YR>
<VL>189</VL>
<NO>3</NO>
<PG>493-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, Newman FK, et al; National Institute of Allergy and Infectious Diseases Smallpox Vaccine Study Group</AU>
<TI>Clinical responses to undiluted and diluted smallpox vaccine</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<NO>17</NO>
<PG>1265-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frey-2002b" MODIFIED="2008-11-08 17:27:47 +0000" MODIFIED_BY="[Empty name]" NAME="Frey 2002b" YEAR="2002">
<REFERENCE MODIFIED="2008-11-08 17:27:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frey SE, Newman FK, Cruz J, Shelton WB, Tennant JM, Polach T, et al</AU>
<TI>Dose-related effects of smallpox vaccine</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<NO>17</NO>
<PG>1275-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frey-2003" MODIFIED="2008-11-08 17:27:54 +0000" MODIFIED_BY="[Empty name]" NAME="Frey 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-08 17:27:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frey SE, Newman FK, Yan L, Belshe RB</AU>
<TI>Response to smallpox vaccine in persons immunized in the distant past</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>24</NO>
<PG>3294-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenberg-2005" MODIFIED="2008-11-08 17:27:58 +0000" MODIFIED_BY="[Empty name]" NAME="Greenberg 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-08 17:27:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg RN, Kennedy JS, Clanton DJ, Plummer EA, Hague L, Cruz J, et al</AU>
<TI>Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<NO>9457</NO>
<PG>398-409</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hsieh-2006" MODIFIED="2008-11-08 17:28:08 +0000" MODIFIED_BY="[Empty name]" NAME="Hsieh 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-08 17:28:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hsieh SM, Chen SY, Sheu GC, Hung MN, Chou WH, Chang SC, et al</AU>
<TI>Clinical and immunological responses to undiluted and diluted smallpox vaccine with vaccinia virus of Lister strain</TI>
<SO>Vaccine</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>4</NO>
<PG>510-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2005" MODIFIED="2008-11-08 17:28:11 +0000" MODIFIED_BY="[Empty name]" NAME="Kim 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-08 17:28:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim SH, Yeo SG, Jang HC, Park WB, Lee CS, Lee KD, et al</AU>
<TI>Clinical responses to smallpox vaccine in vaccinia-naive adults and previously vaccinated populations: undiluted and diluted Lancy-Vaxina vaccine in a single-blind, randomized prospective trial</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2005</YR>
<VL>192</VL>
<NO>6</NO>
<PG>1066-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rock-2004" MODIFIED="2008-11-08 17:28:14 +0000" MODIFIED_BY="[Empty name]" NAME="Rock 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-11-08 17:28:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rock MT, Yoder SM, Talbot TR, Edwards KM, Crowe Jr. JE</AU>
<TI>Adverse events after smallpox immunizations are associated with alterations in systemic cytokine levels</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2004</YR>
<VL>189</VL>
<NO>8</NO>
<PG>1401-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Talbot-2004" NAME="Talbot 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Talbot RT, Stapleton JT, Brady RC, Winokur PL, Bernstein DI, Germanson T, et al</AU>
<TI>Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>292</VL>
<NO>10</NO>
<PG>1205-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Talbot TR, Bredenberg HK, Smith M, LaFleur BJ, Boyd A, Edwards KM</AU>
<TI>Focal and generalized folliculitis following smallpox vaccination among vaccinia-naive recipients</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>24</NO>
<PG>3290-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weltzin-2003" MODIFIED="2008-11-08 17:28:21 +0000" MODIFIED_BY="[Empty name]" NAME="Weltzin 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-08 17:28:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS, et al</AU>
<TI>Clonal vaccinia virus grown in cell culture as a new smallpox vaccine</TI>
<SO>Nature Medicine</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>9</NO>
<PG>1125-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-11-08 17:28:29 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Agafonov-1977" NAME="Agafonov 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agafonov VI, Vorob'ev AA, Gapochko KG, Marennikova SS, Patrikeev GT</AU>
<TI>Comparative assessment of the means and methods of immunizing humans against smallpox</TI>
<SO>Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii</SO>
<YR>1977</YR>
<VL>6</VL>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andzhaparidze-1980" NAME="Andzhaparidze 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andzhaparidze OG, Unanov SS, Chernos VI, Strelkov VV, Antonova TP</AU>
<TI>Moscow Research Institute of Viral Preparations tissue-culture smallpox vaccine in a coded control experiments of adult revaccination by scarification</TI>
<SO>Voprosy Virusologii</SO>
<YR>1980</YR>
<VL>4</VL>
<PG>443-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Banerji-1972" NAME="Banerji 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Banerji SC, Sharma KL, Srivastava BC, Gupta RD</AU>
<TI>A comparative study of smallpox vaccination techniques under field conditions</TI>
<SO>Indian Journal of Medical Research</SO>
<YR>1972</YR>
<VL>60</VL>
<NO>5</NO>
<PG>772-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benenson-1977" NAME="Benenson 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benenson AS, Cherry JD, McIntosh K, Connor JD, Alling DW, Nakano J, et al</AU>
<TI>Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Basic study and laboratory standardization</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1977</YR>
<VL>135</VL>
<NO>1</NO>
<PG>135-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chernos-1977" MODIFIED="2008-11-08 17:28:29 +0000" MODIFIED_BY="[Empty name]" NAME="Chernos 1977" YEAR="1977">
<REFERENCE MODIFIED="2008-11-08 17:28:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chernos VI, Unanov SS, Antonova TP, Nemtsov IM, Andzhaparidze OG</AU>
<TI>Study of the properties of a tissue smallpox vaccine manufactured by the Moscow Research Institute of Viral Preparations</TI>
<SO>Voprosy Virusologii</SO>
<YR>1977</YR>
<VL>1</VL>
<PG>71-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chernos-1990" NAME="Chernos 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chernos VI, Cheliapov NV, Antonova TP, Rakhilina LE, Unanov SS, Al'tshtein AD, et al</AU>
<TI>Verification of the safety, inoculability, reactogenicity and antigenic properties of a live recombinant smallpox-hepatitis B vaccine in an experiment in volunteers</TI>
<SO>Voprosy Virusologii</SO>
<YR>1990</YR>
<VL>35</VL>
<NO>2</NO>
<PG>132-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cherry-1977" NAME="Cherry 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cherry JD, McIntosh K, Connor JD, Benenson AS, Alling DW, Rolfe UT, et al</AU>
<TI>Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Primary percutaneous vaccination</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1977</YR>
<VL>135</VL>
<NO>1</NO>
<PG>145-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christensen-1966" NAME="Christensen 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christensen H, Kjolbye E, Aung Tun U</AU>
<TI>Effect of simultaneous BCG and smallpox vaccination in schoolchildren. Report of a WHO-sponsored preliminary study</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1966</YR>
<VL>35</VL>
<NO>4</NO>
<PG>633-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Denisov-1975" NAME="Denisov 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Denisov GM, Kossova ET, Rybalko DI</AU>
<TI>Immunological efficacy of smallpox vaccination in children with relative contraindications to vaccination</TI>
<SO>Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii</SO>
<YR>1975</YR>
<VL>1</VL>
<PG>68-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evgrafov-1978" NAME="Evgrafov 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evgrafov VA., Kossova ET, Piskareva NA, Leonov VM, Khliabich GN</AU>
<TI>Study of the multiple puncture method in smallpox vaccination of children</TI>
<SO>Zhurnal Mikrobiologii, Epidemiologii, i Imunobiologii</SO>
<YR>1978</YR>
<VL>1</VL>
<PG>51-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galasso-1977" NAME="Galasso 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galasso GJ, Mattheis MJ, Cherry JD, Connor JD, McIntosh K, Benenson AS</AU>
<TI>Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Summary</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1977</YR>
<VL>135</VL>
<NO>1</NO>
<PG>183-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gateff-1973" NAME="Gateff 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gateff C, Relyveld EH, Le Gonidec G, Vincent J, Labusquiere R, McBean M, et al</AU>
<TI>Study of a new pentavalent vaccine combination</TI>
<SO>Annales de Microbiologie</SO>
<YR>1973</YR>
<VL>124</VL>
<NO>3</NO>
<PG>387-409</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrero-1969" NAME="Herrero 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herrero E, von Mutzenbecher H</AU>
<TI>Smallpox vaccine from cell cultures. Clinical trials and comparison with dermovaccine</TI>
<SO>Zentralblatt Fur Bakteriologie, Parasitenkunde, Infektionskrankheiten Und Hygiene - 1 - Abt - Medizinisch-Hygienische Bakteriologie, Virusforschung Und Parasitologie - Originale</SO>
<YR>1969</YR>
<VL>209</VL>
<NO>4</NO>
<PG>415-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huerta-2006" NAME="Huerta 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huerta M, Balicer RD, Mimouni D, Goldberg A, Furman MM, Klement E, et al</AU>
<TI>Validity of self-assessment of skin reaction after smallpox vaccination</TI>
<SO>Public Health Reports</SO>
<YR>2006</YR>
<VL>121</VL>
<NO>1</NO>
<PG>45-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karchmer-1971" NAME="Karchmer 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karchmer AW, Friedman JP, Casey HL, Shope TC, Riker JB, Kappelman MM, et al</AU>
<TI>Simultaneous administration of live virus vaccines. Measles, mumps, poliomyelitis, and smallpox</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1971</YR>
<VL>121</VL>
<NO>5</NO>
<PG>382-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kennedy-2004" NAME="Kennedy 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kennedy JS, Frey SE, Yan L, Rothman AL, Cruz J, Newman FK, et al</AU>
<TI>Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2004</YR>
<VL>190</VL>
<NO>7</NO>
<PG>1286-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khliabich-1978" NAME="Khliabich 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khliabich GN, Sumarokov AA, Ozeretskovskii NA, Karinskaia GA, Gurvich EB</AU>
<TI>Comparative study of smallpox vaccines from strains B-51, EM-63 and L-IVP in a controlled epidemiologic trial. I. Reactogenic characteristics of the smallpox vaccines</TI>
<SO>Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii</SO>
<YR>1978</YR>
<VL>8</VL>
<PG>20-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lelong-1952" NAME="Lelong 1952" YEAR="1952">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lelong M, Ramon J</AU>
<TI>Smallpox vaccination trials using a formalin vaccine</TI>
<SO>Presse Médicale</SO>
<YR>1952</YR>
<VL>60</VL>
<NO>13</NO>
<PG>265-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lev-1972" NAME="Lev 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lev MI, Sergeichik II, Kulikov IA</AU>
<TI>Comparative evaluation of the needleless, syringe and scarification methods of vaccination</TI>
<SO>Voenno-Meditsinskii Zhurnal</SO>
<YR>1972</YR>
<VL>9</VL>
<PG>955-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-1965" NAME="Lin 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin HT</AU>
<TI>A study of the effect of simultaneous vaccination with BCG and smallpox vaccine in newborn infants</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1965</YR>
<VL>33</VL>
<NO>3</NO>
<PG>321-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marennikova-1966" NAME="Marennikova 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marennikova SS, Tashpulatov GM</AU>
<TI>Comparative study of the inoculability, reactogenicity and antigenic activity of smallpox vaccines prepared from various strains (preliminary report)</TI>
<SO>Voprosy Virusologii</SO>
<YR>1966</YR>
<VL>11</VL>
<NO>3</NO>
<PG>266-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marennikova-1977" NAME="Marennikova 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marennikova SS, Matsevich GR, Sokolova AF, Shul'ga LG, Manenkova GM</AU>
<TI>Immunological characteristics of the 2-stage method of smallpox vaccination</TI>
<SO>Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii</SO>
<YR>1977</YR>
<VL>5</VL>
<PG>105-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-du-Pan-1966" NAME="Martin du Pan 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin du Pan R</AU>
<TI>Should one vaccinate against smallpox by scarification or multipuncture? Comparative study of 2 smallpox vaccines administered in 2 different ways</TI>
<SO>Pédiatrie</SO>
<YR>1966</YR>
<VL>21</VL>
<NO>3</NO>
<PG>299-309</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mel_x0027_nikov-2005" NAME="Mel'nikov 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mel'nikov SA, Podkuiko VN, Khamitov RA, Maksimov VA, Markov VI, Vorob'ev AA, et al</AU>
<TI>Clinical studies of vaccine TEOVac under the conditions of remote revaccination</TI>
<SO>Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii</SO>
<YR>2005</YR>
<VL>6</VL>
<PG>29-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer-1964" NAME="Meyer 1964" YEAR="1964">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer HM, Hostetler DD, Bernheim BC, Rogers NG, Lambin P, Chassary A, et al</AU>
<TI>Response of volta children to jet inoculation of combined live measles, smallpox and yellow fever vaccines</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1964</YR>
<VL>30</VL>
<PG>783-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mihailescu-1988" NAME="Mihailescu 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mihailescu R, Velea V, Chirescu N, Topciu V, Doroiu N</AU>
<TI>Immunogenic capacity of a fractionated lyophilized smallpox vaccine</TI>
<SO>Revista de Igiena, Bacteriologie, Virusologie, Parazitologie, Epidemiologie, Pneumoftiziologie</SO>
<YR>1988</YR>
<VL>33</VL>
<NO>1</NO>
<PG>35-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Millar-1969" NAME="Millar 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Millar JD, Roberto RR, Wulff H, Wenner HA, Henderson DA</AU>
<TI>Smallpox vaccination by intradermal jet injection. I. Introduction, background and results of pilot studies</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1969</YR>
<VL>41</VL>
<NO>6</NO>
<PG>749-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mobest-1974" NAME="Mobest 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mobest H</AU>
<TI>Analysis of the immunogenic effect of liquid and freeze-dried smallpox vaccine (as demonstrated in more than 20,000 persons vaccinated three times)</TI>
<SO>Zentralblatt für Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische Mikrobiologie und Parasitologie</SO>
<YR>1974</YR>
<VL>227</VL>
<NO>1-4</NO>
<PG>263-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murruzzu-1967" NAME="Murruzzu 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murruzzu I</AU>
<TI>Comparison of the 3 types of smallpox vaccines. (Ist. Sier. Milanese, Ist. Sier. Sclavo and Ist Sier. Berna)</TI>
<SO>Giornale di Batteriologia, Virologia ed Immunologia</SO>
<YR>1967</YR>
<VL>60</VL>
<NO>1</NO>
<PG>17-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nath-1970" NAME="Nath 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nath LM, Rao YS, Rao TM</AU>
<TI>A comparative study of the rotary lancet and bifurcate needle techniques of smallpox vaccination</TI>
<SO>Indian Journal of Medical Research</SO>
<YR>1970</YR>
<VL>58</VL>
<NO>3</NO>
<PG>388-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neff-1969" NAME="Neff 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neff JM, Millar JD, Roberto RR, Wulff H</AU>
<TI>Smallpox vaccination by intradermal jet injection. 3. Evaluation in a well vaccinated population</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1969</YR>
<VL>41</VL>
<NO>6</NO>
<PG>771-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nyerges-1968" NAME="Nyerges 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nyerges G, Hollos I, Losonczy G</AU>
<TI>Efficiency of smallpox revaccination repeated at three-year intervals. II. Comparative study of the international reference strain (Elstree) and the Hungarian vaccine strain (Budapest)</TI>
<SO>Acta Microbiologica Academiae Scientiarum Hungaricae</SO>
<YR>1968</YR>
<VL>15</VL>
<NO>3</NO>
<PG>187-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nyerges-1972" NAME="Nyerges 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nyerges G, Csukas M</AU>
<TI>Immunogenicity of smallpox vaccines prepared from strains of different reactogenicity</TI>
<SO>Acta Microbiologica Academiae Scientiarum Hungaricae</SO>
<YR>1972</YR>
<VL>19</VL>
<NO>2</NO>
<PG>103-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nyerges-1973" NAME="Nyerges 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nyerges G, Erdos L, Melly F</AU>
<TI>Smallpox vaccination immunity in relation to number of insertions</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1973</YR>
<VL>48</VL>
<NO>4</NO>
<PG>397-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pattanayak-1970" NAME="Pattanayak 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pattanayak S, Arora DD, Sehgal CL, Raghavan NG, Topa PK, Subrahmanyam YK</AU>
<TI>Comparative studies of smallpox vaccination by the bifurcated needle and rotary lancet techniques</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1970</YR>
<VL>42</VL>
<NO>2</NO>
<PG>305-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petersen-1966" NAME="Petersen 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petersen ES Norby G</AU>
<TI>A comparison between two techniques of smallpox vaccination</TI>
<SO>Danish Medical Bulletin</SO>
<YR>1966</YR>
<VL>13</VL>
<NO>6</NO>
<PG>168-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Podkuiko-1993" NAME="Podkuiko 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Podkuiko VN, Vorob'ev AA, Krasnianskii VP, Patrikeev GT, Mikhailov VV, Dorokhina TV, et al</AU>
<TI>Peroral immunization--a method for enhancing the safety of the recombinant vector (the vaccinia virus)</TI>
<SO>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk/Rossiiskaia Akademiia Meditsinskikh Nauk</SO>
<YR>1993</YR>
<VL>2</VL>
<PG>39-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roberto-1969" NAME="Roberto 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberto RR, Wulff H, Millar JD</AU>
<TI>Smallpox vaccination by intradermal jet injection. 2. Cutaneous and serological responses to primary vaccination in children</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1969</YR>
<VL>41</VL>
<NO>6</NO>
<PG>761-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sergeev-2004" NAME="Sergeev 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sergeev AA, Sergeev AN, Petrishchenko VA, Shishkina LN, Kochneva GV, Zhukov VA, et al</AU>
<TI>Reactogenicity, safety and immunogenicity of a recombinant bivaccine against smallpox and hepatitis B in limited clinical trials</TI>
<SO>Voprosy Virusologii</SO>
<YR>2004</YR>
<VL>49</VL>
<NO>5</NO>
<PG>22-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sherman-1967" NAME="Sherman 1967" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sherman PM, Hendrickse RG, Montefiore D, Peradze T, Coker G</AU>
<TI>Simultaneous administration of live measles virus vaccine and smallpox vaccine</TI>
<SO>British Medical Journal</SO>
<YR>1967</YR>
<VL>2</VL>
<NO>553</NO>
<PG>672-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shinozaki-1969" NAME="Shinozaki 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shinozaki T</AU>
<TI>Study of postvaccinal changes in blood antibodies. 4. Comparison of inoculation reactions using classic, standard and low toxic strains</TI>
<SO>Nippon Shonika Gakkai Zasshi. Acta Paediatrica Japonica</SO>
<YR>1969</YR>
<VL>73</VL>
<NO>4</NO>
<PG>497-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Snell-1965" NAME="Snell 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Snell PH</AU>
<TI>A comparison of two methods of vaccination against smallpox in Nigeria</TI>
<SO>West African Medical Journal</SO>
<YR>1965</YR>
<VL>14</VL>
<NO>6</NO>
<PG>233-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tauraso-1972" NAME="Tauraso 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tauraso NM, Myers MG, Nau EV, O'Brien TC, Spindel SS, Trimmer RW</AU>
<TI>Effect of interval between inoculation of live smallpox and yellow-fever vaccines on antigenicity in man</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1972</YR>
<VL>126</VL>
<NO>4</NO>
<PG>362-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Unanov-1966" NAME="Unanov 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Unanov SS, Marennikova SS, Akatova EM, Gurvich EB, Kantsova TI, Mal'tseva NN, et al</AU>
<TI>Comparative evaluation of smallpox vaccines</TI>
<SO>Voprosy Virusologii</SO>
<YR>1966</YR>
<VL>11</VL>
<NO>5</NO>
<PG>519-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaughan-1972" NAME="Vaughan 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaughan JP, Lindqvist K, Brooke D, Doyle RF</AU>
<TI>Combined BCG and smallpox immunization: a preliminary report on a method using the W.H.O. bifurcated needle</TI>
<SO>East African Medical Journal</SO>
<YR>1972</YR>
<VL>49</VL>
<NO>3</NO>
<PG>207-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaughan-1973" NAME="Vaughan 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaughan JP, Menu JP, Lindqvist KJ, Vennema A</AU>
<TI>A trial with a mixed BCG/smallpox vaccine given intradermally</TI>
<SO>Journal of Tropical Medicine and Hygiene</SO>
<YR>1973</YR>
<VL>76</VL>
<NO>10</NO>
<PG>262-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vollmar-2006" NAME="Vollmar 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, et al</AU>
<TI>Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine</TI>
<SO>Vaccine</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>12</NO>
<PG>2065-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waibel-2004" NAME="Waibel 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waibel KH, Ager EP, Topolski RL, Walsh DS</AU>
<TI>Randomized trial comparing vaccinia on the external surfaces of 3 conventional bandages applied to smallpox vaccination sites in primary vaccinees</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>7</NO>
<PG>1004-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waibel-2006" NAME="Waibel 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waibel KH, Golding H, Manischewitz J, King LR, Tuchscherer M, Topolski RL, et al</AU>
<TI>Clinical and immunological comparison of smallpox vaccine administered to the outer versus the inner upper arms of vaccinia-naive adults</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2006</YR>
<VL>42</VL>
<NO>4</NO>
<PG>e16-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wesley-1975" NAME="Wesley 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wesley RB, Speers WC, Neff JM, Ruben FL, Lourie B</AU>
<TI>Evaluation of two kinds of smallpox vaccine: CVI-78 and calf lymph vaccine. I. Clinical and serologic response to primary vaccination</TI>
<SO>Pediatric Research</SO>
<YR>1975</YR>
<VL>9</VL>
<NO>8</NO>
<PG>624-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2008-11-08 17:29:49 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Acambis_x002d_a" MODIFIED="2008-11-08 17:28:46 +0000" MODIFIED_BY="[Empty name]" NAME="Acambis-a" YEAR="2003">
<REFERENCE MODIFIED="2008-11-08 17:28:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Acambis</AU>
<TI>Effect of dose on safety, tolerability, and immunogenicity of ACAM2000 smallpox vaccine in adults with previous smallpox vaccination</TI>
<SO>www.clinicaltrials.gov NCT00053482</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="H-400-003"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Acambis_x002d_b" NAME="Acambis-b" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Acambis</AU>
<TI>Effect of dose on safety, tolerability, and immunogenicity of ACAM2000 smallpox vaccine in adults without previous smallpox vaccination</TI>
<SO>www.clinicaltrials.gov NCT00053495</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="H-400-005"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Acambis_x002d_c" NAME="Acambis-c" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Acambis</AU>
<TI>Dose safety, tolerability, and immunogenicity of ACAM1000 smallpox vaccine in adults without previous smallpox vaccination</TI>
<SO>www.clinicaltrials.gov NCT00053508</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="H-300-002"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Acambis_x002d_d" MODIFIED="2008-11-08 17:28:53 +0000" MODIFIED_BY="[Empty name]" NAME="Acambis-d" YEAR="2004">
<REFERENCE MODIFIED="2008-11-08 17:28:53 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Paul S Blum, Study Director, Acambis&lt;/p&gt;" NOTES_MODIFIED="2008-11-08 17:28:53 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Acambis</AU>
<TI>Safety, tolerability, and immune response of ACAM3000 Modified Vaccinia Ankara (MVA) smallpox vaccine in adults</TI>
<SO>www.clinicaltrials.gov NCT00079820</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="H-249-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Acambis_x002d_e" MODIFIED="2008-11-08 17:28:57 +0000" MODIFIED_BY="[Empty name]" NAME="Acambis-e" YEAR="2006">
<REFERENCE MODIFIED="2008-11-08 17:28:57 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Contact: Matt Desmond &lt;br&gt;617-761-4200 &lt;br&gt;matt.desmond@acambis.com&lt;/p&gt;" NOTES_MODIFIED="2008-11-08 17:28:57 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Acambis</AU>
<TI>Safety study of MVA smallpox vaccine in HIV-positive subjects who are vaccinia naive</TI>
<SO>www.clinicaltrials.gov NCT00282581</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="H-249-004"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Acambis_x002d_f" MODIFIED="2008-11-08 17:29:00 +0000" MODIFIED_BY="[Empty name]" NAME="Acambis-f" YEAR="2006">
<REFERENCE MODIFIED="2008-11-08 17:29:00 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Acambis website&lt;/p&gt;" NOTES_MODIFIED="2008-11-08 17:29:00 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Acambis</AU>
<TI>Safety study of MVA smallpox vaccine in subjects with a history of atopic dermatitis (AD)</TI>
<SO>www.clinicaltrials.gov NCT003389103</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="H-249-005"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bavarian-Nordic_x002d_a" NAME="Bavarian Nordic-a" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Collaborators: NIAID&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Bavarian Nordic</AU>
<TI>Safety, tolerability and immune response of IMVAMUNE (MVA-BN) smallpox vaccine in HIV infected patients</TI>
<SO>www.clinicaltrials.gov NCT00189904</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="POX-MVA-010; HHSN266200400072C"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bavarian-Nordic_x002d_b" NAME="Bavarian Nordic-b" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Collaborators: NIAID&lt;br&gt;Principal investigator: Frank von Sonnenburg, Department of Infectious Diseases and Tropical Medicine of the University of Munch&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Bavarian Nordic</AU>
<TI>Safety, tolerability and immune response of IMVAMUNE (MVA-BN®) smallpox vaccine in patients with atopic disorders</TI>
<SO>www.clinicaltrials.gov NCT00189917</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="POX-MVA-007; NIH NO1-AI-30016"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bavarian-Nordic_x002d_c" NAME="Bavarian Nordic-c" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Karl M Eckl, Principal Investigator, PharmPlanNet Contact Research GmbH&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Bavarian Nordic</AU>
<TI>Study on safety, tolerability and immunogenicity of an MVA-BN vaccine administered to healthy subjects</TI>
<SO>www.clinicaltrials.gov NCT00189943</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MVA-POX-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bavarian-Nordic_x002d_d" NAME="Bavarian Nordic-d" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Collaborators: NIAID&lt;br&gt;Rolf Pokorny. Principal Investigator, Swiss Pharma&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Bavarian Nordic</AU>
<TI>Dose-finding study to evaluate the immunogenicity of three different dose levels of the IMVAMUNE (MVA-BN) smallpox vaccine</TI>
<SO>www.clinicaltrials.gov NCT00189956</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="POX-MVA-004; NIH N01-AI-30016"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bavarian-Nordic_x002d_e" NAME="Bavarian Nordic-e" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Andreas Schroedter, Principal Investigator, Focus Clinical Drug Development GmbH, Neuss, Nordrhein, 41460, Germany&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Bavarian Nordic</AU>
<TI>Take rate, immunogenicity and safety of Elstree-BN smallpox vaccine in healthy vaccinia-naive subjects</TI>
<SO>www.clinicaltrials.gov NCT00189969</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="POX-ELS-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bavarian-Nordic_x002d_f" MODIFIED="2008-11-08 17:29:11 +0000" MODIFIED_BY="[Empty name]" NAME="Bavarian Nordic-f" YEAR="2006">
<REFERENCE MODIFIED="2008-11-08 17:29:11 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Nadine Uebler +49-89-8565 Ext. 1323 nadine.uebler@bavarian-nordic.com&lt;/p&gt;" NOTES_MODIFIED="2008-11-08 17:29:11 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bavarian Nordic</AU>
<TI>A randomized, double-blind, placebo-controlled study on immunogenicity and safety of MVA-BN® (IMVAMUNE&#8482;) smallpox vaccine in healthy subjects</TI>
<SO>www.clinicaltrials.gov NCT00316524</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="POX-MVA-004; DMID 05-0128; EudraCT No. 2005-001781-14"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bavarian-Nordic_x002d_g" NAME="Bavarian Nordic-g" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;Collaborators: NIH&lt;br&gt;Edgar Turner Overton, Principal Investigator, Washington University, St. Louis&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Bavarian Nordic</AU>
<TI>Safety and immunogenicity of MVA-BN® (IMVAMUNE) smallpox vaccine in HIV infected patients</TI>
<SO>www.clinicaltrials.gov NCT00316589</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="POX-MVA-011"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bavarian-Nordic_x002d_h" MODIFIED="2008-11-08 17:29:19 +0000" MODIFIED_BY="[Empty name]" NAME="Bavarian Nordic-h" YEAR="2006">
<REFERENCE MODIFIED="2008-11-08 17:29:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Collaborators: NIAID&lt;br&gt;Richard N Greenberg, Principal Investigator, University of Kentucky School of Medicine&lt;/p&gt;" NOTES_MODIFIED="2008-11-08 17:29:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bavarian Nordic</AU>
<TI>A Phase II study on immunogenicity and safety of MVA-BN® (IMVAMUNE&#8482;) smallpox vaccine in subjects with atopic dermatitis</TI>
<SO>www.clinicaltrials.gov NCT00316602</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="POX-MVA-008; DMID 05-0133"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bristol_x002d_Myers-Squibb" NAME="Bristol-Myers Squibb" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Bristol-Myers Squibb Co, Wallingford, Connecticut 064927600, USA&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Bristol-Myers Squibb</AU>
<TI>A comparative Phase I clinical study of HIVAC-1e and smallpox (vaccinia) vaccines in previously (vaccinia) vaccinated and unvaccinated volunteers</TI>
<SO>www.clinicaltrials.gov NCT00002261</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="063A; A1452-003001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DynPort" NAME="DynPort" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;University of Kentucky Medical Center, Lexington, Kentucky, 40536-0084, USA&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>DynPort Vaccine Company</AU>
<TI>Study of reactogenicity, safety, immunogenicity, and pock lesion formation of a cell-cultured smallpox vaccine compared to Dryvax®</TI>
<SO>www.clinicaltrials.gov NCT00042094</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SMPX-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NIAID_x002d_a" NAME="NIAID-a" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Keefer M, Study chair&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>National Institute of Allergy and Infectious Diseases</AU>
<TI>A multicenter, randomized, placebo-controlled, double-blind trial to evaluate the safety and immunogenicity of a recombinant vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)</TI>
<SO>www.clinicaltrials.gov NCT00000767</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="AVEG 014 A/B"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NIAID_x002d_b" NAME="NIAID-b" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>National Institute of Allergy and Infectious Diseases</AU>
<TI>Dryvax dilution - prev vacc adults (dose response study of Dryvax vaccine against smallpox in previously vaccinated adults)</TI>
<SO>www.clinicaltrials.gov NCT00032708</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NIAID_x002d_c" NAME="NIAID-c" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>National Institute of Allergy and Infectious Diseases</AU>
<TI>Vaccinia virus vaccine (APSV) in vaccinia-naive subjects: PILOT (Safety and preliminary efficacy of various concentrations of Aventis Pasteur's smallpox vaccine, USP (APSV) in vaccinia-naive adults)</TI>
<SO>www.clinicaltrials.gov NCT00038987</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="02-009"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NIAID_x002d_d" NAME="NIAID-d" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>National Institute of Allergy and Infectious Diseases</AU>
<TI>Dryvax seropositives #2 (Expanded Trial) (dose-response study of Dryvax vaccine against smallpox in previously vaccinated adults)</TI>
<SO>www.clinicaltrials.gov NCT00050505</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="02-007"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NIAID_x002d_e" NAME="NIAID-e" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>National Institute of Allergy and Infectious Diseases</AU>
<TI>APSV in vaccinia-naive adults</TI>
<SO>www.clinicaltrials.gov NCT00050518</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="02-054"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NIAID_x002d_g" NAME="NIAID-g" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Vanderbilt University, Nashville, Tennessee, 37232, USA&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>National Institute of Allergy and Infectious Diseases</AU>
<TI>Dressing preparations for smallpox (A comparison of dressing preparations for smallpox vaccination sites with a focus upon the risk of secondary transmission of vaccinia virus)</TI>
<SO>www.clinicaltrials.gov NCT00063856</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="03-044"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NIAID_x002d_h" NAME="NIAID-h" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;University of Rochester School of Medicine, Rochester, New York 14642, USA&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>National Institute of Allergy and Infectious Diseases</AU>
<TI>Human immune responses smallpox (evaluation of human immune response to smallpox vaccine (vaccinia virus)</TI>
<SO>www.clinicaltrials.gov NCT00068198</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="02-067"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NIAID_x002d_i" MODIFIED="2008-11-08 17:29:29 +0000" MODIFIED_BY="[Empty name]" NAME="NIAID-i" YEAR="2004">
<REFERENCE MODIFIED="2008-11-08 17:29:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>National Institute of Allergy and Infectious Diseases</AU>
<TI>Combination study with MVA BN and Dryvax (safety and immunogenicity of MVA-BN in a dose response regimen followed by administration of Dryvax)</TI>
<SO>www.clinicaltrials.gov NCT00082446</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="02-017; POX-MVA-002"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NIAID_x002d_j" MODIFIED="2008-11-08 17:29:32 +0000" MODIFIED_BY="[Empty name]" NAME="NIAID-j" YEAR="2005">
<REFERENCE MODIFIED="2008-11-08 17:29:32 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Lindsey Baden (617) 732-6801 lbaden@partners.org&lt;/p&gt;" NOTES_MODIFIED="2008-11-08 17:29:32 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>National Institute of Allergy and Infectious Diseases</AU>
<TI>ACAM 3000 MVA at Harvard Medical School (Acambis Modified Vaccinia Ankara) immunization followed by Dryvax vaccination of healthy vaccinia-naïve adults)</TI>
<SO>www.clinicaltrials.gov NCT00133575</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="05-0010"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NIAID_x002d_k" MODIFIED="2008-11-08 17:29:35 +0000" MODIFIED_BY="[Empty name]" NAME="NIAID-k" YEAR="2005">
<REFERENCE MODIFIED="2008-11-08 17:29:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>National Institute of Allergy and Infectious Diseases</AU>
<TI>Phase II dose finding study of Acambis MVA smallpox vaccine</TI>
<SO>www.clinicaltrials.gov NCT00170651</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="05-0058; H-249-002"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NIAID_x002d_l" NAME="NIAID-l" YEAR="2007">
<REFERENCE NOTES="&lt;p&gt;Sharon E Frey (317) 577-8648&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>National Institute of Allergy and Infectious Diseases</AU>
<TI>MVA post-event: dosage level and boost study (evaluation of IMVAMUNE® smallpox vaccine with respect to safety and optimization of immune responses by administration timing, dose level administered, and subsequent boost with Dryvax® smallpox vaccine in vaccinia naive adults)</TI>
<SO>www.clinicaltrials.gov NCT00437021</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="06-0012; POX-MVA-009"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NIAID_x002d_m" NAME="NIAID-m" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Publications:&lt;br&gt;Sittelaar KJ...Vaccine 2001;19(27):V-VI.&lt;br&gt;Henderson DA...JAMA 1999;281(22):2127-37.&lt;br&gt;Henderson DA.The looming threat of bioterroism. Science 1999;283(5406):1279-82.&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>National Institute of Allergy and Infectious Diseases</AU>
<TI>Phase I trial of smallpox vaccine (A Phase I/II clinical trial of Modified Vaccinia Virus Ankara (MVA) to evaluate its safety, dosing schedule, immunogenicity and protective efficacy against Dryvax challenge in vaccinia-naive individuals)</TI>
<SO>www.clinicaltrials.gov NCT00046397</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="020316; 02-I-0316"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NIAID_x002d_n" NAME="NIAID-n" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Sponsored by NIAID&lt;br&gt;Publications:&lt;br&gt;Sittelaar KJ...Vaccine 2001;19(27):V-VI.&lt;br&gt;Henderson DA...JAMA 1999;281(22):2127-37.&lt;br&gt;Henderson DA.The looming threat of bioterroism. Science 1999;283(5406):1279-82.&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>National Institutes of Health Clinical Center</AU>
<TI>Phase I/II trial of modified vaccinia virus Ankara (MVA) vaccine against smallpox</TI>
<SO>www.clinicaltrials.gov NCT00053742</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="030087; 03-I-0087"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NIAID_x002d_o" NAME="NIAID-o" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Sponsored by NIAID&lt;br&gt;Contact: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland 20892, USA&lt;br&gt;NIH Clinical Center web page&lt;br&gt;Publication:&lt;br&gt;Mathew A, Ennis FA, Rothman AL. Transient decreases in human Tcell proliferative responses following vaccinia immunization. Clin.Immunol. 2000;96(2):100-7&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>National Institutes of Health Clinical Center</AU>
<TI>Immune responses to smallpox vaccination</TI>
<SO>www.clinicaltrials.gov NCT00325975</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="030090; 03-I-0090"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanofi_x002d_Aventis" MODIFIED="2008-11-08 17:29:43 +0000" MODIFIED_BY="[Empty name]" NAME="Sanofi-Aventis" YEAR="2005">
<REFERENCE MODIFIED="2008-11-08 17:29:43 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;www.sanofipasteur.com; www.sanofiaventis.com&lt;/p&gt;" NOTES_MODIFIED="2008-11-08 17:29:43 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sanofi-Aventis</AU>
<TI>Evaluation of take and safety of a smallpox vaccine in healthy young adults</TI>
<SO>www.clinicaltrials.gov NCT00258947</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="VVL04"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seoul-NU" MODIFIED="2008-11-08 17:29:46 +0000" MODIFIED_BY="[Empty name]" NAME="Seoul NU" YEAR="2006">
<REFERENCE MODIFIED="2008-11-08 17:29:46 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Myoung-don Oh, Study Chair, Seoul National University Hospital, Seoul 110-744, Republic of Korea&lt;br&gt;82-2-2072-2945 mdohmd@snu.ac.kr&lt;br&gt;Sung-Han Kim 82-2-2072-2957 kimsunghanmd@hotmail.com&lt;/p&gt;" NOTES_MODIFIED="2008-11-08 17:29:46 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Seoul National University Hospital</AU>
<TI>Safety and imunogenicity of CJ-50300</TI>
<SO>www.clinicaltrials.gov NCT00336635</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CP_SPX_101"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VaxGen" MODIFIED="2008-11-08 17:29:49 +0000" MODIFIED_BY="[Empty name]" NAME="VaxGen" YEAR="2004">
<REFERENCE MODIFIED="2008-11-08 17:29:49 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Marc Gurwith, Study Director, VaxGen&lt;/p&gt;" NOTES_MODIFIED="2008-11-08 17:29:49 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>VaxGen</AU>
<TI>Safety and immunogenicity of LC16m8, a modified vaccinia vaccine, in healthy, previously unvaccinated volunteers</TI>
<SO>www.clinicaltrials.gov NCT00103584</SO>
<YR>(accessed 23 February 2007)</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="VAX012"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-08 17:15:03 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-08 17:15:03 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aragon-2003" NAME="Aragon 2003" TYPE="JOURNAL_ARTICLE">
<AU>Aragón TJ, Ulrich S, Fernyak S, Rutherford GW</AU>
<TI>Risks of serious complications and death from smallpox vaccination: A systematic review of the United States experience, 1963&#8211;1968</TI>
<SO>BMC Public Health</SO>
<YR>2003</YR>
<VL>3</VL>
<PG>26</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="DOI: 10.1186/1471-2458-3-26"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Arness-2004" NAME="Arness 2004" TYPE="JOURNAL_ARTICLE">
<AU>Arness MK, Eckart RE, Love SS, Atwood JE, Wells TS, Engler RJ, et al</AU>
<TI>Myocarditis following smallpox vaccination</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2004</YR>
<VL>160</VL>
<NO>7</NO>
<PG>642-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bicknell-2002" MODIFIED="2008-08-22 14:52:01 +0100" MODIFIED_BY="[Empty name]" NAME="Bicknell 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bicknell WJ</AU>
<TI>The case for voluntary smallpox vaccination</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<NO>17</NO>
<PG>1323-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brighton-2004" NAME="Brighton 2004" TYPE="OTHER">
<AU>Brighton Collaboration</AU>
<TI>Definitions &amp; guidelines</TI>
<SO>brightoncollaboration.org/en/index/aefi.html</SO>
<YR>(accessed 6 April 2004)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CDC-2006" NAME="CDC 2006" TYPE="OTHER">
<AU>Centers for Disease Control and Prevention</AU>
<TI>Smallpox fact sheet</TI>
<SO>www.bt.cdc.gov/agent/smallpox/vaccination/facts.asp</SO>
<YR>21 February 2006 (accessed 11 January 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Drexler-2003" MODIFIED="2008-08-22 14:52:10 +0100" MODIFIED_BY="[Empty name]" NAME="Drexler 2003" TYPE="JOURNAL_ARTICLE">
<AU>Drexler I, Staib C, Kastenmuller W, Stevanovic S, Schmidt B, Lemonnier FA, et al</AU>
<TI>Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>2003</YR>
<VL>100</VL>
<NO>1</NO>
<PG>217-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="22"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fenner-1988" NAME="Fenner 1988" TYPE="BOOK">
<AU>Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID</AU>
<SO>Smallpox and its eradication</SO>
<YR>1988</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Frey-2002c" NAME="Frey 2002c" TYPE="JOURNAL_ARTICLE">
<AU>Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, Newman FK, et al; National Institute of Allergy and Infectious Diseases Smallpox Vaccine Study Group</AU>
<TI>Clinical responses to undiluted and diluted smallpox vaccine</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<NO>17</NO>
<PG>1265-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grabenstein-2003" NAME="Grabenstein 2003" TYPE="JOURNAL_ARTICLE">
<AU>Grabenstein JD, Winkenwerder W Jr</AU>
<TI>US military smallpox vaccination program experience</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>24</NO>
<PG>3278-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henderson-1999a" MODIFIED="2008-08-22 14:52:21 +0100" MODIFIED_BY="[Empty name]" NAME="Henderson 1999a" TYPE="JOURNAL_ARTICLE">
<AU>Henderson DA</AU>
<TI>Smallpox: clinical and epidemiologic features</TI>
<SO>Emerging Infectious Diseases</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>4</NO>
<PG>537-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henderson-1999b" MODIFIED="2008-08-22 14:52:19 +0100" MODIFIED_BY="[Empty name]" NAME="Henderson 1999b" TYPE="JOURNAL_ARTICLE">
<AU>Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, et al</AU>
<TI>Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>281</VL>
<NO>22</NO>
<PG>2127-37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="13"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henderson-2001" MODIFIED="2008-08-22 14:52:26 +0100" MODIFIED_BY="[Empty name]" NAME="Henderson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Henderson DA, Fenner F</AU>
<TI>Recent events and observations pertaining to smallpox virus destruction in 2002</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>7</NO>
<PG>1057-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" NAME="Higgins 2006" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Appendix 5b</TI>
<SO>www.cochrane.org/resources/ handbook/hbook.htm</SO>
<YR>(accessed 1 December 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hopkins-1988" MODIFIED="2008-08-22 14:52:29 +0100" MODIFIED_BY="[Empty name]" NAME="Hopkins 1988" TYPE="JOURNAL_ARTICLE">
<AU>Hopkins JW</AU>
<TI>The eradication of smallpox: organizational learning and innovation in international health administration</TI>
<SO>Journal of Developing Areas</SO>
<YR>1988</YR>
<VL>22</VL>
<NO>3</NO>
<PG>321-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-HRSA-2006" NAME="HRSA 2006" TYPE="JOURNAL_ARTICLE">
<AU>Health Resources and Services Adminstration</AU>
<TI>Smallpox Vaccine Injury Compensation Program: Administrative implementation</TI>
<SO>Federal Register</SO>
<YR>2006</YR>
<VL>71</VL>
<NO>100</NO>
<PG>29805-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" MODIFIED="2008-11-08 17:14:48 +0000" MODIFIED_BY="[Empty name]" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kenner-2006" NAME="Kenner 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M</AU>
<TI>LC16m8: an attenuated smallpox vaccine</TI>
<SO>Vaccine</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>47-48</NO>
<PG>7009-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kretschmar-2006" NAME="Kretschmar 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kretschmmar M, Walling J, Teunis P, Xing S, Mikolajczyk R</AU>
<TI>Frequency of adverse events after vaccination with different vaccinia strains</TI>
<SO>PLoS Medicine</SO>
<YR>2006</YR>
<VL>3</VL>
<NO>8</NO>
<PG>e272</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lane-1970a" MODIFIED="2008-08-22 14:52:33 +0100" MODIFIED_BY="[Empty name]" NAME="Lane 1970a" TYPE="JOURNAL_ARTICLE">
<AU>Lane JM, Ruben FL, Neff JM, Millar JD</AU>
<TI>Complications of smallpox vaccination, 1968: results of ten statewide surveys</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1970a</YR>
<VL>122</VL>
<NO>4</NO>
<PG>303-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lane-1970b" MODIFIED="2008-08-22 14:52:35 +0100" MODIFIED_BY="[Empty name]" NAME="Lane 1970b" TYPE="JOURNAL_ARTICLE">
<AU>Lane JM, Ruben FL, Abrutyn E, Millar JD</AU>
<TI>Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968</TI>
<SO>JAMA</SO>
<YR>1970b</YR>
<VL>212</VL>
<NO>3</NO>
<PG>441-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lane-2003" NAME="Lane 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lane MJ, Goldstein J</AU>
<TI>Evaluation of 21st-century risks of smallpox vaccination and policy options</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2003</YR>
<VL>138</VL>
<NO>6</NO>
<PG>488-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MMWR-2003" MODIFIED="2008-08-22 14:52:37 +0100" MODIFIED_BY="[Empty name]" NAME="MMWR 2003" TYPE="JOURNAL_ARTICLE">
<AU>Centers for Disease Control and Prevention</AU>
<TI>Smallpox vaccine adverse events monitoring and response system for the first stage of the smallpox vaccination program</TI>
<SO>MMWR</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>5</NO>
<PG>88-9, 99</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-MMWR-2006" NAME="MMWR 2006" TYPE="JOURNAL_ARTICLE">
<AU>Casey C, Vellozzi C, Mootrey GT, Chapman LE, McCauly M, Roper MH, et al; Vaccinia Case Definition Development Working Group; Advisory Committee on Immunization Practices-Armed Forces Epidemiological Board Smallpox Vaccine Safety Working Group</AU>
<TI>Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions</TI>
<SO>MMWR</SO>
<YR>2006</YR>
<VL>55</VL>
<NO>RR-1</NO>
<PG>1-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neff-2002" MODIFIED="2008-08-22 14:52:41 +0100" MODIFIED_BY="[Empty name]" NAME="Neff 2002" TYPE="JOURNAL_ARTICLE">
<AU>Neff JM, Lane JM, Fulginiti VA, Henderson DA</AU>
<TI>Contact vaccinia--transmission of vaccinia from smallpox vaccination</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<NO>15</NO>
<PG>1901-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Poland-2005a" NAME="Poland 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Poland GA, Grabenstein JD, Neff M</AU>
<TI>The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program</TI>
<SO>Vaccine</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>17-18</NO>
<PG>2078-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poland-2005b" NAME="Poland 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Poland GA</AU>
<TI>Smallpox vaccines: from first to second to third generation</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<NO>9457</NO>
<PG>362-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prentice-1989" NAME="Prentice 1989" TYPE="JOURNAL_ARTICLE">
<AU>Prentice RL</AU>
<TI>Surrogate endpoints in clinical trials: definition and operational criteria</TI>
<SO>Statistics in Medicine</SO>
<YR>1989</YR>
<VL>8</VL>
<NO>4</NO>
<PG>431-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-5" MODIFIED="2008-11-08 17:15:03 +0000" MODIFIED_BY="[Empty name]" NAME="Review Manager 5" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sejvar-2005" NAME="Sejvar 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sejvar J, Boneva R, Lane JM, Iskander J</AU>
<TI>Severe headaches following smallpox vaccination</TI>
<SO>Headache</SO>
<YR>2005</YR>
<VL>45</VL>
<NO>1</NO>
<PG>87-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1980" NAME="WHO 1980" TYPE="JOURNAL_ARTICLE">
<AU>WHO</AU>
<TI>Declaration of global eradication of smallpox</TI>
<SO>Weekly Epidemiological Record</SO>
<YR>1980</YR>
<VL>55</VL>
<PG>145-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiser-2007" NAME="Wiser 2007" TYPE="JOURNAL_ARTICLE">
<AU>Wiser I, Balicer RD, Cohen D</AU>
<TI>An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies</TI>
<SO>Vaccine</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>6</NO>
<PG>976-84</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-08 17:23:56 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-11-08 17:21:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Artenstein-2005">
<CHAR_METHODS MODIFIED="2008-08-22 14:41:42 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: not described</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: double (participants and investigators)</P>
<P>Inclusion of all randomized participants: adequate; none lost to follow up or withdrew, see 'Participants'</P>
<P>Length of follow up: 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-08 17:20:40 +0000" MODIFIED_BY="[Empty name]">
<P>Number: 656 screened and 353 enrolled; 5 participants excluded from antibody or efficacy analysis (reason: baseline seropositivity or study assessment not performed or outside of allowable window)</P>
<P>Inclusion criteria: healthy adults; 18 to 29 years; women of childbearing potential utilized combined hormonal contraception or an intrauterine device for at least 30 days before screening</P>
<P>Exclusion criteria: military service before 1989; human immunodeficiency virus (HIV) infection; immunosuppression; renal disease; history of atopic dermatitis; open wound or burn; laboratory abnormalities indicating significant organ dysfunction or infection; allergy to latex or the antibiotics present in Dryvax and ACAM2000; hepatitis C seropositivity; hepatitis B surface antigenemia; blood product transfusion within previous 6 months; and household or intimate exposures to pregnant women, immunosuppressed persons, persons with atopic dermatitis, or infants aged 1 year or less; based on previously unsuspected findings of cardiac complications that occurred during the concurrent US Centers for Disease and Prevention (CDC) smallpox vaccination programme using Dryvax, exclusion criteria amended to include known cardiac disease<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>ACAM2000:<BR/>1. Undiluted<BR/>2. Dilution 1:5<BR/>3. Dilution 1:10<BR/>4. Dilution 1:20</P>
<P>Dryvax:<BR/>5. Undiluted<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-08 17:21:40 +0000" MODIFIED_BY="[Empty name]">
<P>1. Success rate<BR/>2. Humoral response (50% plaque-forming units (PFU) reduction)<BR/>3. Adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Location: USA<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-08 17:23:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frey-2002a">
<CHAR_METHODS MODIFIED="2008-08-22 14:42:32 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: not described</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: single (participants)</P>
<P>Inclusion of all randomized participants: adequate; see 'Participants'</P>
<P>Length of follow up: 56 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-08 17:20:49 +0000" MODIFIED_BY="[Empty name]">
<P>Number: 680 enrolled and vaccinated; 665 developed a positive reaction ("take") at vaccination site and this number (665) used in trial report as denominator of analysis of adverse events</P>
<P>Inclusion criteria: healthy adults aged 18 to 32 years</P>
<P>Exclusion criteria: vaccinia scar; vaccinia vaccination; human immunodeficiency virus (HIV)-AB; vaccination contraindications according to package insert (ie pregnancy, immunosuppression, and eczema), and protocol-specified (history of live-attenuated virus vaccination within 60 days before trial, receipt of blood products or immunoglobulin within 6 months before trial, household contact, sexual contact, or occupational exposure to someone with 1 or more of exclusion criteria listed in package insert); contact with infants &lt; 12 months<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-08 17:23:07 +0000" MODIFIED_BY="[Empty name]">
<P>Dryvax smallpox vaccine:<BR/>1. Undiluted (10<SUP>8.1</SUP> plaque-forming units (PFU)/mL)<BR/>2. Dilution 1:5<BR/>3. Dilution 1:10<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Success rate <BR/>2. Humoral response (60% PFU reduction) and cellular response <BR/>3. Adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Location: USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-08 17:23:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frey-2002b">
<CHAR_METHODS MODIFIED="2008-08-22 14:42:46 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: not described</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: double (participants and investigators)</P>
<P>Inclusion of all randomized participants: adequate; see 'Participants'</P>
<P>Length of follow up: 12 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-08 17:20:58 +0000" MODIFIED_BY="[Empty name]">
<P>Number: 60 enrolled; 1 withdrew for reasons unrelated to study; 55 provided blood samples 1 year after the study</P>
<P>Inclusion criteria: healthy adults aged 18 to 30 years</P>
<P>Exclusion criteria: vaccinia scar; vaccinia vaccination; HbS-AB; HepC-AB; human immunodeficiency virus (HIV)-AB; vaccination contraindications according to package insert (ie pregnancy, immunosuppression, and eczema) and protocol-specified (ie history of live-attenuated virus vaccination within 60 days before trial, receipt of blood products or immune globulin within 6 months before study, and household contact, sexual contact, or occupational exposure to pregnant women, immunosuppressed persons, persons with eczema, or infants &lt; 12 months)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-08 17:23:13 +0000" MODIFIED_BY="[Empty name]">
<P>Dryvax smallpox vaccine:<BR/>2. Undiluted (10<SUP>7.8</SUP> plaque-forming units (PFU)/mL)<BR/>2. Dilution 1:10<BR/>3. Dilution 1:100<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Success rate <BR/>2. Humoral response (60% PFU reduction) and cellular response <BR/>3. Adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Location: USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-08 17:23:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frey-2003">
<CHAR_METHODS MODIFIED="2008-08-22 14:42:57 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: not described</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: single (participants)</P>
<P>Inclusion of all randomized participants: adequate; see 'Participants'</P>
<P>Length of follow up: 6 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-22 14:43:01 +0100" MODIFIED_BY="[Empty name]">
<P>Number: 90 (80 vaccinia non-naive volunteers, 10 vaccinia naive volunteers) enrolled; 64/80 developed a positive reaction ("take") at vaccination site, and this number (64) used in the article as denominator of analysis of adverse events</P>
<P>Inclusion criteria: healthy adults; 32 to 60 years; smallpox vaccination before 1971 and typical vaccinia scar or documentation</P>
<P>Exclusion criteria: allergies to vaccine components, vaccinia immunoglobulin, cidofovir, probenecid, or allergies to vaccine components, vaccinia Ig, cidofovir, probenecid, or contraindications according to package insert (ie pregnancy, immunosuppression, and eczema) and protocol-specified (history of live-attenuated virus vaccination within 60 days before trial, receipt of blood products or immunoglobulin within 6 months before study, household contact, sexual contact, or occupational exposure to someone with 1 or more of exclusion criteria listed in package insert); contact with infants &lt; 12 months<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-08 17:23:17 +0000" MODIFIED_BY="[Empty name]">
<P>Dryvax smallpox vaccine<BR/>1. Undiluted (10<SUP>7.5</SUP> plaque-forming units (PFU)/mL)<BR/>2. Dilution 1:3.2<BR/>3. Dilution 1:10<BR/>4. Dilution 1:32<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Success rate <BR/>2. Humoral response (60% PFU reduction) <BR/>3. Adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Location: USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-08 17:23:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greenberg-2005">
<CHAR_METHODS MODIFIED="2008-08-22 14:43:07 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: computer-generated process (PROC PLAN in SAS)</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: double (participants and investigators) and single (1 cohort)</P>
<P>Inclusion of all randomized participants: adequate; see 'Participants'</P>
<P>Length of follow up: 6 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-22 14:43:13 +0100" MODIFIED_BY="[Empty name]">
<P>Number: 457 screened for eligibility, 350 enrolled in 5 cohorts; cohort 1 to 3 and cohort 5 vaccinia-naive, and cohort 4 was vaccinia-non-naive; cohort 5 enrolled half a year after other cohorts; none lost to follow up at day 60, 1 lost to follow up at day 180</P>
<P>Inclusion criteria: healthy adult men and women aged between 18 and 30 years with no previous smallpox vaccination; aged between 32 and 65 with history of smallpox vaccination and characteristic vaccination scar; agreed to use barrier or hormonal contraception if of child-bearing potential</P>
<P>Exclusion criteria: volunteer or any household or intimate contacts of the volunteer with (1) history of any acute or chronic exfoliative skin condition or other conditions that disrupt the integrity of the skin, or (2) condition resulting in immunocompromise whether due to disease or medication; healthcare workers caring for vulnerable people (neonates, pregnant women, those with degraded skin integrity, or who were immunocompromised for any reason) unable to be away from direct patient care until vaccine scab fallen off; household contact or regular contact with a child &lt; 3 years; history of cancer; present medical or psychiatric condition that precluded compliance with protocol; allergy to any components in either vaccine, vaccinia immune globulin, thiomeral, probenecid, or cidofovir; participation in another investigational trial within 1 month of screening; previous vaccination for influenza within 2 weeks or any live vaccine within 3 months before or after vaccination; treatment with any immunosuppressive drug within 3 months of enrolment; admission to hospital within 6 months of enrolment; sex, or other close contact with a woman who is or intends to become pregnant within 60 days after vaccination; positive pregnancy test within 14 days of enrolment; history of any chronic or acute medical condition judged to be not well controlled; previous admission to hospital as a result of previous smallpox vaccination; any other reason volunteer thought to be unsuitable by the principal investigator<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-08 17:23:27 +0000" MODIFIED_BY="[Empty name]">
<P>CCSV (Dynport)<BR/>1. Undiluted (2.5 x 10<SUP>5</SUP> plaque-forming units (PFU)/mL)<BR/>2. Dilution 1:5<BR/>3. Dilution 1:10<BR/>4. Dilution 1:25<BR/>5. Dilution 1:50</P>
<P>Dryvax:<BR/>6. Undiluted (2.5 x 10<SUP>5</SUP> PFU/mL)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Success rate <BR/>2. Humoral response (50% PFU reduction) and cellular response (measured in a semiquantitative cell-mediated cytoxicity assay)<BR/>3. Adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Location: USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-08 17:23:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hsieh-2006">
<CHAR_METHODS MODIFIED="2008-08-22 14:43:24 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: unclear</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: single (participants)</P>
<P>Inclusion of all randomized participants: adequate; 100% (no loss to follow up)</P>
<P>Length of follow up: 8 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-08 17:21:05 +0000" MODIFIED_BY="[Empty name]">
<P>Number: 219; 97 naive (aged 20 to 23 years) and 122 previously vaccinated participants (aged 24 to 65 years)<BR/>Inclusion criteria: healthy adult</P>
<P>Exclusion criteria: pregnancy; severe eczema; human immunodeficiency virus (HIV) infection; history of live-attenuated virus vaccination within 60 days; receipt of blood products or immune globulin within last 6 months; household contact; sexual contact or occupational exposure to pregnant women<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-08 17:23:35 +0000" MODIFIED_BY="[Empty name]">
<P>Lister vaccine, Elstree strain, produced in 1981 or earlier by the Centers for Disease Control Taiwan</P>
<P>For naive participants:<BR/>1. Undiluted vaccine 10<SUP>9</SUP> plaque-forming units (PFU)<BR/>2. 1:5 dilution<BR/>3. 1:10 dilution</P>
<P>For previously vaccinated participants:<BR/>4. Undiluted vaccine 10<SUP>9</SUP> PFU<BR/>5. 1:10 dilution<BR/>6. 1:30 dilution<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Success rate<BR/>2. Humoral response and T-cell response (measured by vaccinia-specific CD69 expression on T-cell subsets)<BR/>3. Adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-08 17:22:43 +0000" MODIFIED_BY="[Empty name]">
<P>Location: China</P>
<P>Significant neutralizing antibody titre defined one that caused a 60% reduction in pock count</P>
<P>Significant antibody response defined as positive seroconversion or &#8805; 4-fold rise of vaccinia-specific antibody titre<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-08 17:23:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2005">
<CHAR_METHODS MODIFIED="2008-08-22 14:43:37 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: not described</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: single (participants)</P>
<P>Inclusion of all randomized participants: adequate 100% (no loss to follow up)</P>
<P>Length of follow up: 1 month<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-08 17:20:13 +0000" MODIFIED_BY="[Empty name]">
<P>Number: 138 screened for eligibility, and 112 enrolled</P>
<P>Inclusion criteria: healthy adults aged 25 to 60 years</P>
<P>Exclusion criteria: according to US Centers for Disease and Prevention (CDC) guidelines for exclusion<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-08 17:23:40 +0000" MODIFIED_BY="[Empty name]">
<P>Lancy-Vaxina vaccine (Berna Biotech)<BR/>1. Undiluted (10<SUP>7.7</SUP> plaque-forming units (PFU)/mL)<BR/>2. Dilution 1:10<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Success rate<BR/>2. Humoral response (60% PFU reduction)<BR/>3. Adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Location: South Korea</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-08 17:21:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rock-2004">
<CHAR_METHODS MODIFIED="2008-08-22 14:43:45 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: not described</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: double (participants and investigators)</P>
<P>Inclusion of all randomized participants: adequate; 100% (no loss to follow up)</P>
<P>Length of follow up: 1 month<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-08 17:21:14 +0000" MODIFIED_BY="[Empty name]">
<P>Number: 148 enrolled; 107 participated in a substudy evaluating adverse events in relation to cytokine levels</P>
<P>Inclusion criteria: healthy adults aged 18 to 32 years</P>
<P>Exclusion criteria: vaccinia scar; vaccinia vaccination; HbS-AB; HepC-AB; human immunodeficiency virus (HIV)-AB; vaccination contraindications according to package insert (ie pregnancy, immunosuppression, and eczema) and protocol-specified (ie history of live-attenuated virus vaccination within 60 days before trial, receipt of blood products or immune globulin within 6 months before trial, household contact, sexual contact, or occupational exposure to pregnant women, immunosuppressed persons, persons with eczema, or infants &lt; 12 months)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Aventis Pasteur Smallpox Vaccine (APVS) <BR/>1. Undiluted<BR/>2. Dilution 1:5<BR/>3. Dilution 1:10<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Success rate<BR/>2. Cellular response (assessed using cytometric Bead Array (CBA) FACS analysis software)<BR/>3. Adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Location: USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-08 17:23:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Talbot-2004">
<CHAR_METHODS MODIFIED="2008-08-22 14:43:57 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: in-house custom-built programme with blocks of size 6</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: double (participants and investigators)</P>
<P>Inclusion of all randomized participants: adequate; 100% (no loss to follow up)</P>
<P>Length of follow up: 6 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-08 17:21:19 +0000" MODIFIED_BY="[Empty name]">
<P>Number: 458 screened for eligibility, and 340 enrolled</P>
<P>Inclusion criteria: healthy adults aged 18 to 32 years</P>
<P>Exclusion criteria: vaccinia scar; vaccinia vaccination; history of any of autoimmune disease, human immunodeficiency virus (HIV) infection, solid organ or bone marrow transplantation, malignancy, eczema, prior vaccination with any vaccinia-vectored or other poxvectored experimental vaccine, or allergies to the vaccine components; volunteers with history of or current illegal injection drug use; current exfoliative skin disorders; use of immunosuppressive medications; medical or psychiatric conditions or occupational responsibilities that precluded volunteer compliance; and pregnant or lactating women; volunteers with household or sexual contacts with a history of or concurrent eczema, a history of exfoliative skin disorders, a history of the immunosuppressive conditions noted above, ongoing pregnancy, or children &lt; 1 year also prohibited from participation<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-08 17:23:47 +0000" MODIFIED_BY="[Empty name]">
<P>Aventis Pasteur Smallpox Vaccine (APVS)<BR/>1. Undiluted (10<SUP>7.6</SUP> plaque-forming units (PFU)/mL)<BR/>2. Dilution 1:5<BR/>3. Dilution 1:10<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Success rate<BR/>2. Humoral response (60% PFU reduction)<BR/>3. Adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Location: USA</P>
<P>Trial terminated before time, because US Food and Drug Administration (FDA) temporarily suspended (in February 2003) all vaccinia trials due to adverse events noted in the ongoing civilian and military vaccination campaigns; number of participants was supposed to be 444, and at time of interruption 340 volunteers were recruited<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-08 17:23:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weltzin-2003">
<CHAR_METHODS MODIFIED="2008-08-22 14:44:18 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: not described</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: double (participants and investigators)</P>
<P>Inclusion of all randomized participants: adequate; 100% (no loss to follow up)</P>
<P>Length of follow up: 6 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-22 14:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>Number: 60 enrolled</P>
<P>Inclusion criteria: healthy adults aged 18 to 29 years</P>
<P>Exclusion criteria: vaccinia vaccination; risk factors for serious adverse events (immune deficiency, eczema) in participants or close contacts<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-08 17:23:56 +0000" MODIFIED_BY="[Empty name]">
<P>1. ACAM1000 undiluted (10<SUP>8</SUP> plaque-forming units (PFU)/mL)<BR/>2. Dryvax undiluted (10<SUP>8</SUP> PFU/mL)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Success rate<BR/>2. Humoral response (50% PFU reduction) and cellullar response (assessed using CTL activity assays, ELISPOT, and lymphoproliferation assays)<BR/>3. Adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Location: [USA]</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Agafonov-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Andzhaparidze-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Banerji-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Benenson-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chernos-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chernos-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cherry-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Christensen-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Denisov-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Evgrafov-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Galasso-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gateff-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Herrero-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Huerta-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Karchmer-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Simultaneous application of vaccines and no appropriate outcomes reported<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kennedy-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Khliabich-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lelong-1952">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lev-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lin-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marennikova-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marennikova-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martin-du-Pan-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mel_x0027_nikov-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meyer-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mihailescu-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Millar-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mobest-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Murruzzu-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nath-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Neff-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nyerges-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nyerges-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nyerges-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pattanayak-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petersen-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Podkuiko-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roberto-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sergeev-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sherman-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shinozaki-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Snell-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tauraso-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Unanov-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vaughan-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Simultaneous administration of Bacille Calmette-Guérin (BCG) vaccine and smallpox vaccine; no smallpox-only group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vaughan-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>No appropriate outcome measures reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vollmar-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Waibel-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Does not fit inclusion criteria (a trial to prevent secondary transmission)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Waibel-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Does not fit inclusion criteria (a trial of different vaccination sites)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wesley-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2008-11-08 17:24:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Acambis_x002d_a">
<CHAR_STUDY_NAME>
<P>"The effect of dose on safety, tolerability, and immunogenicity of ACAM2000 smallpox vaccine in adults with previous smallpox vaccination"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:24:25 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 28+ years</P>
<P>Expected total enrolment: 350<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. ACAM2000: 4 dose levels<BR/>2. Dryvax: standard dose<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Safety and tolerabilty<BR/>2. Immunogenicity by (a) major cutaneous reaction; (b) neutralizing antibodies, including fold-increase in antibody titre between baseline and day 30 sera, and geometric mean vaccinia neutralizing antibody titre on day 30 <BR/>3. Minimum dose calculated to produce major cutaneous reaction in at least 90% of the population<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>January to March 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Acambis website (www.acambis.com)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00053482<BR/>Sponsor: Acambis<BR/>Location: USA <BR/>Phase II<BR/>study design:<BR/>prevention, randomized, double blind, dose comparison, parallel assignment</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Acambis_x002d_b">
<CHAR_STUDY_NAME>
<P>"The effect of dose on safety, tolerability, and immunogenicity of ACAM2000 smallpox vaccine in adults without previous smallpox vaccination"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:24:35 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 29 years<BR/>Expected total enrolment: 350<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. ACAM2000: 4 dose levels<BR/>2. Dryvax: standard dose <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]">
<P>As for <LINK REF="STD-Acambis_x002d_a" TYPE="STUDY">Acambis-a</LINK>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>January to March 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Acambis website (www.acambis.com)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00053495<BR/>Sponsor: Acambis<BR/>Location: USA <BR/>Phase II<BR/>study design: prevention, randomized, double blind, dose comparison, parallel assignment<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Acambis_x002d_c">
<CHAR_STUDY_NAME>
<P>"The effect of dose on safety, tolerability, and immunogenicity of ACAM1000 smallpox vaccine in adults without previous smallpox vaccination A Phase 2, randomized, double-blind, dose-response study"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:24:41 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 29 years<BR/>Expected total enrolment: 350 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. ACAM1000: 3 dose levels<BR/>2. Dryvax: standard dose<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]">
<P>As for <LINK REF="STD-Acambis_x002d_a" TYPE="STUDY">Acambis-a</LINK>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: September 2002</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Acambis website (www.acambis.com)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00053508<BR/>Sponsor: Acambis<BR/>Location: USA<BR/>Phase II study design: prevention, randomized, double blind, dose comparison, parallel assignment<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:24:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Acambis_x002d_d">
<CHAR_STUDY_NAME>
<P>"Safety, tolerability, and immune response of ACAM3000 Modified Vaccinia Ankara (MVA) smallpox vaccine in adults"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:24:44 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 31 years<BR/>Expected total enrolment: 110 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. ACAM3000<BR/>2. MVA<BR/>3. Dryvax <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Safety and effectiveness<BR/>2. Immunogenicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: April 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Paul S Blum, Acambis<BR/>NIH Vaccine Research Center for Disease Control<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00079820<BR/>Sponsor: Acambis<BR/>Location: USA<BR/>Phase I<BR/>study design: prevention, randomized, double blind, placebo controlled, parallel assignment, safety study<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:24:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Acambis_x002d_e">
<CHAR_STUDY_NAME>
<P>"A Phase 1, double-blind, placebo-controlled study to assess the safety and immunogenicity of MVA3000 Modified Vaccinia Ankara (MVA) smallpox vaccine in vaccinia-naive human immunodeficiency virus (HIV)-seropositive subjects"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:24:48 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 35<BR/>Expected total enrolment: 90 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. ACAM3000<BR/>2. MVA <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Safety<BR/>2. Immunogenicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: October 2006<BR/>Last follow up: February 2008 <BR/>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Matt Desmond<BR/>+617 7614200<BR/>matt.desmond@acambis.com<BR/>NCT00282581<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00282581<BR/>Sponsor: Acambis<BR/>Location: USA<BR/>Phase I<BR/>study design:<BR/>prevention, randomized, double blind, placebo controlled, single group assignment</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:24:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Acambis_x002d_f">
<CHAR_STUDY_NAME>
<P>"A Phase 1, placebo-controlled, double-blind study of the safety and immunogenicity of two injections of MVA3000 Modified Vaccinia Ankara (MVA) smallpox vaccine in vaccinia naive adult subjects with a history of atopic dermatitis (AD)"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:24:52 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 35 years<BR/>Expected total enrolment: 45 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>MVA3000</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Primary: safety<BR/>2. Secondary: immunogenicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: October 2006<BR/>Last follow up: September 2007 <BR/>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Acambis website (www.acambis.com)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00389103<BR/>Sponsor: Acambis<BR/>Location:<BR/>USA<BR/>Phase I<BR/>study design: prevention, randomized, double blind, placebo controlled, parallel assignment<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:24:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bavarian-Nordic_x002d_a">
<CHAR_STUDY_NAME>
<P>"A multicenter, open-label Phase I/II study to evaluate safety and immunogenicity of MVA-BN® smallpox vaccine in HIV infected subjects (CD4 counts &gt;350/µl) and healthy subjects with and without previous smallpox vaccination"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:24:55 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 55 years<BR/>Expected total enrolment: 150 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IMVAMUNE (MVA-BN)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>1. Serious and/or unexpected adverse reaction </P>
<P>Secondary: <BR/>2. Neutralization assay specific seroconversion rates and geometric mean titres<BR/>3. ELISA specific seroconversion rates and geometric mean titres <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: July 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Richard N Greenberg, Principal Investigator, University of Kentucky School of Medicine, Kentucky 40536-0093, USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00189904<BR/>Sponsor: Bavarian Nordic<BR/>Location: Kentucky, USA<BR/>Phase I/Phase II study design: prevention, non-randomized, open label, uncontrolled, parallel assignment <BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:24:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bavarian-Nordic_x002d_b">
<CHAR_STUDY_NAME>
<P>"An open-label, controlled Phase I pilot study to evaluate safety and immunogenicity of MVA-BN® smallpox vaccine in 18-40 year old vaccinia-naïve subjects with atopic disorders"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:24:57 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 40 years<BR/>Expected total enrolment: 60 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IMVAMUNE (MVA-BN)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>1. Serious adverse events</P>
<P>Secondary:<BR/>2. ELISA specific seroconversion rates and geometric mean titres<BR/>3. Neutralization assay specific seroconversion rates and geometric mean titres<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: April 2004<BR/>Completion: April 2006<BR/>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Frank von Sonnenburg, Principal Investigator, Dept. of Infectious Diseases and Tropical Medicine, University of Munich</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00189917<BR/>Sponsor: Bavarian Nordic<BR/>Location: Bavaria, Germany<BR/>Phase I<BR/>Study design: prevention, non-randomized, open label, active control, parallel assignment<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:24:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bavarian-Nordic_x002d_c">
<CHAR_STUDY_NAME>
<P>"Phase I study on safety, tolerability and immunogenicity of the MVA-BN vaccine administered to healthy subjects"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:24:59 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 20 to 55 years<BR/>Expected total enrolment: 90 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>MVA-BN</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Safety and tolerability<BR/>2. Immunogenicity <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: April 2001<BR/>Completion: July 2003<BR/>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Karl M Eckl, Principal Investigator, Pharma PlanNet Contract Research GmbH, Moenchengladbach 41061, Germany</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00189943<BR/>Sponsor: Bavarian Nordic<BR/>Location: Germany<BR/>Phase I study design: prevention, randomized, double blind, uncontrolled, parallel assignment<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bavarian-Nordic_x002d_d">
<CHAR_STUDY_NAME>
<P>"Phase II, double-blind, randomised, dose-finding study to evaluate the immunogenicity of three different doses of MVA-BN smallpox vaccine in 18-30 year old smallpox naïve healthy subjects"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:01 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 30 years<BR/>Expected total enrolment: 165 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IMVAMUNE (MVA-BN)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>1. ELISA specific seroconversion rate and geometric mean titres (at all blood sampling time points)<BR/>Secondary:<BR/>2. Occurrence, relationship and intensity of adverse event at any time during the study<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: April 2003 (completed)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Rolf Pokorny, Principal Investigator, Swiss Pharma, Basel 4123, Switzerland</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00189956<BR/>Sponsor: Bavarian Nordic<BR/>Location: Switzerland<BR/>Phase II study design: prevention, randomized, double blind, dose comparison, parallel assignment<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bavarian-Nordic_x002d_e">
<CHAR_STUDY_NAME>
<P>"Phase I study to evaluate take rate, immunogenicity and safety of Bavarian Nordic's smallpox vaccine Elstree-BN administered to healthy vaccinia-naive subjects in the age of 18-32 years"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:03 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 32 years<BR/>Expected total enrolment: 50<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Elstree-BN</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>1. Occurrence of a typical pock ("take") within 1 week after vaccination<BR/>Secondary<BR/>2. Occurrence, relationship and intensity of any serious adverse event<BR/>3. Non-serious adverse event within 4 weeks after vaccination<BR/>4. ELISA/neutralization assay specific seroconversion rates and geometric mean titres 2, 4, 12, 52, and 104 weeks after vaccination<BR/>5. Interferon-gamma producing T cells 2, 4, 12, 52, and 104 weeks after vaccination<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: September 2003<BR/>Completion: April<BR/>2006<BR/>Last follow up: February 2006<BR/>Data entry closure: March 2006<BR/>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Andreas Schroedter, Principal Investigator, Focus Clinical Drug Development GMbH, Neuss, Nordrhein 41460, Germany</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00189969<BR/>Sponsor: Bavarian Nordic<BR/>Location: Nordrhein, Germany<BR/>Phase I study design: prevention, non-randomized, open label, uncontrolled, single group assignment<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bavarian-Nordic_x002d_f">
<CHAR_STUDY_NAME>
<P>"A partially randomized, partially double-blind, placebo-controlled Phase II non-inferiority study to evaluate immunogenicity and safety of one and two doses of MVA-BN® (IMVAMUNE&#8482;) smallpox vaccine in 18-55 year old healthy subjects"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:06 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 55 years<BR/>Expected total enrolment: 800 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>MVA-BN (IMVAMUNE)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary:<BR/>1. MVA-specific seroconversion rate derived from the ELISA specific antibody titres 2 weeks after the last vaccination<BR/>2. ECG changes and cardiac symptoms<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: May 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Frank von Sonnenburg, Principal Investigator, Section of International Medicine and Public Health, Dept. of Infectious Diseases and Tropical Medicine, Ludwig-Maximilians University Munich, Germany</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00316524<BR/>Sponsor: Bavarian Nordic<BR/>Location: Bavaria, Germany<BR/>Phase II study design: prevention, randomized, double blind, placebo control, parallel assignment</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bavarian-Nordic_x002d_g">
<CHAR_STUDY_NAME>
<P>"A multicenter, open-label, controlled Phase II study to evaluate safety and immunogenicity of MVA-BN® (IMVAMUNE) smallpox vaccine in 18-55 year old naive and previously vaccinated HIV infected subjects with CD4 counts &gt;200 - 500/µl"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:10 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 55 years<BR/>Expected total enrolment: 165 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IMVAMUNE (MVA-BN)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: <BR/>1. Serious and/or unexpected adverse reaction </P>
<P>Secondary: <BR/>2. Neutralization assay specific seroconversion rates and geometric mean titres<BR/>3. ELISA specific seroconversion rates and geometric mean titres<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: June 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Edgar Turner Overton, Principal Investigator, Washington University, St. Louis, USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00316589<BR/>Sponsor: Bavarian Nordic<BR/>Location: USA<BR/>Phase II study design: prevention, non-randomized, open label, active control, parallel assignment</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bavarian-Nordic_x002d_h">
<CHAR_STUDY_NAME>
<P>"A multicenter, open-label, controlled Phase II study to evaluate immunogenicity and safety of MVA-BN® (IMVAMUNE&#8482;) smallpox vaccine in 18-40 year old subjects with diagnosed atopic dermatitis"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:13 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 40 years<BR/>Expected total enrolment: 260 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>MVA-BN (IMVAMUNE)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary:<BR/>1. Seroconversion rate at visit 4 assessed by MVA-BN ELISA</P>
<P>Secondary:<BR/>2. Neutralization assay specific seroconversion rates and geometric mean titres (at all blood sampling time points)<BR/>3. ELISA specific seroconversion rates and geometric mean titres (at all blood sampling time points)<BR/>4. Occurrence, relationship, and intensity of any serious and/or unexpected adverse reaction at any time during the study<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: July 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Richard N Greenberg, M.D., Principal Investigator, University of Kentucky School of Medicine, USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00316602<BR/>Sponsor: Bavarian Nordic<BR/>Location: USA; Mexico<BR/>Phase II study design: prevention, non-randomized, open label, active control, parallel assignment</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bristol_x002d_Myers-Squibb">
<CHAR_STUDY_NAME>
<P>"A comparative Phase I clinical study of HIVAC-1e and smallpox (vaccinia) vaccines in previously (vaccinia) vaccinated and unvaccinated volunteers"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:15 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 60 years<BR/>Expected total enrolment: not given<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1.Smallpox vaccine <BR/>2. HIVAC-1e vaccine<BR/>3. gp160 vaccine (MicroGeneSys)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Physiological and immunological responses</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>1999 (completed)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Bristol_x002d_Myers-Squibb" TYPE="STUDY">Bristol-Myers Squibb</LINK> Co, Wallingford, Connecticut, USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov identifier: NCT00002261<BR/>Sponsor: <LINK REF="STD-Bristol_x002d_Myers-Squibb" TYPE="STUDY">Bristol-Myers Squibb</LINK>
<BR/>Location: Connecticut, USA<BR/>Phase I study design: prevention</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DynPort">
<CHAR_STUDY_NAME>
<P>"A Phase 1 study of reactogenicity, safety, immunogenicity, and pock lesion formation (take rate) of a cell-cultured smallpox vaccine (CCSV) Compared to a calf lymph vaccine (Dryvax®)"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:17 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 65<BR/>Enrolment: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cell-cultured vaccine (CCSV)<BR/>Dryvax<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Reactogenicity<BR/>2. Safety<BR/>3. Immunogenicity<BR/>4. Pock lesion formation<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Date: not stated, possibly 2002</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>University of Kentucky Medical Center, Lexington, Kentucky, USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov identifier: NCT00042094<BR/>Sponsor: <LINK REF="STD-DynPort" TYPE="STUDY">DynPort</LINK>
<BR/>Location: Kentucky, USA<BR/>Phase I study design: prevention, randomized, double blind, active control, parallel assignment<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NIAID_x002d_a">
<CHAR_STUDY_NAME>
<P>"A multicenter, randomized, placebo-controlled, double-blind trial to evaluate the safety and immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:20 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 60 years<BR/>Expected total enrolment: 18 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. TBC-3B vaccine<BR/>2. Smallpox vaccine<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Safety<BR/>2. Immunogenicity<BR/>3. Potential of boosting to augment immune responses<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Date: not stated, possibly 1999 (completed)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>M Keefer, Study Chair, University of Washington/Pacific Medicam Center, Seattle, Washington 98144, USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00000767<BR/>Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)<BR/>Location: USA<BR/>Phase I study design: prevention, double blind</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NIAID_x002d_b">
<CHAR_STUDY_NAME>
<P>"A double blind, randomized dose response study of Dryvax vaccine against smallpox in previously vaccinated adults"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:23 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>"Never been vaccinated for smallpox" aged 18 to 31; previously vaccinated aged 32 to 60; healthy adults aged 18 to 60<BR/>Expected enrolment: 90 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dryvax</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Safety<BR/>2. Efficacy<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: April 2004<BR/>Completion: November 2004<BR/>Last follow up: November 2004<BR/>(completed)<BR/>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-08-22 14:58:40 +0100" MODIFIED_BY="[Empty name]">
<P>Saint Louis University Health Sciences Center, St. Louis, Missouri 63110-0250, USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00032708<BR/>Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)<BR/>Location: Missouri, USA<BR/>Phase II study design: prevention, randomized, double blind, dose comparison, parallel assignment<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NIAID_x002d_c">
<CHAR_STUDY_NAME>
<P>"A Phase I/II study to evaluate the safety and preliminary efficacy of various concentrations of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in vaccinia-naive adults"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:25 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 32 years<BR/>Expected total enrolment: 330 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Wetvax (APSV)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Safety<BR/>2. Preliminary efficacy<BR/>3. Immunogenicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: May 2002<BR/>Completion: August 2002<BR/>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Not stated</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00038987<BR/>Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)<BR/>Location: USA<BR/>Phase I/Phase II study design: prevention, randomized, single blind, active control, parallel assignment</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NIAID_x002d_d">
<CHAR_STUDY_NAME>
<P>"A multicenter, double blind, randomized dose-response study of Dryvax vaccine against smallpox in previously vaccinated adults"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:28 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 32 to 70 years<BR/>Expected total enrolment: 927 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dryvax</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Safety<BR/>2. Proportion of 'takes'<BR/>3. Correlation between 'takes/no takes' and immune responses<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Completion: October 2004 (completed)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>National Institute of Allergy and Infectious Diseases (NIAID), USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00050505<BR/>Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)<BR/>Location: USA<BR/>Phase II study design: prevention, <BR/>randomized, dose comparison, parallel assignment</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NIAID_x002d_e">
<CHAR_STUDY_NAME>
<P>"A multicenter, double-blind, randomized study of the safety and efficacy of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in vaccinia-naive adults"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:30 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 32 years<BR/>Expected total enrolment: 444 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Aventis Pasteur's Smallpox Vaccine (APSV); Dryvax at end of study for volunteers without take at day 7 to 9</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Safety and efficacy<BR/>2. Cell-mediated immune response<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: not stated, possibly 2002 (completed)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>National Institute of Allergy and Infectious Diseases (NIAID), USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00050518<BR/>Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)<BR/>Location: USA<BR/>Phase II study design: prevention; randomized, dose comparison, parallel assignment<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NIAID_x002d_g">
<CHAR_STUDY_NAME>
<P>"A comparison of dressing preparations for smallpox vaccination sites with a focus upon the risk of secondary transmission of vaccinia virus"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:32 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 50 years<BR/>Expected total enrolment: 108<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Wetvax (APSV)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Efficacy</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: July 2003<BR/>Completion: June 2004<BR/>Date entry closure: October 2004<BR/>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Vanderbilt University, Nashville, Tennessee 37232, USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00063856<BR/>Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)<BR/>Location: Tennessee, USA<BR/>Phase I/Phase II study design: prevention, randomized, open label, active control, parallel assignment <BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NIAID_x002d_h">
<CHAR_STUDY_NAME>
<P>"Evaluation of human immune response to smallpox vaccine (vaccinia virus)"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:35 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 50 years<BR/>Expected total enrolment: 45 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dryvax</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Immune response to dilution of vaccine<BR/>2. Safety<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Completion: April 2005<BR/>Last follow up: November 2004<BR/>Data entry closure: April 2005 <BR/>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>University of Rochester School of Medicine, New York 14642, USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00068198<BR/>Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)<BR/>Location: New York, USA<BR/>Phase I study design: prevention, non-randomized, open label, single group assignment <BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NIAID_x002d_i">
<CHAR_STUDY_NAME>
<P>"A Phase I clinical trial to evaluate the safety and immunogenicity of MVA-BN in a dose response regimen followed by administration of Dryvax in healthy adult volunteers"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:37 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 32 years<BR/>Expected total enrolment: 90 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Dryvax<BR/>2. MVA-BN<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Safety<BR/>2. Preliminary immunogenicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: May 2004<BR/>Completion: May 2007<BR/>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Saint Louis University Health Sciences Center, St. Louis, Missouri 63110, USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00082446<BR/>Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)<BR/>Location: Missouri, USA<BR/>Phase I study design: prevention, randomized, double blind, active control, parallel assignment<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NIAID_x002d_j">
<CHAR_STUDY_NAME>
<P>"ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) immunization followed by Dryvax vaccination of healthy vaccinia-naïve adults: A Phase I/II, placebo-controlled study of the effects of dose and route of administration of MVA on safety, reactogenicity and immunogenicity, followed by Dryvax immunization to assess effects of MVA vaccination on Dryvax takes"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:40 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18+ years<BR/>Expected total enrolment: 72 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1.ACAM3000 MVA vaccine<BR/>2. GMP Grade PBS vaccine<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Immune response<BR/>2. Adverse reactions<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: October 2005<BR/>Expected completion: November 2007<BR/>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Lindsey Baden +617 732 6801 &lt;lbaden@partners.org&gt;<BR/>Brigham and Women's Hospital, Boston, Massachusetts 02115, USA<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00133575<BR/>Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)<BR/>Location: Massachusetts, USA Phase I/Phase II study design: prevention, randomized, double blind, placebo control, parallel assignment</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NIAID_x002d_k">
<CHAR_STUDY_NAME>
<P>"A double-blind, placebo-controlled, dose-finding, Phase 2 study to assess the safety, tolerability, and immunogenicity of three dose levels of ACAM3000 Modified Vaccinia Ankara (MVA) smallpox vaccine in adults with and without previous smallpox vaccination"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:45 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 55 years<BR/>Expected total enrolment: 700 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. ACAM3000 MVA vaccine<BR/>2. 0.9% sodium chloride INJ., USP vaccine<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Safety, tolerability<BR/>2. Immunogenicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: July 2005<BR/>Completion: June 2006<BR/>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>National Institute of Allergy and Infectious Diseases (NIAID), USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00170651<BR/>Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)<BR/>Location: USA<BR/>Phase II study design: randomized, double blind, placebo controlled, outpatient</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NIAID_x002d_l">
<CHAR_STUDY_NAME>
<P>"Evaluation of IMVAMUNE® smallpox vaccine with respect to safety and optimization of immune responses by administration timing, dose level administered, and subsequent boost with Dryvax® smallpox vaccine in vaccinia naive adults"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:47 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18+ years<BR/>Expected total enrolment: 315 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Dryvax<BR/>2. IMVAMUNE<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Safety<BR/>2. Immunogenicity of dosages and regimens<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>February 2007 to January 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Sharon E Frey +314 577 8648</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00437021<BR/>Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)<BR/>Location: USA<BR/>Dryvax: Phase I<BR/>IMVAMUNE: Phase II study design: prevention,<BR/>randomized, double blind, placebo controlled, parallel assignment</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NIAID_x002d_m">
<CHAR_STUDY_NAME MODIFIED="2008-08-22 14:58:55 +0100" MODIFIED_BY="[Empty name]">
<P>"A Phase I/II clinical trial of Modified Vaccinia Virus Ankara (MVA) to evaluate its safety, dosing schedule, immunogenicity and protective efficacy against Dryvax challenge in vaccinia-naive individuals"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:49 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18+ years<BR/>Expected total enrolment: 195 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Modified Vaccinia Virus Ankara TBC-M</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Safety<BR/>2. Immunogenicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: September 2002<BR/>Completion: August 2005 (completed)<BR/>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>National Institutes of Health Clinical Center (CC)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00046397<BR/>Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)<BR/>Location: Maryland, USA<BR/>Phase I study design: treatment, safety</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NIAID_x002d_n">
<CHAR_STUDY_NAME>
<P>"A Phase I/II clinical trial of Modified Vaccinia Virus Ankara (MVA) to evaluate its safety, immunogenicity and protective efficacy against Dryvax® (registered trademark) challenge in vaccinia-immune individuals"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:51 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female born 1979 to age 60<BR/>Expected total enrolment: 80 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Modified Vaccinia Virus Ankara TBC-MVA</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Safety and protection</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: February 2003<BR/>Completion: March 2006 (completed)<BR/>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>National Institute of Allergy and Infectious Diseases (NIAID), USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00053742<BR/>Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)<BR/>Location: Maryland, USA<BR/>Phase I study design: treatment, "Study participants will be randomly assigned ..."</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:25:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NIAID_x002d_o">
<CHAR_STUDY_NAME>
<P>"Immune responses to vaccinia virus vaccination"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:54 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18+ years<BR/>Expected total enrolment: 340 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Standard smallpox vaccine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Immunogenicity</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: February 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>NIH Clinical Center website, USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov identifier: NCT00325975<BR/>Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)<BR/>Location: Maryland, USA<BR/>Observational study design</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanofi_x002d_Aventis">
<CHAR_STUDY_NAME>
<P>"Evaluation of take and safety of a smallpox vaccine in healthy young adults"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:56 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 25 years<BR/>Expected total enrolment: 230 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Smallpox vaccine, LISTER strain, from chick embryo cells</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. 'Vaccine take'<BR/>2. Antibody response<BR/>3. Safety<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: October 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Clinical Trials Study Director, Sanofi Pasteur</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov identifier: NCT00258947<BR/>Sponsor: <LINK REF="STD-Sanofi_x002d_Aventis" TYPE="STUDY">Sanofi-Aventis</LINK>
<BR/>Location: France<BR/>Phase II study design: prevention, randomized, double blind, uncontrolled, parallel assignment</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seoul-NU">
<CHAR_STUDY_NAME>
<P>"Randomized, double blind, placebo control study to evaluate the safety and immunogenicity of CJ-50300 in healthy volunteers: Phase I"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:25:59 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 20 to 28 years<BR/>Expected total enrolment: 24 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cell-culture derived smallpox vaccine (CJ-50300)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: safety and immunogenicity</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-08-22 14:59:01 +0100" MODIFIED_BY="[Empty name]">
<P>Start: June 2006<BR/>Expected completion: March 2007<BR/>Last follow up: February 2007<BR/>Data entry closure: February 2007<BR/>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Myoung-don Oh +82 2 2072 2945 &lt;mdohmd@snu.ac.kr&gt;, Seoul National University Hospital, Seoul 110-744, Republic of Korea</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov identifier: NCT00336635<BR/>Sponsor: <LINK REF="STD-Seoul-NU" TYPE="STUDY">Seoul NU</LINK>
<BR/>Location: Seoul, Republic of Korea<BR/>Phase I study design: prevention, randomized, double blind, placebo controlled, single group assignment</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-VaxGen">
<CHAR_STUDY_NAME>
<P>"A Phase I/II clinical trial to evaluate the safety and immunogenicity of LC16m8, a modified vaccinia vaccine, in healthy volunteers"</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-08 17:26:01 +0000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Male/female 18 to 34 years<BR/>Expected total enrolment: 150 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LC16m8</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: safety and immunogenicity</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Start: October 2004<BR/>Last follow up: July 2006<BR/>Data entry closure: January 2007 <BR/>
</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]">
<P>Marc Gurwith, Study Director, <LINK REF="STD-VaxGen" TYPE="STUDY">VaxGen</LINK>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-11-08 17:27:03 +0000" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov identifier: NCT00103584<BR/>Sponsor: <LINK REF="STD-VaxGen" TYPE="STUDY">VaxGen</LINK>
<BR/>Location: USA<BR/>Phase I/Phase II study design: prevention, randomized, double blind, active control, parallel assignment</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-08-22 14:44:35 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-08-22 14:44:35 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-08 17:31:48 +0000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Diluted vaccine vs undiluted smallpox vaccine</NAME>
<DICH_OUTCOME CHI2="146.27430142570347" CI_END="0.9602320161080722" CI_START="0.8203009241095077" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8875129352144606" ESTIMABLE="YES" EVENTS_1="1415" EVENTS_2="1004" I2="91.79623496195939" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.01762381785522606" LOG_CI_START="-0.08602679919456857" LOG_EFFECT_SIZE="-0.0518253085248973" METHOD="MH" NO="1" P_CHI2="-2.220446049250313E-16" P_Q="0.0" P_Z="0.0029787597754456748" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.013895093238607914" TOTALS="SUB" TOTAL_1="1519" TOTAL_2="1015" WEIGHT="700.0" Z="2.9699213749928544">
<NAME>Vaccination success rate (pustule at vaccination site, 'take' rate)</NAME>
<GROUP_LABEL_1>Diluted</GROUP_LABEL_1>
<GROUP_LABEL_2>Undiluted</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours undiluted</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diluted</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1311963391113777" CI_START="0.7934139230973833" DF="0.0" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.053537990948669116" LOG_CI_START="-0.1005001826477149" LOG_EFFECT_SIZE="-0.023481095849522914" NO="1" P_CHI2="1.0" P_Z="0.550145898145103" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.5975415198467168">
<NAME>Dilution 1:3.2</NAME>
<DICH_DATA CI_END="1.1311963391113777" CI_START="0.7934139230973833" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.053537990948669116" LOG_CI_START="-0.1005001826477149" LOG_EFFECT_SIZE="-0.023481095849522914" ORDER="57" O_E="0.0" SE="0.09048278567177276" STUDY_ID="STD-Frey-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.008187134502923965" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.836636418223994" CI_END="1.032395572398601" CI_START="0.9020851229418524" DF="2.0" EFFECT_SIZE="0.9650433600889734" ESTIMABLE="YES" EVENTS_1="521" EVENTS_2="346" I2="86.51985568950535" ID="CMP-001.01.02" LOG_CI_END="0.01384613333116971" LOG_CI_START="-0.044752479442914266" LOG_EFFECT_SIZE="-0.015453173055872276" NO="2" P_CHI2="6.001591946694917E-4" P_Z="0.3012609721075161" STUDIES="6" TAU2="0.0028890913063661914" TOTAL_1="539" TOTAL_2="349" WEIGHT="100.0" Z="1.0337330937557458">
<NAME>Dilution 1:5</NAME>
<DICH_DATA CI_END="0.9407340659531009" CI_START="0.7949042620040259" EFFECT_SIZE="0.8647505527251754" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="51" LOG_CI_END="-0.026533128976472215" LOG_CI_START="-0.09968517447196826" LOG_EFFECT_SIZE="-0.06310915172422021" ORDER="58" O_E="0.0" SE="0.042969873632519584" STUDY_ID="STD-Artenstein-2005" TOTAL_1="100" TOTAL_2="51" VAR="0.0018464100399947017" WEIGHT="31.033539982381726"/>
<DICH_DATA CI_END="1.0562500278799487" CI_START="0.9856320172437197" EFFECT_SIZE="1.0203302630487097" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="103" LOG_CI_END="0.023766733421046005" LOG_CI_START="-0.006285197340336256" LOG_EFFECT_SIZE="0.008740768040354875" ORDER="59" O_E="0.0" SE="0.017652652888692368" STUDY_ID="STD-Frey-2002a" TOTAL_1="234" TOTAL_2="106" VAR="3.1161615400865893E-4" WEIGHT="34.38618739067016"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="60" O_E="0.0" SE="0.0" STUDY_ID="STD-Greenberg-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="37" EVENTS_2="20" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="61" O_E="0.0" SE="0.0" STUDY_ID="STD-Hsieh-2006" TOTAL_1="37" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="39" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="62" O_E="0.0" SE="0.0" STUDY_ID="STD-Rock-2004" TOTAL_1="34" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0123377273820762" CI_START="0.9536783455374573" EFFECT_SIZE="0.9825703888144034" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="113" LOG_CI_END="0.005325422256535645" LOG_CI_START="-0.020598078454334246" LOG_EFFECT_SIZE="-0.007636328098899315" ORDER="63" O_E="0.0" SE="0.015227592640963072" STUDY_ID="STD-Talbot-2004" TOTAL_1="114" TOTAL_2="113" VAR="2.318795776391127E-4" WEIGHT="34.58027262694812"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="18.40487060892248" CI_END="1.0226536900508867" CI_START="0.772010444293423" DF="3.0" EFFECT_SIZE="0.8885377479963885" ESTIMABLE="YES" EVENTS_1="745" EVENTS_2="475" I2="83.69996690688153" ID="CMP-001.01.03" LOG_CI_END="0.00972858976029638" LOG_CI_START="-0.11237682418716739" LOG_EFFECT_SIZE="-0.05132411721343549" NO="3" P_CHI2="3.628783063199803E-4" P_Z="0.09942475383968856" STUDIES="9" TAU2="0.014050295739367537" TOTAL_1="779" TOTAL_2="480" WEIGHT="100.00000000000001" Z="1.6476488310326107">
<NAME>Dilution 1:10</NAME>
<DICH_DATA CI_END="0.9407340659531009" CI_START="0.7949042620040259" EFFECT_SIZE="0.8647505527251754" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="51" LOG_CI_END="-0.026533128976472215" LOG_CI_START="-0.09968517447196826" LOG_EFFECT_SIZE="-0.06310915172422021" ORDER="64" O_E="0.0" SE="0.042969873632519584" STUDY_ID="STD-Artenstein-2005" TOTAL_1="100" TOTAL_2="51" VAR="0.0018464100399947017" WEIGHT="32.40067490539122"/>
<DICH_DATA CI_END="1.0369107359169834" CI_START="0.9622013362987306" EFFECT_SIZE="0.9988577955454027" ESTIMABLE="YES" EVENTS_1="330" EVENTS_2="103" LOG_CI_END="0.01574137107824736" LOG_CI_START="-0.016734044287786496" LOG_EFFECT_SIZE="-4.963366047695956E-4" ORDER="65" O_E="0.0" SE="0.01907621974190698" STUDY_ID="STD-Frey-2002a" TOTAL_1="340" TOTAL_2="106" VAR="3.639021596415215E-4" WEIGHT="35.76937336797023"/>
<DICH_DATA CI_END="0.9986358551201121" CI_START="0.5436779435716739" EFFECT_SIZE="0.7368421052631579" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="-5.928450491188232E-4" LOG_CI_START="-0.2646582855000631" LOG_EFFECT_SIZE="-0.13262556527459096" ORDER="66" O_E="0.0" SE="0.15511334686589623" STUDY_ID="STD-Frey-2002b" TOTAL_1="20" TOTAL_2="20" VAR="0.024060150375939837" WEIGHT="13.43780942184925"/>
<DICH_DATA CI_END="1.0730751135703969" CI_START="0.6766777861027636" EFFECT_SIZE="0.8521303258145363" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.030630122960721914" LOG_CI_START="-0.16961808024970815" LOG_EFFECT_SIZE="-0.06949397864449314" ORDER="67" O_E="0.0" SE="0.11762678581039909" STUDY_ID="STD-Frey-2003" TOTAL_1="21" TOTAL_2="20" VAR="0.013836060740085504" WEIGHT="18.392142304789303"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68" O_E="0.0" SE="0.0" STUDY_ID="STD-Greenberg-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="75" EVENTS_2="55" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="69" O_E="0.0" SE="0.0" STUDY_ID="STD-Hsieh-2006" TOTAL_1="75" TOTAL_2="55" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="56" EVENTS_2="56" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="70" O_E="0.0" SE="0.0" STUDY_ID="STD-Kim-2005" TOTAL_1="56" TOTAL_2="56" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="39" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="71" O_E="0.0" SE="0.0" STUDY_ID="STD-Rock-2004" TOTAL_1="34" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="113" EVENTS_2="113" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="72" O_E="0.0" SE="0.0" STUDY_ID="STD-Talbot-2004" TOTAL_1="113" TOTAL_2="113" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7393761972517786" CI_START="0.4613499137272349" DF="0.0" EFFECT_SIZE="0.5840472111174567" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="51" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="-0.1311345347861754" LOG_CI_START="-0.335969556266155" LOG_EFFECT_SIZE="-0.23355204552616518" NO="4" P_CHI2="1.0" P_Z="7.840790770204701E-6" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="51" WEIGHT="100.0" Z="4.469485681106377">
<NAME>Dilution 1:20</NAME>
<DICH_DATA CI_END="0.7393761972517786" CI_START="0.4613499137272349" EFFECT_SIZE="0.5840472111174567" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="51" LOG_CI_END="-0.1311345347861754" LOG_CI_START="-0.335969556266155" LOG_EFFECT_SIZE="-0.23355204552616518" ORDER="73" O_E="0.0" SE="0.12032110556704907" STUDY_ID="STD-Artenstein-2005" TOTAL_1="50" TOTAL_2="51" VAR="0.014477168444876967" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.089942761339205" CI_START="0.8301523643947886" DF="0.0" EFFECT_SIZE="0.9512195121951219" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="0.037403691438561856" LOG_CI_START="-0.08084219082503442" LOG_EFFECT_SIZE="-0.021719249693236308" NO="5" P_CHI2="1.0" P_Z="0.4715205275581579" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.7200072654552174">
<NAME>Dilution 1:25</NAME>
<DICH_DATA CI_END="1.089942761339205" CI_START="0.8301523643947886" EFFECT_SIZE="0.9512195121951219" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.037403691438561856" LOG_CI_START="-0.08084219082503442" LOG_EFFECT_SIZE="-0.021719249693236308" ORDER="74" O_E="0.0" SE="0.0694582165681937" STUDY_ID="STD-Greenberg-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.004824443848834098" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="18.092579735674008" CI_END="1.9063407006141109" CI_START="0.2891173261367989" DF="1.0" EFFECT_SIZE="0.742398899559599" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="54" I2="94.47287222380868" ID="CMP-001.01.06" LOG_CI_END="0.28020052021302444" LOG_CI_START="-0.5389258812794195" LOG_EFFECT_SIZE="-0.12936268053319758" NO="6" P_CHI2="2.1042332335352576E-5" P_Z="0.5358736201117271" STUDIES="2" TAU2="0.4386408227820864" TOTAL_1="71" TOTAL_2="55" WEIGHT="100.0" Z="0.6190648826033888">
<NAME>Dilution 1:30 to 1:32</NAME>
<DICH_DATA CI_END="0.8587312055593936" CI_START="0.35742781187131023" EFFECT_SIZE="0.554016620498615" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="-0.06614275492356243" LOG_CI_START="-0.44681165755979096" LOG_EFFECT_SIZE="-0.2564772062416767" ORDER="75" O_E="0.0" SE="0.22360679774997896" STUDY_ID="STD-Frey-2003" TOTAL_1="19" TOTAL_2="20" VAR="0.05" WEIGHT="19.238188926544243"/>
<DICH_DATA CI_END="1.0377130390060516" CI_START="0.8997089458716302" EFFECT_SIZE="0.9662503321817698" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="35" LOG_CI_END="0.016077273737783015" LOG_CI_START="-0.04589796127765203" LOG_EFFECT_SIZE="-0.014910343769934515" ORDER="76" O_E="0.0" SE="0.0364045598304276" STUDY_ID="STD-Hsieh-2006" TOTAL_1="52" TOTAL_2="35" VAR="0.0013252919764471828" WEIGHT="80.76181107345576"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="20" I2="0.0" ID="CMP-001.01.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Dilution 1:50</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="77" O_E="0.0" SE="0.0" STUDY_ID="STD-Greenberg-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.4503534857660062" CI_START="0.055358176877509845" DF="0.0" EFFECT_SIZE="0.15789473684210528" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="19" I2="0.0" ID="CMP-001.01.08" LOG_CI_END="-0.3464464714389692" LOG_CI_START="-1.2568182210273637" LOG_EFFECT_SIZE="-0.8016323462331665" NO="8" P_CHI2="1.0" P_Z="5.570420436861095E-4" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.451711958701972">
<NAME>Dilution 1:100</NAME>
<DICH_DATA CI_END="0.4503534857660062" CI_START="0.055358176877509845" EFFECT_SIZE="0.15789473684210525" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="19" LOG_CI_END="-0.3464464714389692" LOG_CI_START="-1.2568182210273637" LOG_EFFECT_SIZE="-0.8016323462331666" ORDER="78" O_E="0.0" SE="0.5347568721210619" STUDY_ID="STD-Frey-2002b" TOTAL_1="20" TOTAL_2="20" VAR="0.28596491228070176" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="84.69931746572081" CI_END="0.9778462538476482" CI_START="0.8325786750320767" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9022937096165277" ESTIMABLE="YES" EVENTS_1="1071" EVENTS_2="640" I2="87.01288235946899" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.009729423693476926" LOG_CI_START="-0.07957471695933101" LOG_EFFECT_SIZE="-0.04465207032640396" METHOD="MH" NO="2" P_CHI2="1.8196555373606316E-13" P_Q="0.0" P_Z="0.012210268079377964" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.013732494011471365" TOTALS="SUB" TOTAL_1="1182" TOTAL_2="663" WEIGHT="700.0" Z="2.5060085106031447">
<NAME>Seroconversion</NAME>
<GROUP_LABEL_1>Diluted</GROUP_LABEL_1>
<GROUP_LABEL_2>Undiluted</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours undiluted</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours diluted</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.0217007238624" CI_END="1.0666625180390121" CI_START="0.8207031469319839" DF="2.0" EFFECT_SIZE="0.935635230882747" ESTIMABLE="YES" EVENTS_1="366" EVENTS_2="204" I2="77.83123092622658" ID="CMP-001.02.01" LOG_CI_END="0.02802703447874203" LOG_CI_START="-0.08581390130006882" LOG_EFFECT_SIZE="-0.028893433410663378" NO="1" P_CHI2="0.010989126287590634" P_Z="0.3197856392847094" STUDIES="4" TAU2="0.009797738502879419" TOTAL_1="390" TOTAL_2="211" WEIGHT="99.99999999999999" Z="0.9948985132138578">
<NAME>Dryvax dilution 1:5</NAME>
<DICH_DATA CI_END="0.9959368622581378" CI_START="0.7998059718303104" EFFECT_SIZE="0.8925" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="48" LOG_CI_END="-0.0017681929438052302" LOG_CI_START="-0.09701535748773318" LOG_EFFECT_SIZE="-0.049391775215769214" ORDER="79" O_E="0.0" SE="0.055948655934171726" STUDY_ID="STD-Artenstein-2005" TOTAL_1="100" TOTAL_2="51" VAR="0.003130252100840329" WEIGHT="34.74072811075912"/>
<DICH_DATA CI_END="1.0608311836820952" CI_START="0.9749994243928296" EFFECT_SIZE="1.017010222892576" ESTIMABLE="YES" EVENTS_1="229" EVENTS_2="102" LOG_CI_END="0.025646277559573397" LOG_CI_START="-0.010995640694377683" LOG_EFFECT_SIZE="0.007325318432597872" ORDER="80" O_E="0.0" SE="0.021523644162791518" STUDY_ID="STD-Frey-2002a" TOTAL_1="234" TOTAL_2="106" VAR="4.6326725804646945E-4" WEIGHT="41.267535200560516"/>
<DICH_DATA CI_END="1.0453758184710666" CI_START="0.6971013526512311" EFFECT_SIZE="0.8536585365853658" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.019272449821380405" LOG_CI_START="-0.15670407456030017" LOG_EFFECT_SIZE="-0.06871581236945987" ORDER="81" O_E="0.0" SE="0.10336948151964373" STUDY_ID="STD-Greenberg-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.010685249709639966" WEIGHT="23.99173668868035"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="36" EVENTS_2="34" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="82" O_E="0.0" SE="0.0" STUDY_ID="STD-Talbot-2004" TOTAL_1="36" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="19.765301283635523" CI_END="1.0388077341883737" CI_START="0.8078180754501537" DF="3.0" EFFECT_SIZE="0.9160609502619282" ESTIMABLE="YES" EVENTS_1="474" EVENTS_2="221" I2="84.82188580406907" ID="CMP-001.02.02" LOG_CI_END="0.016535174402421693" LOG_CI_START="-0.09268643343833327" LOG_EFFECT_SIZE="-0.03807562951795577" NO="2" P_CHI2="1.8985359295320414E-4" P_Z="0.17177519458724932" STUDIES="5" TAU2="0.01167807007237039" TOTAL_1="519" TOTAL_2="231" WEIGHT="100.0" Z="1.3665219551187964">
<NAME>Dryvax dilution 1:10</NAME>
<DICH_DATA CI_END="0.8899843682404992" CI_START="0.6759603450275793" EFFECT_SIZE="0.775625" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="48" LOG_CI_END="-0.05061762127251721" LOG_CI_START="-0.17007878104187266" LOG_EFFECT_SIZE="-0.11034820115719494" ORDER="83" O_E="0.0" SE="0.07017207659079733" STUDY_ID="STD-Artenstein-2005" TOTAL_1="100" TOTAL_2="51" VAR="0.004924120333064726" WEIGHT="25.177567166427913"/>
<DICH_DATA CI_END="1.049162626690312" CI_START="0.9638346541807448" EFFECT_SIZE="1.005594002306805" ESTIMABLE="YES" EVENTS_1="329" EVENTS_2="102" LOG_CI_END="0.020842811739841347" LOG_CI_START="-0.01599746291869764" LOG_EFFECT_SIZE="0.0024226744105718483" ORDER="84" O_E="0.0" SE="0.021640159696726436" STUDY_ID="STD-Frey-2002a" TOTAL_1="340" TOTAL_2="106" VAR="4.6829651169982313E-4" WEIGHT="33.0776064889664"/>
<DICH_DATA CI_END="1.1580564088921894" CI_START="0.5856370094184767" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.06372971437755584" LOG_CI_START="-0.23237148577762762" LOG_EFFECT_SIZE="-0.08432088570003592" ORDER="85" O_E="0.0" SE="0.17393131069573445" STUDY_ID="STD-Frey-2002b" TOTAL_1="20" TOTAL_2="20" VAR="0.03025210084033611" WEIGHT="10.679379049421826"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86" O_E="0.0" SE="0.0" STUDY_ID="STD-Greenberg-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0504203786327937" CI_START="0.9076872524089769" EFFECT_SIZE="0.9764492753623188" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="34" LOG_CI_END="0.02136313867350241" LOG_CI_START="-0.04206376375842277" LOG_EFFECT_SIZE="-0.010350312542460195" ORDER="87" O_E="0.0" SE="0.03725727645674348" STUDY_ID="STD-Talbot-2004" TOTAL_1="39" TOTAL_2="34" VAR="0.0013881046489742123" WEIGHT="31.065447295183866"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.509049304571488" CI_START="0.06117652697379794" DF="0.0" EFFECT_SIZE="0.1764705882352941" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="17" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="-0.2932401515211587" LOG_CI_START="-1.2134151817960643" LOG_EFFECT_SIZE="-0.7533276666586115" NO="3" P_CHI2="1.0" P_Z="0.0013312273989080025" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.2091614021896806">
<NAME>Dryvax dilution 1:100</NAME>
<DICH_DATA CI_END="0.509049304571488" CI_START="0.06117652697379794" EFFECT_SIZE="0.17647058823529413" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="17" LOG_CI_END="-0.2932401515211587" LOG_CI_START="-1.2134151817960643" LOG_EFFECT_SIZE="-0.7533276666586115" ORDER="88" O_E="0.0" SE="0.5405153677233405" STUDY_ID="STD-Frey-2002b" TOTAL_1="20" TOTAL_2="20" VAR="0.29215686274509806" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7811499331827402" CI_START="0.4718971778921694" DF="0.0" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="48" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="-0.10726560004786263" LOG_CI_START="-0.326152619880028" LOG_EFFECT_SIZE="-0.21670910996394532" NO="4" P_CHI2="1.0" P_Z="1.0405994210759555E-4" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="51" WEIGHT="100.0" Z="3.880924971948905">
<NAME>ACAM2000 dilution 1:20</NAME>
<DICH_DATA CI_END="0.7811499331827402" CI_START="0.4718971778921694" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="48" LOG_CI_END="-0.10726560004786263" LOG_CI_START="-0.326152619880028" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="89" O_E="0.0" SE="0.12857531895763674" STUDY_ID="STD-Artenstein-2005" TOTAL_1="49" TOTAL_2="51" VAR="0.016531612645058022" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.089942761339205" CI_START="0.8301523643947886" DF="0.0" EFFECT_SIZE="0.9512195121951219" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="0.0" ID="CMP-001.02.05" LOG_CI_END="0.037403691438561856" LOG_CI_START="-0.08084219082503442" LOG_EFFECT_SIZE="-0.021719249693236308" NO="5" P_CHI2="1.0" P_Z="0.4715205275581579" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.7200072654552174">
<NAME>CCSV dilution 1:25</NAME>
<DICH_DATA CI_END="1.089942761339205" CI_START="0.8301523643947886" EFFECT_SIZE="0.9512195121951219" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.037403691438561856" LOG_CI_START="-0.08084219082503442" LOG_EFFECT_SIZE="-0.021719249693236308" ORDER="90" O_E="0.0" SE="0.0694582165681937" STUDY_ID="STD-Greenberg-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.004824443848834098" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.089942761339205" CI_START="0.8301523643947886" DF="0.0" EFFECT_SIZE="0.9512195121951219" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="0.0" ID="CMP-001.02.06" LOG_CI_END="0.037403691438561856" LOG_CI_START="-0.08084219082503442" LOG_EFFECT_SIZE="-0.021719249693236308" NO="6" P_CHI2="1.0" P_Z="0.4715205275581579" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.7200072654552174">
<NAME>CCSV dilution 1:50</NAME>
<DICH_DATA CI_END="1.089942761339205" CI_START="0.8301523643947886" EFFECT_SIZE="0.9512195121951219" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.037403691438561856" LOG_CI_START="-0.08084219082503442" LOG_EFFECT_SIZE="-0.021719249693236308" ORDER="91" O_E="0.0" SE="0.0694582165681937" STUDY_ID="STD-Greenberg-2005" TOTAL_1="20" TOTAL_2="20" VAR="0.004824443848834098" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="75" EVENTS_2="55" I2="0.0" ID="CMP-001.02.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Lister dilution 1:10</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="75" EVENTS_2="55" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="92" O_E="0.0" SE="0.0" STUDY_ID="STD-Hsieh-2006" TOTAL_1="75" TOTAL_2="55" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="37" EVENTS_2="20" I2="0.0" ID="CMP-001.02.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Lister dilution 1:5</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="37" EVENTS_2="20" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="93" O_E="0.0" SE="0.0" STUDY_ID="STD-Hsieh-2006" TOTAL_1="37" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0377130390060516" CI_START="0.8997089458716302" DF="0.0" EFFECT_SIZE="0.9662503321817698" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="35" I2="0.0" ID="CMP-001.02.09" LOG_CI_END="0.016077273737783015" LOG_CI_START="-0.04589796127765203" LOG_EFFECT_SIZE="-0.014910343769934515" NO="9" P_CHI2="1.0" P_Z="0.3456410778507645" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="35" WEIGHT="100.0" Z="0.9430778851876753">
<NAME>Lister dilution 1:30</NAME>
<DICH_DATA CI_END="1.0377130390060516" CI_START="0.8997089458716302" EFFECT_SIZE="0.9662503321817698" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="35" LOG_CI_END="0.016077273737783015" LOG_CI_START="-0.04589796127765203" LOG_EFFECT_SIZE="-0.014910343769934515" ORDER="94" O_E="0.0" SE="0.0364045598304276" STUDY_ID="STD-Hsieh-2006" TOTAL_1="52" TOTAL_2="35" VAR="0.0013252919764471828" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.153760096776389" CI_END="1.6063643282664608" CI_START="0.9054394064916045" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2060122569836798" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.20584405141048887" LOG_CI_START="-0.04314060808526426" LOG_EFFECT_SIZE="0.08135172166261231" METHOD="MH" NO="3" P_CHI2="0.641205434317906" P_Q="0.0" P_Z="0.2002733258923588" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="628" TOTAL_2="502" WEIGHT="400.0" Z="1.2807732401021015">
<NAME>Adverse event: fever</NAME>
<GROUP_LABEL_1>Diluted</GROUP_LABEL_1>
<GROUP_LABEL_2>Undiluted</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diluted</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours undiluted</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.35267633763456" CI_END="1.9030667377877792" CI_START="0.8196014603912032" DF="2.0" EFFECT_SIZE="1.2489020287888026" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="30" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.27945401863108255" LOG_CI_START="-0.08639727643082808" LOG_EFFECT_SIZE="0.0965283711001273" NO="1" P_CHI2="0.8383344727408388" P_Z="0.3010160495137547" STUDIES="3" TAU2="0.0" TOTAL_1="249" TOTAL_2="198" WEIGHT="99.99999999999999" Z="1.0342569967426283">
<NAME>APVS dilution 1:5</NAME>
<DICH_DATA CI_END="3.8288690345744296" CI_START="0.41620482469551223" EFFECT_SIZE="1.2623762376237624" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.5830705116769185" LOG_CI_START="-0.3806928897022557" LOG_EFFECT_SIZE="0.1011888109873314" ORDER="95" O_E="0.0" SE="0.5661193926759047" STUDY_ID="STD-Artenstein-2005" TOTAL_1="101" TOTAL_2="51" VAR="0.3204911667637352" WEIGHT="14.410144416323712"/>
<DICH_DATA CI_END="10.202195094184932" CI_START="0.3920724866631818" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0086936241861348" LOG_CI_START="-0.4066336328581724" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="96" O_E="0.0" SE="0.8313702367707394" STUDY_ID="STD-Rock-2004" TOTAL_1="34" TOTAL_2="34" VAR="0.6911764705882353" WEIGHT="6.681830464065164"/>
<DICH_DATA CI_END="1.92436606760214" CI_START="0.7454748671719015" EFFECT_SIZE="1.197733918128655" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="24" LOG_CI_END="0.2842876903719351" LOG_CI_START="-0.12756699370334063" LOG_EFFECT_SIZE="0.07836034833429721" ORDER="97" O_E="0.0" SE="0.24192548013938306" STUDY_ID="STD-Talbot-2004" TOTAL_1="114" TOTAL_2="113" VAR="0.05852793794067103" WEIGHT="78.90802511961111"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.406935178121099" CI_END="2.517868562041971" CI_START="0.5867031987153198" DF="2.0" EFFECT_SIZE="1.2154182569365852" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="30" I2="41.29621212508699" ID="CMP-001.03.02" LOG_CI_END="0.4010330552913917" LOG_CI_START="-0.2315815439966807" LOG_EFFECT_SIZE="0.08472575564735549" NO="2" P_CHI2="0.18205141043027728" P_Z="0.5995873747236903" STUDIES="3" TAU2="0.181283003312328" TOTAL_1="253" TOTAL_2="198" WEIGHT="100.0" Z="0.5249939847061281">
<NAME>APVS dilution 1:10</NAME>
<DICH_DATA CI_END="3.8288690345744296" CI_START="0.41620482469551223" EFFECT_SIZE="1.2623762376237624" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.5830705116769185" LOG_CI_START="-0.3806928897022557" LOG_EFFECT_SIZE="0.1011888109873314" ORDER="98" O_E="0.0" SE="0.5661193926759047" STUDY_ID="STD-Artenstein-2005" TOTAL_1="101" TOTAL_2="51" VAR="0.3204911667637352" WEIGHT="16.96301356682201"/>
<DICH_DATA CI_END="15.313963717393216" CI_START="0.7940740229124278" EFFECT_SIZE="3.4871794871794872" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.185087613806987" LOG_CI_START="-0.10013901111955048" LOG_EFFECT_SIZE="0.5424743013437183" ORDER="99" O_E="0.0" SE="0.7549484814562462" STUDY_ID="STD-Rock-2004" TOTAL_1="39" TOTAL_2="34" VAR="0.569947209653092" WEIGHT="9.538595711642962"/>
<DICH_DATA CI_END="1.4201029688500069" CI_START="0.4890099237006755" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" LOG_CI_END="0.1523198353563599" LOG_CI_START="-0.31068232745160945" LOG_EFFECT_SIZE="-0.07918124604762482" ORDER="100" O_E="0.0" SE="0.27196976233107034" STUDY_ID="STD-Talbot-2004" TOTAL_1="113" TOTAL_2="113" VAR="0.07396755162241889" WEIGHT="73.49839072153503"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0329592658835376E-31" CI_END="4.049355987370656" CI_START="0.5312230186281743" DF="0.0" EFFECT_SIZE="1.4666666666666666" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="100.0" ID="CMP-001.03.03" LOG_CI_END="0.6073859581847512" LOG_CI_START="-0.2747231146517012" LOG_EFFECT_SIZE="0.16633142176652496" NO="3" P_CHI2="0.0" P_Z="0.45981849065638813" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="55" WEIGHT="100.0" Z="0.7391457727817143">
<NAME>Lister dilution 1:10</NAME>
<DICH_DATA CI_END="4.049355987370656" CI_START="0.5312230186281743" EFFECT_SIZE="1.4666666666666666" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.6073859581847512" LOG_CI_START="-0.2747231146517012" LOG_EFFECT_SIZE="0.16633142176652496" ORDER="101" O_E="0.0" SE="0.5181552358944649" STUDY_ID="STD-Hsieh-2006" TOTAL_1="75" TOTAL_2="55" VAR="0.26848484848484855" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.226943091080638" CI_START="0.6423697698039876" DF="0.0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.7942748966604416" LOG_CI_START="-0.19221490533247917" LOG_EFFECT_SIZE="0.3010299956639812" NO="4" P_CHI2="1.0" P_Z="0.2316277185910537" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="1.1961764806401634">
<NAME>ACAM2000 dilution 1:20</NAME>
<DICH_DATA CI_END="6.226943091080638" CI_START="0.6423697698039876" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7942748966604416" LOG_CI_START="-0.19221490533247917" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="102" O_E="0.0" SE="0.5794689928939168" STUDY_ID="STD-Artenstein-2005" TOTAL_1="51" TOTAL_2="51" VAR="0.3357843137254902" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.062162543528329" CI_END="1.0315210216656643" CI_START="0.8335185171326586" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9272496278618447" ESTIMABLE="YES" EVENTS_1="328" EVENTS_2="291" I2="15.040188284843152" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.013478083012389437" LOG_CI_START="-0.07908474760657473" LOG_EFFECT_SIZE="-0.03280333229709263" METHOD="MH" NO="4" P_CHI2="0.3151369171226045" P_Q="0.0" P_Z="0.1647771458368926" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0031643270381903304" TOTALS="SUB" TOTAL_1="611" TOTAL_2="490" WEIGHT="400.0" Z="1.3891828814065836">
<NAME>Adverse event: headache</NAME>
<GROUP_LABEL_1>Diluted</GROUP_LABEL_1>
<GROUP_LABEL_2>Undiluted</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diluted</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours undiluted</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7121124211935614" CI_END="1.0298886833988707" CI_START="0.7924789088600569" DF="1.0" EFFECT_SIZE="0.9034185409140426" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="117" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.012790286066156087" LOG_CI_START="-0.10101228732798108" LOG_EFFECT_SIZE="-0.04411100063091249" NO="1" P_CHI2="0.39874390763321277" P_Z="0.1286611454469985" STUDIES="2" TAU2="0.0" TOTAL_1="215" TOTAL_2="164" WEIGHT="100.0" Z="1.5194027688492693">
<NAME>APVS dilution 1:5</NAME>
<DICH_DATA CI_END="1.4683916548274065" CI_START="0.7238113244415609" EFFECT_SIZE="1.0309405940594059" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="24" LOG_CI_END="0.1668419076538597" LOG_CI_START="-0.14037462638945697" LOG_EFFECT_SIZE="0.013233640632201395" ORDER="103" O_E="0.0" SE="0.180460512843414" STUDY_ID="STD-Artenstein-2005" TOTAL_1="101" TOTAL_2="51" VAR="0.032565996695707984" WEIGHT="18.9311436111134"/>
<DICH_DATA CI_END="1.0186570893699571" CI_START="0.7682621899951001" EFFECT_SIZE="0.884644406715714" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="93" LOG_CI_END="0.008028012016451874" LOG_CI_START="-0.11449054007828001" LOG_EFFECT_SIZE="-0.0532312640309141" ORDER="104" O_E="0.0" SE="0.0719680039770595" STUDY_ID="STD-Talbot-2004" TOTAL_1="114" TOTAL_2="113" VAR="0.005179393596442053" WEIGHT="81.0688563888866"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.011443586138145" CI_END="1.163932652704374" CI_START="0.7629971863623475" DF="2.0" EFFECT_SIZE="0.9423785540475234" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="134" I2="33.586668891752794" ID="CMP-001.04.02" LOG_CI_END="0.06592785195903035" LOG_CI_START="-0.11747706355175072" LOG_EFFECT_SIZE="-0.025774605796360154" NO="2" P_CHI2="0.2218571721673941" P_Z="0.5817140783850472" STUDIES="3" TAU2="0.013359743366169007" TOTAL_1="270" TOTAL_2="220" WEIGHT="100.0" Z="0.5508827169205691">
<NAME>APVS dilution 1:10</NAME>
<DICH_DATA CI_END="1.5216570260585762" CI_START="0.756656379015925" EFFECT_SIZE="1.073019801980198" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="24" LOG_CI_END="0.18231677564386956" LOG_CI_START="-0.12110130224062132" LOG_EFFECT_SIZE="0.030607736701624116" ORDER="105" O_E="0.0" SE="0.17822928089305853" STUDY_ID="STD-Artenstein-2005" TOTAL_1="101" TOTAL_2="51" VAR="0.03176567656765676" WEIGHT="18.54175847583203"/>
<DICH_DATA CI_END="1.9986423485015108" CI_START="0.6925116172087618" EFFECT_SIZE="1.1764705882352942" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.30073508527920045" LOG_CI_START="-0.15957293670778597" LOG_EFFECT_SIZE="0.07058107428570727" ORDER="106" O_E="0.0" SE="0.2703872106766128" STUDY_ID="STD-Kim-2005" TOTAL_1="56" TOTAL_2="56" VAR="0.07310924369747901" WEIGHT="8.49132516247438"/>
<DICH_DATA CI_END="0.985087799445789" CI_START="0.7325096412341099" EFFECT_SIZE="0.8494623655913979" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="93" LOG_CI_END="-0.006525059740461642" LOG_CI_START="-0.13518665478652575" LOG_EFFECT_SIZE="-0.07085585726349368" ORDER="107" O_E="0.0" SE="0.07557645781522505" STUDY_ID="STD-Talbot-2004" TOTAL_1="113" TOTAL_2="113" VAR="0.005711800975896492" WEIGHT="72.96691636169359"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3352383087312267" CI_START="0.40275790041463544" DF="0.0" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.12555878400066298" LOG_CI_START="-0.3949559317955755" LOG_EFFECT_SIZE="-0.13469857389745624" NO="3" P_CHI2="1.0" P_Z="0.31039323991126844" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="55" WEIGHT="100.0" Z="1.0143972709938478">
<NAME>Lister dilution 1:10</NAME>
<DICH_DATA CI_END="1.3352383087312267" CI_START="0.40275790041463544" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.12555878400066298" LOG_CI_START="-0.3949559317955755" LOG_EFFECT_SIZE="-0.13469857389745624" ORDER="108" O_E="0.0" SE="0.3057529206481084" STUDY_ID="STD-Hsieh-2006" TOTAL_1="75" TOTAL_2="55" VAR="0.09348484848484848" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8110465568997978" CI_START="0.8627608131039618" DF="0.0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="24" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="0.257929614943977" LOG_CI_START="-0.06410958892786416" LOG_EFFECT_SIZE="0.09691001300805642" NO="4" P_CHI2="1.0" P_Z="0.23815587252091686" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="1.1796087740465748">
<NAME>ACAM2000 dilution 1:20</NAME>
<DICH_DATA CI_END="1.8110465568997978" CI_START="0.8627608131039618" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="24" LOG_CI_END="0.257929614943977" LOG_CI_START="-0.06410958892786416" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="109" O_E="0.0" SE="0.18916742247408827" STUDY_ID="STD-Artenstein-2005" TOTAL_1="51" TOTAL_2="51" VAR="0.035784313725490194" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.875208870011571" CI_END="1.0311751258355115" CI_START="0.8127761727212236" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9154859759613543" ESTIMABLE="YES" EVENTS_1="370" EVENTS_2="337" I2="66.38702660451375" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.013332428353617948" LOG_CI_START="-0.09002903661450051" LOG_EFFECT_SIZE="-0.03834830413044124" METHOD="MH" NO="5" P_CHI2="0.010909086404542245" P_Q="0.0" P_Z="0.14585239563298336" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.010994882308301387" TOTALS="SUB" TOTAL_1="536" TOTAL_2="435" WEIGHT="300.0" Z="1.4543388096721879">
<NAME>Adverse event: pain at vaccination site</NAME>
<GROUP_LABEL_1>Diluted</GROUP_LABEL_1>
<GROUP_LABEL_2>Undiluted</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diluted</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours undiluted</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.390068868605997" CI_END="1.1343041740667255" CI_START="0.7750003708111873" DF="1.0" EFFECT_SIZE="0.9375959446981359" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="139" I2="58.16020144292963" ID="CMP-001.05.01" LOG_CI_END="0.054729530222734586" LOG_CI_START="-0.1106980896985749" LOG_EFFECT_SIZE="-0.027984279737920142" NO="1" P_CHI2="0.12210843335448462" P_Z="0.5072614587687214" STUDIES="2" TAU2="0.012450330118569846" TOTAL_1="215" TOTAL_2="164" WEIGHT="100.0" Z="0.663107895110957">
<NAME>APVS dilution 1:5</NAME>
<DICH_DATA CI_END="1.074721998539612" CI_START="0.6515104176801647" EFFECT_SIZE="0.8367751060820368" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="35" LOG_CI_END="0.03129613856396532" LOG_CI_START="-0.18607863550805442" LOG_EFFECT_SIZE="-0.07739124847204457" ORDER="110" O_E="0.0" SE="0.1276870183123899" STUDY_ID="STD-Artenstein-2005" TOTAL_1="101" TOTAL_2="51" VAR="0.016303974645508597" WEIGHT="31.586992238524047"/>
<DICH_DATA CI_END="1.0723097886319934" CI_START="0.9162772712885494" EFFECT_SIZE="0.9912280701754386" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="104" LOG_CI_END="0.030320270484954597" LOG_CI_START="-0.03797308619106038" LOG_EFFECT_SIZE="-0.003826407853052883" ORDER="111" O_E="0.0" SE="0.040115855769058885" STUDY_ID="STD-Talbot-2004" TOTAL_1="114" TOTAL_2="113" VAR="0.0016092818840839351" WEIGHT="68.41300776147595"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.032301578738823" CI_END="1.1106805514791134" CI_START="0.8297723459269603" DF="2.0" EFFECT_SIZE="0.9600062535089414" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="163" I2="34.04349969596929" ID="CMP-001.05.02" LOG_CI_END="0.04558916724054018" LOG_CI_START="-0.0810410431289447" LOG_EFFECT_SIZE="-0.017725937944202252" NO="2" P_CHI2="0.21955545388012598" P_Z="0.5831983209567979" STUDIES="3" TAU2="0.006897648666632444" TOTAL_1="270" TOTAL_2="220" WEIGHT="99.99999999999999" Z="0.5487189804306056">
<NAME>APVS dilution 1:10</NAME>
<DICH_DATA CI_END="1.0907914246907524" CI_START="0.6642381634818983" EFFECT_SIZE="0.8512022630834511" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="35" LOG_CI_END="0.03774171505605558" LOG_CI_START="-0.17767617584173093" LOG_EFFECT_SIZE="-0.06996723039283768" ORDER="112" O_E="0.0" SE="0.12653753544911742" STUDY_ID="STD-Artenstein-2005" TOTAL_1="101" TOTAL_2="51" VAR="0.016011747877536647" WEIGHT="27.742201053862843"/>
<DICH_DATA CI_END="1.4295691868481435" CI_START="0.5877839180560321" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.15520517874909948" LOG_CI_START="-0.2307823005278991" LOG_EFFECT_SIZE="-0.0377885608893998" ORDER="113" O_E="0.0" SE="0.2267309559961463" STUDY_ID="STD-Kim-2005" TOTAL_1="56" TOTAL_2="56" VAR="0.05140692640692642" WEIGHT="12.006436669519294"/>
<DICH_DATA CI_END="1.0875711395020569" CI_START="0.9372474018745724" EFFECT_SIZE="1.0096153846153846" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="104" LOG_CI_END="0.036457674346406954" LOG_CI_START="-0.028145754804091528" LOG_EFFECT_SIZE="0.004155959771157703" ORDER="114" O_E="0.0" SE="0.03794837407513467" STUDY_ID="STD-Talbot-2004" TOTAL_1="113" TOTAL_2="113" VAR="0.0014400790949463532" WEIGHT="60.251362276617854"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9060824001699173" CI_START="0.4360553088132307" DF="0.0" EFFECT_SIZE="0.6285714285714286" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="35" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="-0.04283230529024376" LOG_CI_START="-0.36045842176589504" LOG_EFFECT_SIZE="-0.2016453635280694" NO="3" P_CHI2="1.0" P_Z="0.012825744550159614" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="99.99999999999999" Z="2.488571497519156">
<NAME>ACAM2000 dilution 1:20</NAME>
<DICH_DATA CI_END="0.9060824001699173" CI_START="0.4360553088132307" EFFECT_SIZE="0.6285714285714286" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="35" LOG_CI_END="-0.04283230529024376" LOG_CI_START="-0.36045842176589504" LOG_EFFECT_SIZE="-0.2016453635280694" ORDER="115" O_E="0.0" SE="0.18657515309243142" STUDY_ID="STD-Artenstein-2005" TOTAL_1="51" TOTAL_2="51" VAR="0.03481028775146422" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.931767929644067" CI_END="1.0426122745837396" CI_START="0.7188255363092765" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8657114573807437" ESTIMABLE="YES" EVENTS_1="429" EVENTS_2="328" I2="58.21453713992818" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.018122833532306835" LOG_CI_START="-0.14337650295814824" LOG_EFFECT_SIZE="-0.0626268347129207" METHOD="MH" NO="6" P_CHI2="0.00778358939152024" P_Q="0.0" P_Z="0.12848967300319625" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.04694096687178851" TOTALS="SUB" TOTAL_1="1258" TOTAL_2="770" WEIGHT="400.0" Z="1.520084765305794">
<NAME>Adverse event: lymphadenopathy</NAME>
<GROUP_LABEL_1>Diluted</GROUP_LABEL_1>
<GROUP_LABEL_2>Undiluted</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours diluted</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours undiluted</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.121437713769977" CI_END="1.3517651158442519" CI_START="0.5424794663523302" DF="3.0" EFFECT_SIZE="0.8563321894433757" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="133" I2="78.75570419381118" ID="CMP-001.06.01" LOG_CI_END="0.13090123468638493" LOG_CI_START="-0.26561669585481956" LOG_EFFECT_SIZE="-0.06735773058421735" NO="1" P_CHI2="0.0027444341580306064" P_Z="0.5054812118451976" STUDIES="4" TAU2="0.13744700325582423" TOTAL_1="483" TOTAL_2="304" WEIGHT="99.99999999999999" Z="0.6658903210012553">
<NAME>Dryvax dilution 1:5</NAME>
<DICH_DATA CI_END="1.356808456692266" CI_START="0.5220072827546797" EFFECT_SIZE="0.8415841584158416" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="18" LOG_CI_END="0.13251854178420458" LOG_CI_START="-0.2823234379209043" LOG_EFFECT_SIZE="-0.07490244806834986" ORDER="116" O_E="0.0" SE="0.24368023237969896" STUDY_ID="STD-Artenstein-2005" TOTAL_1="101" TOTAL_2="51" VAR="0.05938005565262408" WEIGHT="22.826362768481477"/>
<DICH_DATA CI_END="0.7799736214918894" CI_START="0.41825430933940067" EFFECT_SIZE="0.5711631363805277" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="46" LOG_CI_END="-0.10792008478930326" LOG_CI_START="-0.37855957573871546" LOG_EFFECT_SIZE="-0.24323983026400936" ORDER="117" O_E="0.0" SE="0.15897497667077112" STUDY_ID="STD-Frey-2002a" TOTAL_1="234" TOTAL_2="106" VAR="0.025273043207472222" WEIGHT="33.60735994849736"/>
<DICH_DATA CI_END="160.96009561105961" CI_START="0.5032303173808164" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2067182213488903" LOG_CI_START="-0.2982332024702403" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="118" O_E="0.0" SE="1.4714208660608852" STUDY_ID="STD-Rock-2004" TOTAL_1="34" TOTAL_2="34" VAR="2.1650793650793654" WEIGHT="1.097151863842689"/>
<DICH_DATA CI_END="1.3133252304051468" CI_START="0.8838920790086007" EFFECT_SIZE="1.0774218154080855" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="69" LOG_CI_END="0.11837228761262143" LOG_CI_START="-0.05360075800983763" LOG_EFFECT_SIZE="0.032385764801391874" ORDER="119" O_E="0.0" SE="0.10101781827893752" STUDY_ID="STD-Talbot-2004" TOTAL_1="114" TOTAL_2="113" VAR="0.010204599609836443" WEIGHT="42.46912541917847"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.96769091698212" CI_END="1.1398158975183224" CI_START="0.6747325740401877" DF="4.0" EFFECT_SIZE="0.8769668833339515" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="157" I2="55.39542969277411" ID="CMP-001.06.02" LOG_CI_END="0.05683470997798998" LOG_CI_START="-0.17086832291952259" LOG_EFFECT_SIZE="-0.057016806470766304" NO="2" P_CHI2="0.06191221077413167" P_Z="0.3263219008086756" STUDIES="5" TAU2="0.04303397901580824" TOTAL_1="649" TOTAL_2="360" WEIGHT="100.0" Z="0.9815493959317667">
<NAME>Dryvax dilution 1:10</NAME>
<DICH_DATA CI_END="1.278418101192201" CI_START="0.4826093658754481" EFFECT_SIZE="0.7854785478547854" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="18" LOG_CI_END="0.10667291121290313" LOG_CI_START="-0.31640425410448925" LOG_EFFECT_SIZE="-0.10486567144579308" ORDER="120" O_E="0.0" SE="0.24851762117318052" STUDY_ID="STD-Artenstein-2005" TOTAL_1="101" TOTAL_2="51" VAR="0.06176100803357647" WEIGHT="17.392422625284063"/>
<DICH_DATA CI_END="0.8571493661574947" CI_START="0.4938831288629232" EFFECT_SIZE="0.6506393861892583" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="46" LOG_CI_END="-0.06694349167580559" LOG_CI_START="-0.3063758091631754" LOG_EFFECT_SIZE="-0.18665965041949054" ORDER="121" O_E="0.0" SE="0.1406437285011674" STUDY_ID="STD-Frey-2002a" TOTAL_1="340" TOTAL_2="106" VAR="0.019780658366710092" WEIGHT="28.335501136238104"/>
<DICH_DATA CI_END="1.7405943804534103" CI_START="0.7819806420129618" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="24" LOG_CI_END="0.2406975770594467" LOG_CI_START="-0.10680399779822024" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="122" O_E="0.0" SE="0.2041241452319315" STUDY_ID="STD-Kim-2005" TOTAL_1="56" TOTAL_2="56" VAR="0.04166666666666667" WEIGHT="21.3366570379811"/>
<DICH_DATA CI_END="114.506895159516" CI_START="0.32762765026279117" EFFECT_SIZE="6.125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0588316389865478" LOG_CI_START="-0.48461945291340736" LOG_EFFECT_SIZE="0.7871060930365701" ORDER="123" O_E="0.0" SE="1.494035761667992" STUDY_ID="STD-Rock-2004" TOTAL_1="39" TOTAL_2="34" VAR="2.232142857142857" WEIGHT="0.8295397772719134"/>
<DICH_DATA CI_END="1.18502079106263" CI_START="0.7720825189983995" EFFECT_SIZE="0.9565217391304348" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="69" LOG_CI_END="0.07372597006305293" LOG_CI_START="-0.11233628045382624" LOG_EFFECT_SIZE="-0.01930515519538663" ORDER="124" O_E="0.0" SE="0.10929388697660895" STUDY_ID="STD-Talbot-2004" TOTAL_1="113" TOTAL_2="113" VAR="0.011945153730455772" WEIGHT="32.10587942322482"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6202991469140153" CI_START="0.6505245938393248" DF="0.0" EFFECT_SIZE="1.0266666666666666" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.20959520334527781" LOG_CI_START="-0.1867362797837142" LOG_EFFECT_SIZE="0.011429461780781804" NO="3" P_CHI2="1.0" P_Z="0.9099961304480678" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="55" WEIGHT="100.0" Z="0.11304342151248438">
<NAME>Lister dilution 1:10</NAME>
<DICH_DATA CI_END="1.6202991469140153" CI_START="0.6505245938393248" EFFECT_SIZE="1.0266666666666666" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" LOG_CI_END="0.20959520334527781" LOG_CI_START="-0.1867362797837142" LOG_EFFECT_SIZE="0.011429461780781804" ORDER="125" O_E="0.0" SE="0.23280707506245207" STUDY_ID="STD-Hsieh-2006" TOTAL_1="75" TOTAL_2="55" VAR="0.0541991341991342" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3140719315464757" CI_START="0.39693788882451064" DF="0.0" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="0.11861913890616539" LOG_CI_START="-0.401277444499104" LOG_EFFECT_SIZE="-0.1413291527964693" NO="4" P_CHI2="1.0" P_Z="0.28660599423650257" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="1.0655967293815094">
<NAME>ACAM2000 dilution 1:20</NAME>
<DICH_DATA CI_END="1.3140719315464757" CI_START="0.39693788882451064" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.11861913890616539" LOG_CI_START="-0.401277444499104" LOG_EFFECT_SIZE="-0.1413291527964693" ORDER="126" O_E="0.0" SE="0.3053898266218485" STUDY_ID="STD-Artenstein-2005" TOTAL_1="51" TOTAL_2="51" VAR="0.09326294620412268" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>New-generation versus original (Dryvax) smallpox vaccine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1327158768972028" CI_START="0.9437015292707155" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0338983050847457" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="178" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.05412098791282871" LOG_CI_START="-0.025165341175583132" LOG_EFFECT_SIZE="0.014477823368622805" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.47412365625090114" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="251" TOTAL_2="179" WEIGHT="100.0" Z="0.7157857528096951">
<NAME>Vaccination success rate (pustule at vaccination site, 'take' rate)</NAME>
<GROUP_LABEL_1>New</GROUP_LABEL_1>
<GROUP_LABEL_2>Original</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours original</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours new</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1327158768972028" CI_START="0.9437015292707155" DF="0.0" EFFECT_SIZE="1.0338983050847457" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.05412098791282871" LOG_CI_START="-0.025165341175583132" LOG_EFFECT_SIZE="0.014477823368622805" NO="1" P_CHI2="1.0" P_Z="0.47412365625090114" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.7157857528096951">
<NAME>ACAM1000</NAME>
<DICH_DATA CI_END="1.1327158768972028" CI_START="0.9437015292707155" EFFECT_SIZE="1.0338983050847457" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" LOG_CI_END="0.05412098791282871" LOG_CI_START="-0.025165341175583132" LOG_EFFECT_SIZE="0.014477823368622805" ORDER="127" O_E="0.0" SE="0.046573182180191866" STUDY_ID="STD-Weltzin-2003" TOTAL_1="30" TOTAL_2="30" VAR="0.002169061298389341" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="51" EVENTS_2="49" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="49" WEIGHT="0.0" Z="0.0">
<NAME>ACAM2000</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="51" EVENTS_2="49" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="128" O_E="0.0" SE="0.0" STUDY_ID="STD-Artenstein-2005" TOTAL_1="51" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="170" EVENTS_2="100" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="170" TOTAL_2="100" WEIGHT="0.0" Z="0.0">
<NAME>CCSV</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="170" EVENTS_2="100" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="129" O_E="0.0" SE="0.0" STUDY_ID="STD-Greenberg-2005" TOTAL_1="170" TOTAL_2="100" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7658784653135864" CI_END="1.0397032232736485" CI_START="0.9385823468681926" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.987849731156822" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="167" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.016909390367948036" LOG_CI_START="-0.027527618384583317" LOG_EFFECT_SIZE="-0.00530911400831766" METHOD="MH" NO="2" P_CHI2="0.4135655937793761" P_Q="0.0" P_Z="0.6395460420909194" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="250" TOTAL_2="179" WEIGHT="100.0" Z="0.4683336047243248">
<NAME>Seroconversion</NAME>
<GROUP_LABEL_1>New</GROUP_LABEL_1>
<GROUP_LABEL_2>Original</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours original</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours new</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1329548377772851" CI_START="0.9424716168498153" DF="0.0" EFFECT_SIZE="1.0333333333333334" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.054212598217294544" LOG_CI_START="-0.02573171998807393" LOG_EFFECT_SIZE="0.014240439114610285" NO="1" P_CHI2="1.0" P_Z="0.4850179311649653" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="30" WEIGHT="30.89686590052833" Z="0.6982546956488357">
<NAME>ACAM1000</NAME>
<DICH_DATA CI_END="1.1329548377772851" CI_START="0.9424716168498153" EFFECT_SIZE="1.0333333333333334" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" LOG_CI_END="0.054212598217294544" LOG_CI_START="-0.02573171998807393" LOG_EFFECT_SIZE="0.014240439114610285" ORDER="130" O_E="0.0" SE="0.04695968824459082" STUDY_ID="STD-Weltzin-2003" TOTAL_1="29" TOTAL_2="30" VAR="0.002205212320029161" WEIGHT="30.89686590052833"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.260193290637513E-30" CI_END="1.0732966038228688" CI_START="0.8970544637526521" DF="0.0" EFFECT_SIZE="0.981226533166458" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="47" I2="100.0" ID="CMP-002.02.02" LOG_CI_END="0.030719755146988513" LOG_CI_START="-0.04718118840609441" LOG_EFFECT_SIZE="-0.008230716629552971" NO="2" P_CHI2="0.0" P_Z="0.6787535362772222" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="49" WEIGHT="32.5389997122929" Z="0.4141646410196867">
<NAME>ACAM2000</NAME>
<DICH_DATA CI_END="1.0732966038228688" CI_START="0.8970544637526521" EFFECT_SIZE="0.981226533166458" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="47" LOG_CI_END="0.030719755146988513" LOG_CI_START="-0.04718118840609441" LOG_EFFECT_SIZE="-0.008230716629552971" ORDER="131" O_E="0.0" SE="0.045759399858970616" STUDY_ID="STD-Artenstein-2005" TOTAL_1="51" TOTAL_2="49" VAR="0.00209392267545316" WEIGHT="32.5389997122929"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0411551804304369" CI_START="0.8790778534246148" DF="0.0" EFFECT_SIZE="0.9566903684550744" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="91" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.017515464363534915" LOG_CI_START="-0.05597266097235519" LOG_EFFECT_SIZE="-0.01922859830441012" NO="3" P_CHI2="1.0" P_Z="0.30504618098863934" STUDIES="1" TAU2="0.0" TOTAL_1="170" TOTAL_2="100" WEIGHT="36.56413438717876" Z="1.0256721062777205">
<NAME>CCSV</NAME>
<DICH_DATA CI_END="1.0411551804304369" CI_START="0.8790778534246148" EFFECT_SIZE="0.9566903684550744" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="91" LOG_CI_END="0.017515464363534915" LOG_CI_START="-0.05597266097235519" LOG_EFFECT_SIZE="-0.01922859830441012" ORDER="132" O_E="0.0" SE="0.04316728859438913" STUDY_ID="STD-Greenberg-2005" TOTAL_1="170" TOTAL_2="100" VAR="0.001863414804591278" WEIGHT="36.56413438717876"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4399791719115136" CI_END="1.5368222460102285" CI_START="0.059856885832621984" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.30329753333066845" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" I2="30.554551100031482" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.18662363845538169" LOG_CI_START="-1.2228858818975927" LOG_EFFECT_SIZE="-0.5181311217211055" METHOD="MH" NO="3" P_CHI2="0.23014298126280752" P_Q="0.0" P_Z="0.14959802070687309" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.5700346933750672" TOTALS="YES" TOTAL_1="151" TOTAL_2="99" WEIGHT="100.0" Z="1.4409527898589802">
<NAME>Adverse event: fever</NAME>
<GROUP_LABEL_1>New</GROUP_LABEL_1>
<GROUP_LABEL_2>Original</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours new</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours original</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.493663092519479" CI_START="0.15450380044268974" DF="0.0" EFFECT_SIZE="0.48039215686274517" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.1742526499827638" LOG_CI_START="-0.8110608334495714" LOG_EFFECT_SIZE="-0.31840409173340384" NO="1" P_CHI2="1.0" P_Z="0.2052537054496023" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="49" WEIGHT="75.74495022937991" Z="1.2667248806009372">
<NAME>ACAM2000</NAME>
<DICH_DATA CI_END="1.4936630925194787" CI_START="0.15450380044268971" EFFECT_SIZE="0.4803921568627451" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.1742526499827637" LOG_CI_START="-0.8110608334495715" LOG_EFFECT_SIZE="-0.3184040917334039" ORDER="133" O_E="0.0" SE="0.5787780175485581" STUDY_ID="STD-Artenstein-2005" TOTAL_1="51" TOTAL_2="49" VAR="0.33498399359743897" WEIGHT="75.74495022937991"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3699747467250383" CI_START="0.0037982973708280457" DF="0.0" EFFECT_SIZE="0.07213578500707214" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.13671256171184615" LOG_CI_START="-2.4204110371097722" LOG_EFFECT_SIZE="-1.141849237698963" NO="2" P_CHI2="1.0" P_Z="0.08005082545607069" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="50" WEIGHT="24.25504977062009" Z="1.7503912463955964">
<NAME>CCSV</NAME>
<DICH_DATA CI_END="1.3699747467250383" CI_START="0.0037982973708280457" EFFECT_SIZE="0.07213578500707214" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.13671256171184615" LOG_CI_START="-2.4204110371097722" LOG_EFFECT_SIZE="-1.141849237698963" ORDER="134" O_E="0.0" SE="1.502067059913778" STUDY_ID="STD-Greenberg-2005" TOTAL_1="100" TOTAL_2="50" VAR="2.256205452478021" WEIGHT="24.25504977062009"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.007410152305052256" CI_END="1.0244884623442654" CI_START="0.6448288463679387" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8127851581388013" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.010507071796818793" LOG_CI_START="-0.1905555426387613" LOG_EFFECT_SIZE="-0.09002423542097121" METHOD="MH" NO="4" P_CHI2="0.9314010406969477" P_Q="0.0" P_Z="0.07923920718228457" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="151" TOTAL_2="99" WEIGHT="100.0" Z="1.7551175255148286">
<NAME>Adverse event: headache</NAME>
<GROUP_LABEL_1>New</GROUP_LABEL_1>
<GROUP_LABEL_2>Original</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours new</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours original</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.154376365219493E-31" CI_END="1.2028639129986765" CI_START="0.563821629955465" DF="0.0" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" I2="100.00000000000001" ID="CMP-002.04.01" LOG_CI_END="0.08021649585449572" LOG_CI_START="-0.24885826725456758" LOG_EFFECT_SIZE="-0.08432088570003592" NO="1" P_CHI2="0.0" P_Z="0.31517253105199383" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="49" WEIGHT="37.331332872188064" Z="1.0044276720291416">
<NAME>ACAM2000</NAME>
<DICH_DATA CI_END="1.2028639129986765" CI_START="0.563821629955465" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" LOG_CI_END="0.08021649585449572" LOG_CI_START="-0.24885826725456758" LOG_EFFECT_SIZE="-0.08432088570003592" ORDER="135" O_E="0.0" SE="0.1933001447966125" STUDY_ID="STD-Artenstein-2005" TOTAL_1="51" TOTAL_2="49" VAR="0.037364945978391365" WEIGHT="37.331332872188064"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.652728735652797E-31" CI_END="1.0803643333916317" CI_START="0.6019860003268521" DF="0.0" EFFECT_SIZE="0.8064516129032258" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="31" I2="100.0" ID="CMP-002.04.02" LOG_CI_END="0.03357023817101661" LOG_CI_START="-0.22041360849548686" LOG_EFFECT_SIZE="-0.0934216851622351" NO="2" P_CHI2="0.0" P_Z="0.1493450636990078" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="50" WEIGHT="62.66866712781193" Z="1.4418486899558345">
<NAME>CCSV</NAME>
<DICH_DATA CI_END="1.0803643333916317" CI_START="0.6019860003268521" EFFECT_SIZE="0.8064516129032258" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="31" LOG_CI_END="0.03357023817101661" LOG_CI_START="-0.22041360849548686" LOG_EFFECT_SIZE="-0.0934216851622351" ORDER="136" O_E="0.0" SE="0.14919136877222164" STUDY_ID="STD-Greenberg-2005" TOTAL_1="100" TOTAL_2="50" VAR="0.022258064516129033" WEIGHT="62.66866712781193"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.187516565172605" CI_END="1.2499198313457958" CI_START="0.6010140554690699" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8667291311871044" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="71" I2="76.11949745304993" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.09688215867151499" LOG_CI_START="-0.22111537135619605" LOG_EFFECT_SIZE="-0.06211660634234047" METHOD="MH" NO="5" P_CHI2="0.04072284441388396" P_Q="0.0" P_Z="0.44385125165447736" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.05344386551777017" TOTALS="YES" TOTAL_1="169" TOTAL_2="99" WEIGHT="100.0" Z="0.7657060182966229">
<NAME>Adverse event: pain at vaccination site</NAME>
<GROUP_LABEL_1>New</GROUP_LABEL_1>
<GROUP_LABEL_2>Original</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours new</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours original</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9512461374737435" CI_START="0.5301528155948597" DF="0.0" EFFECT_SIZE="0.7101449275362319" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="35" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="-0.021707093666569255" LOG_CI_START="-0.27559892775091394" LOG_EFFECT_SIZE="-0.14865301070874162" NO="1" P_CHI2="1.0" P_Z="0.021726954951448437" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="49" WEIGHT="46.10077841592226" Z="2.2951076645166184">
<NAME>ACAM2000</NAME>
<DICH_DATA CI_END="0.9512461374737435" CI_START="0.5301528155948597" EFFECT_SIZE="0.7101449275362319" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="35" LOG_CI_END="-0.021707093666569255" LOG_CI_START="-0.27559892775091394" LOG_EFFECT_SIZE="-0.14865301070874162" ORDER="137" O_E="0.0" SE="0.14913732012599198" STUDY_ID="STD-Artenstein-2005" TOTAL_1="69" TOTAL_2="49" VAR="0.022241940254362613" WEIGHT="46.10077841592226"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2657511032374973" CI_START="0.8345457158141024" DF="0.0" EFFECT_SIZE="1.0277777777777777" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="36" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.10234831459314558" LOG_CI_START="-0.07854986799373018" LOG_EFFECT_SIZE="0.01189922329970769" NO="2" P_CHI2="1.0" P_Z="0.796524800057286" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="50" WEIGHT="53.89922158407775" Z="0.2578472462013442">
<NAME>CCSV</NAME>
<DICH_DATA CI_END="1.2657511032374973" CI_START="0.8345457158141024" EFFECT_SIZE="1.0277777777777777" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="36" LOG_CI_END="0.10234831459314558" LOG_CI_START="-0.07854986799373018" LOG_EFFECT_SIZE="0.01189922329970769" ORDER="138" O_E="0.0" SE="0.10626048791197643" STUDY_ID="STD-Greenberg-2005" TOTAL_1="100" TOTAL_2="50" VAR="0.011291291291291288" WEIGHT="53.89922158407775"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.23686636115220683" CI_END="1.1632163682929715" CI_START="0.9057088426437808" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0264187014425104" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="75" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.06566050476779998" LOG_CI_START="-0.043011392119608756" LOG_EFFECT_SIZE="0.011324556324095632" METHOD="MH" NO="6" P_CHI2="0.8883111735775165" P_Q="0.0" P_Z="0.6829135535451489" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="181" TOTAL_2="129" WEIGHT="100.00000000000001" Z="0.40849056972142395">
<NAME>Adverse event: lymphadenopathy</NAME>
<GROUP_LABEL_1>New</GROUP_LABEL_1>
<GROUP_LABEL_2>Original</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours new</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours original</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8999851981257125" CI_START="0.6874382233440811" DF="0.0" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.2787502175857947" LOG_CI_START="-0.16276632363042126" LOG_EFFECT_SIZE="0.05799194697768673" NO="1" P_CHI2="1.0" P_Z="0.6066428653864142" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="6.058157192685169" Z="0.5148714345176062">
<NAME>ACAM1000</NAME>
<DICH_DATA CI_END="1.8999851981257125" CI_START="0.6874382233440811" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.2787502175857947" LOG_CI_START="-0.16276632363042126" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="139" O_E="0.0" SE="0.25934900185253223" STUDY_ID="STD-Weltzin-2003" TOTAL_1="30" TOTAL_2="30" VAR="0.06726190476190477" WEIGHT="6.058157192685169"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6202701622663658" CI_START="0.5697238145827228" DF="0.0" EFFECT_SIZE="0.9607843137254902" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="0.20958743441868902" LOG_CI_START="-0.24433562655753444" LOG_EFFECT_SIZE="-0.017374096069422692" NO="2" P_CHI2="1.0" P_Z="0.8807355093923999" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="49" WEIGHT="5.731522497891943" Z="0.1500368916563641">
<NAME>ACAM2000</NAME>
<DICH_DATA CI_END="1.6202701622663658" CI_START="0.5697238145827228" EFFECT_SIZE="0.9607843137254902" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.20958743441868902" LOG_CI_START="-0.24433562655753444" LOG_EFFECT_SIZE="-0.017374096069422692" ORDER="140" O_E="0.0" SE="0.26663665297282385" STUDY_ID="STD-Artenstein-2005" TOTAL_1="51" TOTAL_2="49" VAR="0.07109510470855009" WEIGHT="5.731522497891943"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1690617280945064" CI_START="0.8956348802011017" DF="0.0" EFFECT_SIZE="1.0232558139534884" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="43" I2="0.0" ID="CMP-002.06.03" LOG_CI_END="0.06783744312339324" LOG_CI_START="-0.04786900131019136" LOG_EFFECT_SIZE="0.009984220906600923" NO="3" P_CHI2="1.0" P_Z="0.7351766108095981" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="50" WEIGHT="88.2103203094229" Z="0.3382475969497461">
<NAME>CCSV</NAME>
<DICH_DATA CI_END="1.1690617280945064" CI_START="0.8956348802011017" EFFECT_SIZE="1.0232558139534884" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="43" LOG_CI_END="0.06783744312339324" LOG_CI_START="-0.04786900131019136" LOG_EFFECT_SIZE="0.009984220906600923" ORDER="141" O_E="0.0" SE="0.06796653821642483" STUDY_ID="STD-Greenberg-2005" TOTAL_1="100" TOTAL_2="50" VAR="0.004619450317124737" WEIGHT="88.2103203094229"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Non-naive vs naive participants</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.159082756330078" CI_START="0.816437530755864" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9727891156462585" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="220" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.06411444488026438" LOG_CI_START="-0.08807703944649295" LOG_EFFECT_SIZE="-0.011981297283114303" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.7576281694551921" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="190" TOTAL_2="220" WEIGHT="100.0" Z="0.3085969135113168">
<NAME>Vaccination success rate (pustule at vaccination site, 'take' rate)</NAME>
<GROUP_LABEL_1>Non-naive</GROUP_LABEL_1>
<GROUP_LABEL_2>Naive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours naive</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours non-naive</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.159082756330078" CI_START="0.816437530755864" DF="0.0" EFFECT_SIZE="0.9727891156462585" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="60" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.06411444488026438" LOG_CI_START="-0.08807703944649295" LOG_EFFECT_SIZE="-0.011981297283114303" NO="1" P_CHI2="1.0" P_Z="0.7576281694551921" STUDIES="2" TAU2="0.0" TOTAL_1="70" TOTAL_2="60" WEIGHT="100.0" Z="0.3085969135113168">
<NAME>Dryvax</NAME>
<DICH_DATA CI_END="1.159082756330078" CI_START="0.816437530755864" EFFECT_SIZE="0.9727891156462585" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.06411444488026438" LOG_CI_START="-0.08807703944649295" LOG_EFFECT_SIZE="-0.011981297283114303" ORDER="142" O_E="0.0" SE="0.08939803125353472" STUDY_ID="STD-Frey-2003" TOTAL_1="20" TOTAL_2="10" VAR="0.007992007992007971" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="50" EVENTS_2="50" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="143" O_E="0.0" SE="0.0" STUDY_ID="STD-Greenberg-2005" TOTAL_1="50" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="50" EVENTS_2="100" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="100" WEIGHT="0.0" Z="0.0">
<NAME>CCSV</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="50" EVENTS_2="100" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="144" O_E="0.0" SE="0.0" STUDY_ID="STD-Greenberg-2005" TOTAL_1="50" TOTAL_2="100" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="20" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Lister undiluted</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="20" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="145" O_E="0.0" SE="0.0" STUDY_ID="STD-Hsieh-2006" TOTAL_1="35" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="40" I2="0.0" ID="CMP-003.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Lister dilution 1:10</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="40" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="146" O_E="0.0" SE="0.0" STUDY_ID="STD-Hsieh-2006" TOTAL_1="35" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5664771747238416" CI_END="1.105353568601033" CI_START="0.9222211427501197" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0096437149698736" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="190" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.043501217687519356" LOG_CI_START="-0.03516492541041565" LOG_EFFECT_SIZE="0.0041681461385518394" METHOD="MH" NO="2" P_CHI2="0.4516623139343722" P_Q="0.0" P_Z="0.8354644615048629" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="170" TOTAL_2="210" WEIGHT="100.0" Z="0.20769840727264122">
<NAME>Seroconversion</NAME>
<GROUP_LABEL_1>Non-naive</GROUP_LABEL_1>
<GROUP_LABEL_2>Naive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours naive</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours non-naive</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1066968970168274" CI_START="0.8647302902015314" DF="0.0" EFFECT_SIZE="0.9782608695652174" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="46" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.044028692262939595" LOG_CI_START="-0.06311932807540033" LOG_EFFECT_SIZE="-0.009545317906230389" NO="1" P_CHI2="1.0" P_Z="0.7269330720202621" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="53.902314375410654" Z="0.3492081189763716">
<NAME>Dryvax</NAME>
<DICH_DATA CI_END="1.1066968970168274" CI_START="0.8647302902015314" EFFECT_SIZE="0.9782608695652174" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="46" LOG_CI_END="0.044028692262939595" LOG_CI_START="-0.06311932807540033" LOG_EFFECT_SIZE="-0.009545317906230389" ORDER="147" O_E="0.0" SE="0.06293927753799557" STUDY_ID="STD-Greenberg-2005" TOTAL_1="50" TOTAL_2="50" VAR="0.003961352657004834" WEIGHT="53.902314375410654"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.197113577766289" CI_START="0.9167932678385385" DF="0.0" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="84" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.07813535663627483" LOG_CI_START="-0.03772858445970086" LOG_EFFECT_SIZE="0.02020338608828699" NO="2" P_CHI2="1.0" P_Z="0.4942756108308092" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="100" WEIGHT="46.097685624589346" Z="0.6835242910647967">
<NAME>CCSV</NAME>
<DICH_DATA CI_END="1.197113577766289" CI_START="0.9167932678385385" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="84" LOG_CI_END="0.07813535663627483" LOG_CI_START="-0.03772858445970086" LOG_EFFECT_SIZE="0.02020338608828699" ORDER="148" O_E="0.0" SE="0.0680590525355344" STUDY_ID="STD-Greenberg-2005" TOTAL_1="50" TOTAL_2="100" VAR="0.004632034632034631" WEIGHT="46.097685624589346"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="20" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Lister undiluted</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="20" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="149" O_E="0.0" SE="0.0" STUDY_ID="STD-Hsieh-2006" TOTAL_1="35" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="40" I2="0.0" ID="CMP-003.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Lister dilution 1:10</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="40" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150" O_E="0.0" SE="0.0" STUDY_ID="STD-Hsieh-2006" TOTAL_1="35" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4769591744610842" CI_END="0.8196666221724043" CI_START="0.1084497202075059" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2981486472181765" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-0.0863627495559105" LOG_CI_START="-0.9647715640969342" LOG_EFFECT_SIZE="-0.5255671568264224" METHOD="MH" NO="3" P_CHI2="0.6875982844046846" P_Q="0.0" P_Z="0.019008686811631797" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="220" TOTAL_2="160" WEIGHT="100.0" Z="2.345360569668543">
<NAME>Adverse event: fever</NAME>
<GROUP_LABEL_1>Non-naive</GROUP_LABEL_1>
<GROUP_LABEL_2>Naive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-naive</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours naive</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0967497955252377" CI_START="0.035879912310534466" DF="0.0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.4909061175904471" LOG_CI_START="-1.4451486270297722" LOG_EFFECT_SIZE="-0.4771212547196625" NO="1" P_CHI2="1.0" P_Z="0.3340307360779813" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="20.58534279416977" Z="0.966026893720445">
<NAME>Dryvax</NAME>
<DICH_DATA CI_END="3.0967497955252377" CI_START="0.035879912310534466" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4909061175904471" LOG_CI_START="-1.4451486270297722" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="151" O_E="0.0" SE="1.1372481406154653" STUDY_ID="STD-Greenberg-2005" TOTAL_1="50" TOTAL_2="50" VAR="1.2933333333333332" WEIGHT="20.58534279416977"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="36.5312209294687" CI_START="0.06281681705868011" DF="0.0" EFFECT_SIZE="1.5148514851485149" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="1.5626641872425815" LOG_CI_START="-1.2019240731726688" LOG_EFFECT_SIZE="0.18037005703495623" NO="2" P_CHI2="1.0" P_Z="0.798145509153541" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="50" WEIGHT="10.095607352845057" Z="0.2557478961621938">
<NAME>CCSV</NAME>
<DICH_DATA CI_END="36.5312209294687" CI_START="0.06281681705868011" EFFECT_SIZE="1.5148514851485149" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5626641872425815" LOG_CI_START="-1.2019240731726688" LOG_EFFECT_SIZE="0.18037005703495623" ORDER="152" O_E="0.0" SE="1.6239328291005148" STUDY_ID="STD-Greenberg-2005" TOTAL_1="100" TOTAL_2="50" VAR="2.6371578334304018" WEIGHT="10.095607352845057"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1917334478704718" CI_START="0.01712477173630881" DF="0.0" EFFECT_SIZE="0.1428571428571428" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="0.07617912867255255" LOG_CI_START="-1.7663752087010667" LOG_EFFECT_SIZE="-0.845098040014257" NO="3" P_CHI2="1.0" P_Z="0.07219328620587782" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="20" WEIGHT="22.7275573288476" Z="1.7978972866486151">
<NAME>Lister undiluted</NAME>
<DICH_DATA CI_END="1.191733447870472" CI_START="0.01712477173630881" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.07617912867255264" LOG_CI_START="-1.7663752087010667" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="153" O_E="0.0" SE="1.082325538564332" STUDY_ID="STD-Hsieh-2006" TOTAL_1="35" TOTAL_2="20" VAR="1.1714285714285715" WEIGHT="22.7275573288476"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2571289885994759" CI_START="0.06493578129334893" DF="0.0" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" ID="CMP-003.03.04" LOG_CI_END="0.09937984106141219" LOG_CI_START="-1.1875159297619633" LOG_EFFECT_SIZE="-0.5440680443502757" NO="4" P_CHI2="1.0" P_Z="0.09746901564989058" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="40" WEIGHT="46.59149252413758" Z="1.6572496331748943">
<NAME>Lister dilution 1:10</NAME>
<DICH_DATA CI_END="1.2571289885994759" CI_START="0.06493578129334893" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.09937984106141219" LOG_CI_START="-1.1875159297619633" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="154" O_E="0.0" SE="0.7559289460184544" STUDY_ID="STD-Hsieh-2006" TOTAL_1="35" TOTAL_2="40" VAR="0.5714285714285714" WEIGHT="46.59149252413758"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.082135131849613" CI_END="0.9052254824285205" CI_START="0.3103520896787151" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.530036432806382" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="103" I2="66.9681197598627" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-0.04324322899667032" LOG_CI_START="-0.5081453260547093" LOG_EFFECT_SIZE="-0.2756942775256898" METHOD="MH" NO="4" P_CHI2="0.028218590236342322" P_Q="0.0" P_Z="0.020094476159920577" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.185429728387744" TOTALS="YES" TOTAL_1="170" TOTAL_2="210" WEIGHT="100.0" Z="2.3245791237060582">
<NAME>Adverse event: headache</NAME>
<GROUP_LABEL_1>Non-naive</GROUP_LABEL_1>
<GROUP_LABEL_2>Naive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours naive</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours non-naive</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7405891781787375" CI_START="0.2753945377133479" DF="0.0" EFFECT_SIZE="0.45161290322580644" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="31" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="-0.13042263834598278" LOG_CI_START="-0.5600446779660865" LOG_EFFECT_SIZE="-0.3452336581560347" NO="1" P_CHI2="1.0" P_Z="0.0016329433685632138" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="29.936150762618297" Z="3.1499572826159907">
<NAME>Dryvax</NAME>
<DICH_DATA CI_END="0.7405891781787375" CI_START="0.2753945377133479" EFFECT_SIZE="0.45161290322580644" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="31" LOG_CI_END="-0.13042263834598278" LOG_CI_START="-0.5600446779660865" LOG_EFFECT_SIZE="-0.3452336581560347" ORDER="155" O_E="0.0" SE="0.2523621127362434" STUDY_ID="STD-Greenberg-2005" TOTAL_1="50" TOTAL_2="50" VAR="0.06368663594470045" WEIGHT="29.936150762618297"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.316839156471966" CI_START="0.6427512394662143" DF="0.0" EFFECT_SIZE="0.92" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="50" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="0.11953273189224767" LOG_CI_START="-0.19195707720113703" LOG_EFFECT_SIZE="-0.03621217265444471" NO="2" P_CHI2="1.0" P_Z="0.6485983294416746" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="100" WEIGHT="34.06721273806775" Z="0.4557102809317249">
<NAME>CCSV</NAME>
<DICH_DATA CI_END="1.316839156471966" CI_START="0.6427512394662143" EFFECT_SIZE="0.92" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="50" LOG_CI_END="0.11953273189224767" LOG_CI_START="-0.19195707720113703" LOG_EFFECT_SIZE="-0.03621217265444471" ORDER="156" O_E="0.0" SE="0.18297065576087662" STUDY_ID="STD-Greenberg-2005" TOTAL_1="50" TOTAL_2="100" VAR="0.033478260869565214" WEIGHT="34.06721273806775"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8021929991685617" CI_START="0.14653708088951137" DF="0.0" EFFECT_SIZE="0.34285714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="-0.09572113247619875" LOG_CI_START="-0.8340524641291029" LOG_EFFECT_SIZE="-0.4648867983026508" NO="3" P_CHI2="1.0" P_Z="0.01358081084298153" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="20" WEIGHT="19.96542589993425" Z="2.4681639326385154">
<NAME>Lister undiluted</NAME>
<DICH_DATA CI_END="0.8021929991685617" CI_START="0.14653708088951137" EFFECT_SIZE="0.34285714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="-0.09572113247619875" LOG_CI_START="-0.8340524641291029" LOG_EFFECT_SIZE="-0.4648867983026508" ORDER="157" O_E="0.0" SE="0.43369947901195144" STUDY_ID="STD-Hsieh-2006" TOTAL_1="35" TOTAL_2="20" VAR="0.1880952380952381" WEIGHT="19.96542589993425"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.4058720770322477E-32" CI_END="1.0742186027119216" CI_START="0.13509793647858356" DF="0.0" EFFECT_SIZE="0.38095238095238093" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="100.0" ID="CMP-003.04.04" LOG_CI_END="0.031092668971506015" LOG_CI_START="-0.8693512844554574" LOG_EFFECT_SIZE="-0.4191293077419757" NO="4" P_CHI2="0.0" P_Z="0.06806029670344264" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="40" WEIGHT="16.0312105993797" Z="1.8246073948590489">
<NAME>Lister dilution 1:10</NAME>
<DICH_DATA CI_END="1.0742186027119216" CI_START="0.13509793647858356" EFFECT_SIZE="0.38095238095238093" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="0.031092668971506015" LOG_CI_START="-0.8693512844554574" LOG_EFFECT_SIZE="-0.4191293077419757" ORDER="158" O_E="0.0" SE="0.5289252355124537" STUDY_ID="STD-Hsieh-2006" TOTAL_1="35" TOTAL_2="40" VAR="0.2797619047619047" WEIGHT="16.0312105993797"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3630302770236273" CI_END="0.9481276105249422" CI_START="0.430226379569175" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6386779385932464" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="124" I2="70.26491236691966" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-0.0231332061038506" LOG_CI_START="-0.3663029641250099" LOG_EFFECT_SIZE="-0.19471808511443028" METHOD="MH" NO="5" P_CHI2="0.06667535556052495" P_Q="0.0" P_Z="0.026134463489379815" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0571073063011361" TOTALS="YES" TOTAL_1="100" TOTAL_2="150" WEIGHT="99.99999999999999" Z="2.2242078449078067">
<NAME>Adverse event: pain at vaccination site</NAME>
<GROUP_LABEL_1>Non-naive</GROUP_LABEL_1>
<GROUP_LABEL_2>Naive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-naive</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours naive</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0503165775151022" CI_START="0.5759580345157791" DF="0.0" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="36" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.02132022016099321" LOG_CI_START="-0.23960915901112934" LOG_EFFECT_SIZE="-0.10914446942506803" NO="1" P_CHI2="1.0" P_Z="0.10107349430038703" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="50.41520934742938" Z="1.639671468683136">
<NAME>Dryvax</NAME>
<DICH_DATA CI_END="1.0503165775151022" CI_START="0.5759580345157791" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="36" LOG_CI_END="0.02132022016099321" LOG_CI_START="-0.23960915901112934" LOG_EFFECT_SIZE="-0.10914446942506803" ORDER="159" O_E="0.0" SE="0.15327120894696264" STUDY_ID="STD-Greenberg-2005" TOTAL_1="50" TOTAL_2="50" VAR="0.023492063492063484" WEIGHT="50.41520934742938"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7119273786007355" CI_START="0.3838085314122097" DF="0.0" EFFECT_SIZE="0.5227272727272727" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="88" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="-0.147564305073134" LOG_CI_START="-0.41588537586405516" LOG_EFFECT_SIZE="-0.2817248404685946" NO="2" P_CHI2="1.0" P_Z="3.8593095046398115E-5" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="100" WEIGHT="49.584790652570604" Z="4.115744911431092">
<NAME>CCSV</NAME>
<DICH_DATA CI_END="0.7119273786007355" CI_START="0.3838085314122097" EFFECT_SIZE="0.5227272727272727" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="88" LOG_CI_END="-0.147564305073134" LOG_CI_START="-0.41588537586405516" LOG_EFFECT_SIZE="-0.2817248404685946" ORDER="160" O_E="0.0" SE="0.1576131251933086" STUDY_ID="STD-Greenberg-2005" TOTAL_1="50" TOTAL_2="100" VAR="0.024841897233201578" WEIGHT="49.584790652570604"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0053935190114163" CI_END="0.5587632344874157" CI_START="0.3596216628054951" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.44826706716079556" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="165" I2="0.179461324358961" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-0.25277217733331847" LOG_CI_START="-0.4441541552215568" LOG_EFFECT_SIZE="-0.3484631662774377" METHOD="MH" NO="6" P_CHI2="0.3907945486576404" P_Q="0.0" P_Z="9.518224905515255E-13" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.0901572356399573E-4" TOTALS="YES" TOTAL_1="170" TOTAL_2="210" WEIGHT="100.0" Z="7.137299586708296">
<NAME>Adverse event: lymphadenopathy</NAME>
<GROUP_LABEL_1>Non-naive</GROUP_LABEL_1>
<GROUP_LABEL_2>Naive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours non-naive</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours naive</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6158796759155909" CI_START="0.28451962425065924" DF="0.0" EFFECT_SIZE="0.4186046511627907" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="43" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="-0.2105041274300362" LOG_CI_START="-0.5458877735225247" LOG_EFFECT_SIZE="-0.3781959504762804" NO="1" P_CHI2="1.0" P_Z="9.855777908801487E-6" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="32.47133550562854" Z="4.42031357622005">
<NAME>Dryvax</NAME>
<DICH_DATA CI_END="0.6158796759155909" CI_START="0.28451962425065924" EFFECT_SIZE="0.4186046511627907" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="43" LOG_CI_END="-0.2105041274300362" LOG_CI_START="-0.5458877735225247" LOG_EFFECT_SIZE="-0.3781959504762804" ORDER="161" O_E="0.0" SE="0.19700601389055086" STUDY_ID="STD-Greenberg-2005" TOTAL_1="50" TOTAL_2="50" VAR="0.038811369509043916" WEIGHT="32.47133550562854"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7119273786007355" CI_START="0.3838085314122097" DF="0.0" EFFECT_SIZE="0.5227272727272727" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="88" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="-0.147564305073134" LOG_CI_START="-0.41588537586405516" LOG_EFFECT_SIZE="-0.2817248404685946" NO="2" P_CHI2="1.0" P_Z="3.8593095046398115E-5" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="100" WEIGHT="50.651328433801325" Z="4.115744911431092">
<NAME>CCSV</NAME>
<DICH_DATA CI_END="0.7119273786007355" CI_START="0.3838085314122097" EFFECT_SIZE="0.5227272727272727" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="88" LOG_CI_END="-0.147564305073134" LOG_CI_START="-0.41588537586405516" LOG_EFFECT_SIZE="-0.2817248404685946" ORDER="162" O_E="0.0" SE="0.1576131251933086" STUDY_ID="STD-Greenberg-2005" TOTAL_1="50" TOTAL_2="100" VAR="0.024841897233201578" WEIGHT="50.651328433801325"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5847210650084985" CI_START="0.11895726179892817" DF="0.0" EFFECT_SIZE="0.26373626373626374" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" I2="0.0" ID="CMP-003.06.03" LOG_CI_END="-0.23305126010121288" LOG_CI_START="-0.9246090411177623" LOG_EFFECT_SIZE="-0.5788301506094875" NO="3" P_CHI2="1.0" P_Z="0.0010345490301637472" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="20" WEIGHT="7.653468878945565" Z="3.280958668971558">
<NAME>Lister undiluted</NAME>
<DICH_DATA CI_END="0.5847210650084985" CI_START="0.11895726179892817" EFFECT_SIZE="0.26373626373626374" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="-0.23305126010121288" LOG_CI_START="-0.9246090411177623" LOG_EFFECT_SIZE="-0.5788301506094875" ORDER="163" O_E="0.0" SE="0.4062244638353468" STUDY_ID="STD-Hsieh-2006" TOTAL_1="35" TOTAL_2="20" VAR="0.165018315018315" WEIGHT="7.653468878945565"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.786720995851197" CI_START="0.18446783207593115" DF="0.0" EFFECT_SIZE="0.38095238095238093" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" I2="0.0" ID="CMP-003.06.04" LOG_CI_END="-0.10417925931270217" LOG_CI_START="-0.7340793561712493" LOG_EFFECT_SIZE="-0.4191293077419757" NO="4" P_CHI2="1.0" P_Z="0.009099811732131981" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="40" WEIGHT="9.223867181624572" Z="2.6082813834650094">
<NAME>Lister dilution 1:10</NAME>
<DICH_DATA CI_END="0.786720995851197" CI_START="0.18446783207593115" EFFECT_SIZE="0.38095238095238093" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.10417925931270217" LOG_CI_START="-0.7340793561712493" LOG_EFFECT_SIZE="-0.4191293077419757" ORDER="164" O_E="0.0" SE="0.3700064349504774" STUDY_ID="STD-Hsieh-2006" TOTAL_1="35" TOTAL_2="40" VAR="0.1369047619047619" WEIGHT="9.223867181624572"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-11-08 17:31:16 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-11-08 17:30:56 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-08 17:30:22 +0000" MODIFIED_BY="[Empty name]">Search methods: detailed search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-08 17:30:56 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="5" ROWS="7">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Search set</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>CIDG SR<SUP>a</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>CENTRAL</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>MEDLINE and EMBASE<SUP>b</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>LILACS<SUP>b</SUP>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>smallpox</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SMALLPOX VACCINE</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SMALLPOX VACCINE</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>smallpox</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>vaccin*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>smallpox</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>smallpox</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>vaccin*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 and 2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SMALLPOX</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SMALLPOX</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 and 2</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 or 3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 or 3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>vaccin*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>vaccin*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(4 and 5) or 1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(4 and 5) or 1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>a</SUP>Cochrane Infectious Diseases Group Specialized Register.<BR/>
<SUP>b</SUP>Search terms used in combination with the search strategy for retrieving trials developed by the Cochrane Collaboration (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>); upper case: MeSH or EMTREE heading; lower case: free text term.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-11-08 17:31:16 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-11-08 17:31:05 +0000" MODIFIED_BY="[Empty name]">Smallpox vaccines used in the included trials</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-08 17:31:16 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="7">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Vaccine</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Company</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Generation</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Strain</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Growing procedure</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Other information</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial(s)</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dryvax</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Wyeth</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>First</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NYCBOH</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Calf lymph derived</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lyophilized, about 15 million doses stock</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Frey-2002a" TYPE="STUDY">Frey 2002a</LINK>, <LINK REF="STD-Frey-2002b" TYPE="STUDY">Frey 2002b</LINK>, <LINK REF="STD-Frey-2003" TYPE="STUDY">Frey 2003</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>APSV</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Aventis Pasteur</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>First</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NYCBOH</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Calf lymph derived</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Frozen, about 85 million doses stock</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Rock-2004" TYPE="STUDY">Rock 2004</LINK>, <LINK REF="STD-Talbot-2004" TYPE="STUDY">Talbot 2004</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lancy-vaxina</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Berna Biotech</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>First</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lister</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Calf lymph derived</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lyophilised</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Kim-2005" TYPE="STUDY">Kim 2005</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ACAM</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acambis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Second</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NYCBOH</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cell culture</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MRC-5 cells (human diploid fibroblasts)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Artenstein-2005" TYPE="STUDY">Artenstein 2005</LINK> (ACAM2000), <LINK REF="STD-Weltzin-2003" TYPE="STUDY">Weltzin 2003</LINK> (ACAM1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CCSV</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Dynport</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Second</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NYCBOH</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cell culture</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MRC-5 cells (human diploid fibroblasts)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Greenberg-2005" TYPE="STUDY">Greenberg 2005</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lister/Elstree</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CDC Taiwan</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>First</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lister</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Calf lymph derived</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lyophilized</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hsieh-2006" TYPE="STUDY">Hsieh 2006</LINK>
</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>